Jianjun Zhang, MD, PhD

Peer-Reviewed Articles

1. Zhang J, Park MD, Pandya T, Shum E, Wu J, Heeke S, Salehi-Rad R, Marron TU, Wei Z, Li H, Blum TG, Heymach JV, Dubinett SM, Yang PC, Swanton C, Merad M. Innovative approaches for lung cancer screening and interception. Nat Rev Clin Oncol, 2026. e-Pub 2026. PMID: 41731061.
2. Di Federico A, Hong L, Elkrief A, Thummalapalli R, Cooper AJ, Ricciuti B, Digumarthy S, Alessi JV, Gogia P, Hambelton GM, Pecci F, Makarem M, Gandhi MM, Garbo E, De Giglio A, Gagliano A, Sperandi F, Gelsomino F, Scalera S, Cipriani L, Marinelli D, Lamberti G, Shaverdian N, Haradon J, Nguyen T, Voligny E, Ladanyi M, Zhang J, Gibbons DL, Heymach JV, Nishino M, Rodig SJ, Pfaff K, Wang X, Rekhtman N, Sholl LM, Luo J, Johnson BE, Janne PA, Arvind R, Gainor JF, Maugeri-Sacca M, Ardizzoni A, Heist RS, Arbour KC, Schoenfeld AJ, Vokes NI, Awad MM. TTF-1 expression in lung adenocarcinoma: clinicopathologic, genomic, and immunophenotypic correlates and outcomes to immunotherapy-based treatments and KRAS(G12C) inhibitors. J Thorac Oncol:103610, 2026. e-Pub 2026. PMID: 41690367.
3. Han X, Li W, Lin J, Li S, Saad MB, Kitsel Y, Heeke S, Hong L, Mohamed MQ, Le X, Vokes N, Godoy MC, Carter BW, Shroff GS, Eapen G, Byers LA, Vaporciyan AA, Gibbons DL, Heymach J, Wu CC, Zhang J, Wu J. Development of PET/CT-clinical nomograms for predicting lymph node metastasis in primary lung cancer. Eur Radiol, 2025. e-Pub 2025. PMID: 41405691.
4. Li R, Yang P, Di Pilato M, Zhang J, Flowers CR, Shang L, Li Z. Accurate imputation of pathway-specific gene expression in spatial transcriptomics with PASTA. Nat Commun, 2025. e-Pub 2025. PMID: 41397970.
5. Lin Y, Mekala V, Li J, Wang X, Aminu M, Wu J, Zhang J, Ripley RT, Amos CI, Cheng C. Gene signatures characterizing driver mutations in lung squamous carcinoma are predictive of the progression of pre-cancer lesions. Int J Cancer, 2025. e-Pub 2025. PMID: 41402247.
6. Feng H, Wu L, Zhao B, Huff C, Zhang J, Wu J, Lin L, Wei P, Wu C. Benchmarking DNA foundation models for genomic and genetic tasks. Nat Commun 16(1):10780, 2025. e-Pub 2025. PMID: 41315262.
7. Li H, Hong L, Rocha P, Bach R, Solis Soto LM, Rinsurongkawong W, Zhang B, Araujo HA, Elamin YY, Altan M, Arrechedera CA, Zhou J, Khan KB, Lu W, Young E, Gay CM, Cascone T, Byers LA, Skoulidis F, Blumenschein G, Fossella FV, Tsao A, Negrao MV, Vokes N, Wu J, Tran HT, Wistuba II, Lee JJ, Gibbons DL, Vaporciyan AA, Heymach JV, Le X, Zhang J. MET Overexpression Is Associated with Superior Immunotherapy Benefit in Advanced Non-Small Cell Lung Cancer. Cancers (Basel) 17(23), 2025. e-Pub 2025. PMID: 41375002.
8. Salehjahromi M, Li H, Showkatian E, Saad MB, Qayati M, Ismail SM, Sujit SJ, Muneer A, Aminu M, Hong L, Han X, Heeke S, Cascone T, Le X, Vokes N, Gibbons DL, Toumazis I, Ostrin EJ, Antonoff MB, Vaporciyan AA, Jaffray D, Kay FU, Carter BW, Wu CC, Godoy MCB, Lee JJ, Gerber DE, Heymach JV, Zhang J, Wu J. Radiomics for Dynamic Lung Cancer Risk Prediction in USPSTF-Ineligible Patients. Cancers (Basel) 17(21), 2025. e-Pub 2025. PMID: 41228201.
9. Grippin AJ, Marconi C, Copling S, Li N, Braun C, Woody C, Young E, Gupta P, Wang M, Wu A, Jeong SD, Soni D, Weidert F, Xie C, Goldenberg E, Kim A, Zhao C, DeVries A, Castillo P, Lohray R, Rooney MK, Schrank BR, Wang Y, Ma Y, Chang E, Kouzy R, Dyson K, Jafarnia J, Nariman N, Gladish G, New J, Argueta A, Amaya D, Thomas N, Doty A, Chen J, Copling N, Alatrash G, Simon J, Davies AB, Dennis W, Liang R, Lewis J, Wei X, Rinsurongkawong W, Vaporciyan AA, Johns A, Lee J, Lee JH, Sun R, Sharma P, Tran H, Zhang J, Gibbons DL, Wargo J, Kim BYS, Heymach JV, Mendez-Gomez HR, Jiang W, Sayour EJ, Lin SH. SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade. Nature, 2025. e-Pub 2025. PMID: 41125896.
10. Aminu M, Zhu B, Vokes N, Chen H, Hong L, Li J, Fujimoto J, Chaib M, Yang Y, Wang B, Poteete A, Nilsson MB, Le X, Cascone T, Jaffray D, Navin N, Wang T, Byers LA, Gibbons DL, Heymach J, Chen K, Cheng C, Zhang J, Wu J. CoCo-ST detects global and local biological structures in spatial transcriptomics datasets. Nat Cell Biol, 2025. e-Pub 2025. PMID: 41083603.
11. Saad MB, Showkatian E, Verma V, Al-Tashi Q, Aminu M, Xu X, Qayati Mohamed M, Salehjahromi M, Sujit SJ, Kitsel Y, Lin SH MD,, Liao Z, Gandhi S, Qian D, Jaffray D, Chung C, Vokes NI, Zhang J, Lee JJ, Heymach JV, Wu J, Chang JY. Causal AI-based clinical and radiomic analysis for optimizing patient selection in combined immunotherapy and SABR in early-stage NSCLC: a secondary analysis of the phase II I-SABR trial. J Immunother Cancer 13(10), 2025. e-Pub 2025. PMID: 41052882.
12. Ozirmak Lermi N, Molina Ayala M, Hernandez S, Lu W, Khan K, Serrano A, Lubo I, Hamana L, Tomczak K, Barnes S, Dou J, Liang Q, Raso MG, Tang X, Jiang M, Sanchez-Espiridion B, Weissferdt A, Heymach J, Zhang J, Sepesi B, Cascone T, Tsao A, Altan M, Mehran R, Gibbons D, Wistuba I, Haymaker C, Chen K, Solis Soto LM. Comparison of imaging based single-cell resolution spatial transcriptomics profiling platforms using formalin-fixed paraffin-embedded tumor samples. Nat Commun 16(1):8499, 2025. e-Pub 2025. PMID: 41006245.
13. Nofal S, J Ostrin E, Zhang J, Wu J, Scheet P, Antonoff MB, V Heymach J, Toumazis I. Risk of second primary lung cancer among cancer survivors stratified by the site of first primary cancer and the lung cancer screening eligibility status. Int J Cancer 157(5):941-953, 2025. e-Pub 2025. PMID: 40249102.
14. Lin JK, Niu J, Giordano SH, Li P, Snyder RA, Liao K, Li M, Aparicio A, Chapin W, Zhang J, Xiang J, Perera N, Pain D, Guerra CE, Doshi JA. Racial and Ethnic Disparities Along the Treatment Cascade Among Medicare Fee-for-Service Beneficiaries With Metastatic Breast, Colorectal, Lung, and Prostate Cancers. J Clin Oncol:JCO2402440. e-Pub 2025. PMID: 40865035.
15. Waqas M, Bandyopadhyay R, Showkatian E, Muneer A, Zafar A, Alvarez FR, Marin MC, Li W, Jaffray D, Haymaker C, Heymach J, Vokes NI, Soto LMS, Zhang J, Wu J. The Next Layer: Augmenting Foundation Models with Structure-Preserving and Attention-Guided Learning for Local Patches to Global Context Awareness in Computational Pathology. ArXiv, 2025. e-Pub 2025. PMID: 40909163.
16. Pecci F, Li H, Di Federico A, Wu J, Chen H, Gariazzo E, Mantuano F, Garbo E, Aldea M, Santo V, Gibbons D, Tran H, Paoloni F, Rossato de Almeida G, Metro G, De Giglio A, Gelsomino F, Wang X, Tiseo M, Rotow J, Ardizzoni A, Lee JJ, Awad MM, Addeo A, Hong L, Negrao MV, Janne PA, Heymach JV, Zhang J, Ricciuti B, Le X. First-line MET tyrosine kinase inhibitors versus immunotherapy +/- chemotherapy for patients with MET exon 14 skipping mutant metastatic NSCLC. Clin Cancer Res. e-Pub 2025. PMID: 40864503.
17. Zhang B, Shah KB, Parma M, Wang K, Singhi EK, Lewis W, Rivera M, Altan M, Pozadzides J, Le X, Vokes N, Fossella F, O'Brien B, Wang C, Tom MC, Beckham T, Swanson T, Bronk J, Lin SH, Vega MF, Jacome J, Halliday A, Negrao M, Zhang J, Gibbons DL, Heymach JV, Byers LA, Gay CM. Rapid Intracranial Response With Tarlatamab in Patients With Untreated Brain Metastases From SCLC-A Real-World Case Series: Case Report. J Thorac Oncol 20(8):1131-1138, 2025. e-Pub 2025. PMID: 40126456.
18. Li J, Chi Y, Jia B, Zheng Q, Yuan M, Zhang J, Zhou A, Sun W, Yang Y, Zhao J, An T, Wang Y, Zhuo M, Yang X, Chen H, Wang J, Zhai X, Tai Y, He Y, Kong L, Ji X, Liu Y, Wu N, Onodera K, Schil PV, Thomas M, Yang F, Wang Z. Prognostic significance of micropapillary pattern and risk factors in patients with resected stage I lung adenocarcinoma and possible benefit of adjuvant therapy: a real-world multicenter study. Transl Lung Cancer Res 14(7):2760-2770, 2025. e-Pub 2025. PMID: 40799419.
19. Hong L, Di Federico A, Liu B, Cooper AJ, Alessi JV, Clark P, Rinsurongkawong W, Young C, Li H, Qin K, Aminu M, Santo V, Elamin Y, Sepesi B, Lewis J, Gibbons DL, Vaporciyan AA, Lee JJ, Le X, Wu J, Roy-Chowdhuri S, Routbort MJ, Futreal PA, Heymach JV, Awad MM, Schoenfeld AJ, Zhang J, Ricciuti B, Deng L, Vokes NI. Distinct Clinicogenomic Features and Immunotherapy Associations in Pulmonary Sarcomatoid Carcinoma: A Multicenter Retrospective Study. J Thorac Oncol, 2025. e-Pub 2025. PMID: 40716572.
20. Saad MB, Al-Tashi Q, Hong L, Verma V, Li W, Boiarsky D, Li S, Petranovic M, Wu CC, Carter BW, Shroff GS, Cascone T, Le X, Elamin YY, Altan M, Heeke S, Sheshadri A, Chang JY, Lee PP, Liao Z, Gibbons DL, Vaporciyan AA, Lee JJ, Wistuba II, Haymaker C, Mirjalili S, Jaffray D, Gainor JF, Lou Y, Di Federico A, Pecci F, Awad M, Ricciuti B, Heymach JV, Vokes NI, Zhang J, Wu J. Machine-learning driven strategies for adapting immunotherapy in metastatic NSCLC. Nat Commun 16(1):6828, 2025. e-Pub 2025. PMID: 40707438.
21. Patel SP, Fisher J, Chae YK, Soto LS, Kasi A, Konda B, Walshauser M, Parra E, Zhang J, Duault C, Gonzalez-Kozlova E, Manyam G, Zhang J, Chen H, Duose DY, Laberiano Fernandez C, Luthra R, Al-Atrash G, Kim-Schulze S, Maecker HT, Wistuba II, Gnjatic S, Lee JJ, Zhang J, Magner CM, Chen HX, Sharon E, Othus M, Ryan CW, Blanke C, Haymaker CL, Kurzrock R. Phase II basket trial of Dual Anti-CTLA-4 and anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: pancreatic neuroendocrine neoplasm (PNEN) cohort. J Immunother Cancer 13(6), 2025. e-Pub 2025. PMID: 40588371.
22. Mitchell KG, Lee Y, Deboever N, Negrao MV, Tran HT, Parra E, Byers L, Reuben A, Federico L, Bernatchez C, Wang J, Antonoff MB, Vaporciyan AA, Swisher SG, Cascone T, Wistuba II, Heymach JV, Gibbons DL, Zhang J, McGrail DJ, Sepesi B, Haymaker CL. Intratumoral neutrophil-to-lymphocyte ratio is mirrored by circulating neutrophil-to-lymphocyte ratio in non-small cell lung cancer. J Immunother Cancer 13(6), 2025. e-Pub 2025. PMID: 40555561.
23. Zhu B, Chen P, Aminu M, Li JR, Fujimoto J, Tian Y, Hong L, Chen H, Hu X, Li C, Vokes N, Moreira AL, Gibbons DL, Solis Soto LM, Parra Cuentas ER, Shi O, Diao S, Ye J, Rojas FR, Vilar E, Maitra A, Chen K, Navin N, Nilsson M, Huang B, Heeke S, Zhang J, Haymaker CL, Velcheti V, Sterman DH, Kochat V, Padron WI, Alexandrov LB, Wei Z, Le X, Wang L, Fukuoka J, Lee JJ, Wistuba II, Pass HI, Davis M, Hanash S, Cheng C, Dubinett S, Spira A, Rai K, Lippman SM, Futreal PA, Heymach JV, Reuben A, Wu J, Zhang J. Spatial and multiomics analysis of human and mouse lung adenocarcinoma precursors reveals TIM-3 as a putative target for precancer interception. Cancer Cell 43(6):1125-1140.e10, 2025. e-Pub 2025. PMID: 40345189.
24. Li H, Salehjahromi M, Godoy MCB, Qin K, Plummer CM, Zhang Z, Hong L, Heeke S, Le X, Vokes N, Zhang B, Araujo HA, Altan M, Wu CC, Antonoff MB, Ostrin EJ, Gibbons DL, Heymach JV, Lee JJ, Gerber DE, Wu J, Zhang J. Lung Cancer Risk Prediction in Patients with Persistent Pulmonary Nodules Using the Brock Model and Sybil Model. Cancers (Basel) 17(9), 2025. e-Pub 2025. PMID: 40361426.
25. Xunhui Cai, Jennifer Y. Cho, Lijun Chen, Yufeng Liu, Fenghu Ji, Katia Salgado, Siyi Ge, Dehua Yang, Hui Yu, Jianbo Shao, P. Andrew Futreal, Boris Sepesi, Don Gibbons, Yaobing Chen, Guoping Wang, Chao Cheng, Meng Wu, Jianjun Zhang, Ansel Hsiao, Tian Xia. Enriched pathways in the gut microbiome predict response to immune checkpoint inhibitor treatment across demographic regions and various cancer types. e-Pub 2025.
26. Altan, M, Sui, D, Xu, C, Simon, GR, Sulihem, ST, Malveaux, D, Ponce, D, Rinsurongkawong, W, Rinsurongkawong, V, Lee, JJ, Zhang, J, Gibbons, DL, Vaporciyan, AA, Heymach, JV, Santorelli, ML, Burke, T, Williams, LA. PD-L1 Testing, Treatment Patterns, and Clinical Outcomes Among Patients with Metastatic NSCLC at an Academic Medical Center, 2017–2021, 2025. e-Pub 2025. PMID: 40235643.
27. Di Federico A, Hong L, Elkrief A, Thummalapalli R, Cooper AJ, Ricciuti B, Digumarthy S, Alessi JV, Gogia P, Pecci F, Makarem M, Gandhi MM, Garbo E, Saini A, De Giglio A, Favorito V, Scalera S, Cipriani L, Marinelli D, Haradon D, Nguyen T, Haradon J, Voligny E, Vaz V, Gelsomino F, Sperandi F, Melotti B, Ladanyi M, Zhang J, Gibbons DL, Heymach JV, Nishino M, Lindsay J, Rodig SJ, Pfaff K, Sholl LM, Wang X, Johnson BE, Janne PA, Rekhtman N, Maugeri-Sacca M, Heist RS, Ardizzoni A, Awad MM, Arbour KC, Schoenfeld AJ, Vokes NI, Luo J. Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRAS(G12C) inhibitors. Ann Oncol 36(3):297-308, 2025. e-Pub 2025. PMID: 39637943.
28. Roudko, V, Del Valle, DM, Radkevich, E, Kelly, G, Hui, X, Patel, M, Gonzalez-Kozlova, E, Tuballes, K, Streicher, H, Atale, S, Wang, LI, Czinczin, B, Kim-Schulze, S, Wistuba, II, Haymaker, CL, Al-Atrash, G, Manyam, GC, Zhang, J, Thompson, R, Suárez-Fariñas, M, Lheureux, S, Gnjatic, S. Immunological biomarkers of response and resistance to treatment with cabozantinib and nivolumab in recurrent endometrial cancer. Journal for immunotherapy of cancer 13(2), 2025. e-Pub 2025. PMID: 40010771.
29. Le, X, Patel, JD, Shum, E, Baik, C, Sanborn, RE, Shu, CA, Kim, C, Fidler, MJ, Hall, R, Elamin, YY, Tu, J, Blumenschein, GR, Zhang, J, Gibbons, DL, Gay, CM, Mohindra, N, Chae, YK, Boumber, YA, Sabari, JK, Santana-Davila, R, Rogosin, S, Herzberg, B, Creelan, BC, Pellini, B, Tanvetyanon, T, Heeke, S, Hernandez, M, Gray, J, Saltos, A, Heymach, JV. A Multicenter Open-Label Randomized Phase II Study of Osimertinib with and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve EGFR -Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial). Journal of Clinical Oncology 43(4):403-411, 2025. e-Pub 2025. PMID: 39378386.
30. Lermi NO, Ayala MM, Ruiz SH, Lu W, Khan K, Serrano A, Lubo I, Hamana L, Tomczak K, Barnes S, Dou J, Liang Q, Raso MG, Tang X, Jiang M, Sanchez-Espiridion B, Weissferdt A, Heymach J, Zhang J, Sepesi B, Cascone T, Tsao A, Altan M, Mehran R, Gibbons D, Wistuba I, Haymaker C, Chen K, Solis Soto LM. Comparison of imaging-based single-cell resolution spatial transcriptomics profiling platforms using formalin-fixed, paraffin-embedded tumor samples. Res Sq, 2025. e-Pub 2025. PMID: 39877088.
31. Zhang J, Wang X, Dong J, Li JR, Lin Y, Sahoo B, Li Y, Liu Y, Ripley RT, Wu J, Amos CI, Cheng C. Cytotoxic and regulatory T cell interactions calculated from image mass cytometry predict immunochemotherapy response in triple-negative breast cancer. Cancer Commun (Lond), 2025. e-Pub 2025. PMID: 39749721.
32. Von Itzstein, MS, Liu, J, Mu-Mosley, H, Fattah, FJ, Park, JY, SoRelle, JA, Farrar, JD, Gwin, ME, Hsiehchen, D, Gloria-McCutchen, Y, Wakeland, E, Cole, S, Bhalla, S, Kainthla, R, Puzanov, I, Switzer, B, Daniels, GA, Zakharia, Y, Shaheen, M, Zhang, J, Xie, Y, Gerber, DE. Racial Differences in Systemic Immune Parameters in Individuals With Lung Cancer. JTO Clinical and Research Reports 6(1), 2025. e-Pub 2025. PMID: 39619775.
33. Altan, M, Li, R, Li, Z, Chen, R, Sheshadri, A, Tran, HT, Little, L, Baguley, J, Sinson, JC, Vokes, N, Gandhi, S, Antonoff, MB, Swisher, SG, Lizee, GA, Reuben, A, Heymach, JV, Zhang, J. High peripheral T cell diversity is associated with lower risk of toxicity and superior response to dual immune checkpoint inhibitor therapy in patients with metastatic NSCLC. Journal for immunotherapy of cancer 12(12), 2024. e-Pub 2024. PMID: 39721752.
34. Han, J, Dong, Y, Zhu, X, Reuben, A, Zhang, J, Xu, J, Bai, H, Duan, J, Wan, R, Zhao, J, Bai, J, Xia, X, Yi, X, Cheng, C, Wang, J, Wang, Z. Assessment of human leukocyte antigen-based neoantigen presentation to determine pan-cancer response to immunotherapy. Nature communications 15(1), 2024. e-Pub 2024. PMID: 38331912.
35. Jin, Y, Wu, Y, Reuben, A, Zhu, L, Gay, CM, Wu, Q, Zhou, X, Mo, H, Zheng, Q, Ren, J, Fang, Z, Peng, T, Wang, N, Ma, L, Fan, Y, Song, H, Zhang, J, Chen, M. Single-cell and spatial proteo-transcriptomic profiling reveals immune infiltration heterogeneity associated with neuroendocrine features in small cell lung cancer. Cell Discovery 10(1), 2024. e-Pub 2024. PMID: 39231924.
36. Xia Y, Wang K, Zhao J, Arter Z, Zhang Y, Zhou J, Lu Y, Zeng L, Du R, Owens JA, Elamin YY, Gay CM, Skoulidis F, Tsao AS, Lu C, Cascone T, Gibbons DL, Zhang J, Chen O, Mok KK, Nagasaka M, Li W, Heymach JV, Ignatius Ou SH, Li M, Le X. Receptor tyrosine kinase fusion-mediated resistance to EGFR-TKI in EGFR-mutant NSCLC: a multi-center analysis and literature review. J Thorac Oncol, 2024. e-Pub 2024. PMID: 39622411.
37. Skoulidis, F, Araujo, HA, Do, MT, Qian, Y, Sun, X, Cobo, AG, Le, JT, Montesion, M, Palmer, R, Jahchan, NS, Juan, J, Min, C, Yu, Y, Pan, X, Arbour, KC, Vokes, N, Schmidt, S, Molkentine, D, Owen, D, Memmott, R, Patil, P, Marmarelis, ME, Awad, MM, Murray, J, Hellyer, JA, Gainor, J, Dimou, A, Bestvina, CM, Shu, CA, Riess, JW, Blakely, CM, Pecot, CV, Mezquita, L, Tabbò, F, Scheffler, M, Digumarthy, S, Mooradian, MJ, Sacher, A, Lau, SC, Saltos, A, Rotow, JK, Johnson, RP, Liu, C, Stewart, TF, Goldberg, SB, Killam, J, Walther, Z, Schalper, K, Davies, KD, Woodcock, MG, Anagnostou, V, Marrone, KA, Forde, PM, Ricciuti, B, Venkatraman, D, Van Allen, EM, Cummings, AL, Goldman, JW, Shaish, H, Kier, M, Katz, S, Aggarwal, C, Ni, Y, Azok, J, Segal, J, Ritterhouse, LL, Neal, JW, Lacroix, L, Elamin, YY, Vailati Negrao, M, Le, X, Lam, VK, Lewis, WE, Kemp, HN, Carter, B, Roth, JA, Swisher, SG, Lee, R, Zhou, T, Poteete, A, Kong, Y, Takehara, T, Paula, AG, Parra Cuentas, ER, Behrens, C, Wistuba, II, Zhang, J, Blumenschein, GR, Gay, CM, Byers, LA, Gibbons, DL, Tsao, A, Lee, JJ, Bivona, T, Camidge, DR, Gray, J, Lieghl, N, Levy, BP, Brahmer, JR, Garassino, MC, Gandara, D, Garon, EB, Rizvi, NA, Scagliotti, G, Wolf, J, Planchard, D, Besse, B, Herbst, RS, Wakelee, HA, Pennell, N, Shaw, AT, Jänne, PA, Carbone, DP, Hellmann, MD, Rudin, CM, Albacker, LA, Mann, H, Zhu, Z, Lai, Z, Stewart, RA, Peters, S, Johnson, M, Wong, KK, Huang, A, Winslow, MM, Rosen, MJ, Winters, IP, Papadimitrakopoulou, VA, Cascone, T, Jewsbury, P, Heymach, JV. CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature 635(8038):462-471, 2024. e-Pub 2024. PMID: 39385035.
38. Araujo, HA, Pechuan-Jorge, X, Zhou, T, Do, MT, Hu, X, Rojas Alvarez, F, Salvatierra De Aranguren, M, Ibarguen, H, Lee, R, Raghulan, R, Shah, H, Ayala, MA, Chen, K, Tovbis Shifrin, N, Wu, S, Solis Soto, LM, Vailati Negrao, M, Gibbons, DL, Hong, DS, Roth, JA, Heymach, JV, Zhang, J, Jiang, J, Singh, M, Smith, JA, Quintana, E, Skoulidis, F. Mechanisms of Response and Tolerance to Active RAS Inhibition in KRAS-Mutant Non–Small Cell Lung Cancer. Cancer discovery 14(11):2183-2208, 2024. e-Pub 2024. PMID: 38975897.
39. Zhou, N, Leung, CH, William Jr, WN, Weissferdt, A, Pataer, A, Godoy, M, Carter, B, Fossella, FV, Tsao, A, Blumenschein, GR, Le, X, Zhang, J, Skoulidis, F, Kurie, JM, Altan, M, Lu, C, Glisson, BS, Byers, LA, Elamin, YY, Mehran, RJ, Rice, DC, Walsh, GL, Hofstetter, WL, Roth, JA, Tran, HT, Wu, J, Solis Soto, LM, Kadara, HN, Swisher, SG, Vaporciyan, AA, Gibbons, DL, Lin, HY, Jack Lee, J, Heymach, JV, Vailati Negrao, M, Sepesi, B, Cascone, T. Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer. Journal for immunotherapy of cancer 12(10), 2024. e-Pub 2024. PMID: 39448200.
40. Li C, Nguyen TT, Li JR, Song X, Fujimoto J, Little L, Gumb C, Chow CB, Wistuba II, Futreal AP, Zhang J, Hubert SM, Heymach JV, Wu J, Amos CI, Zhang J, Cheng C. Multiregional transcriptomic profiling provides improved prognostic insight in localized non-small cell lung cancer. NPJ Precis Oncol 8(1):225, 2024. e-Pub 2024. PMID: 39369068.
41. Hong L, Patel S, Drusbosky LM, Xiong Y, Chen R, Geng R, Heeke S, Nilsson M, Wu J, Heymach JV, Wang Y, Zhang J, Le X. Molecular landscape of ERBB2 alterations in 3000 advanced NSCLC patients. NPJ Precis Oncol 8(1):217, 2024. e-Pub 2024. PMID: 39354054.
42. Pan, K, Owens, J, Elamin, YY, Lu, C, Routbort, MJ, Zhang, J, Fossella, FV, Vailati Negrao, M, Altan, M, Pozadzides, JV, Skoulidis, F, Tsao, A, Cascone, T, Heymach, JV, Ostrin, EJ, Le, X. Mutational Characteristics and Clinical Outcomes for Lung Adenocarcinoma With EGFR Germline Mutations. Journal of Thoracic Oncology 19(10):1438-1448, 2024. e-Pub 2024. PMID: 38866326.
43. Ricciuti, B, Elkrief, A, Lin, JJ, Zhang, J, Alessi, JV, Lamberti, G, Gandhi, M, Di Federico, A, Pecci, F, Wang, X, Makarem, M, Murilo Hidalgo Filho, C, Gorria, T, Saini, A, Pabon, CM, Lindsay, J, Pfaff, KL, Welsh, EL, Nishino, M, Sholl, LM, Rodig, SJ, Kiliçkap, S, Rietschel, P, McIntyre, DA, Pouliot, JF, Altan, M, Gainor, J, Heymach, JV, Schoenfeld, AJ, Awad, MM. Three-Year Overall Survival Outcomes and Correlative Analyses in Patients With NSCLC and High (50%–89%) Versus Very High (≥90%) Programmed Death-Ligand 1 Expression Treated With First-Line Pembrolizumab or Cemiplimab. JTO Clinical and Research Reports 5(9), 2024. e-Pub 2024. PMID: 39399157.
44. Feng H, Wu L, Zhao B, Huff C, Zhang J, Wu J, Lin L, Wei P, Wu C. Benchmarking DNA Foundation Models for Genomic Sequence Classification. bioRxiv, 2024. e-Pub 2024. PMID: 39185205.
45. Li C, Hong W, Reuben A, Wang L, Maitra A, Zhang J, Cheng C. TimiGP-Response: the pan-cancer immune landscape associated with response to immunotherapy. bioRxiv, 2024. e-Pub 2024. PMID: 38979334.
46. Zhang, B, Li, C, Wu, J, Zhang, J, Cheng, C. DeepCG. International journal of cancer 154(12):2151-2161, 2024. e-Pub 2024. PMID: 38429627.
47. Li, Y, Ji, L, Zhang, Y, Zhang, J, Reuben, A, Zeng, H, Huang, Q, Wei, Q, Tan, S, Xia, X, Li, W, Zhang, J, Tian, P. The combination of tumor mutational burden and T-cell receptor repertoire predicts the response to immunotherapy in patients with advanced non–small cell lung cancer. MedComm 5(6), 2024. e-Pub 2024. PMID: 38840771.
48. Seth, S, Chen, R, Liu, Y, Fujimoto, J, Hong, L, Reuben, A, Varghese, S, Behrens, MC, McDowell, TL, Solis Soto, LM, Haymaker, CL, Weissferdt, A, Kalhor, N, Wu, J, Le, X, Vokes, N, Cheng, C, Heymach, JV, Gibbons, DL, Futreal, A, Wistuba, II, Kadara, HN, Zhang, J, Moran, C, Zhang, J. Integrative genomic and transcriptomic profiling of pulmonary sarcomatoid carcinoma identifies molecular subtypes associated with distinct immune features and clinical outcomes. Cancer Innovation 3(3), 2024. e-Pub 2024. PMID: 38947760.
49. Aminu M, Zhu B, Vokes N, Chen H, Hong L, Li J, Fujimoto J, Yang Y, Wang T, Wang B, Poteete A, Nilsson MB, Le X, Tina C, Jaffray D, Navin N, Byers LA, Gibbons D, Heymach J, Chen K, Cheng C, Zhang J, Wu J. CoCo-ST: Comparing and Contrasting Spatial Transcriptomics data sets using graph contrastive learning. Res Sq, 2024. e-Pub 2024. PMID: 38826463.
50. Aminu M, Hong L, Vokes N, Schmidt ST, Saad M, Zhu B, Le X, Tina C, Sheshadri A, Wang B, Jaffray D, Futreal A, Lee JJ, Byers LA, Gibbons D, Heymach J, Chen K, Cheng C, Zhang J, Wu J. Joint multi-omics discriminant analysis with consistent representation learning using PANDA. Res Sq, 2024. e-Pub 2024. PMID: 38798352.
51. Hu X, Zhu B, Vokes N, Fujimoto J, Rojas Alvarez FR, Heeke S, Moreira AL, Solis LM, Haymaker C, Velcheti V, Sterman DH, Pass HI, Cheng C, Lee JJ, Zhang J, Wei Z, Wu J, Le X, Ostrin E, Toumazis I, Gibbons D, Su D, Fukuoka J, Antonoff MB, Gerber DE, Li C, Kadara H, Wang L, Davis M, Heymach JV, Hannash S, Wistuba I, Dubinett S, Alexandrov L, Lippman S, Spira A, Futreal AP, Reuben A, Zhang J. The evolution of lung adenocarcinoma precursors is associated with chromosomal instability and transition from innate to adaptive immune response/evasion. Res Sq, 2024. e-Pub 2024. PMID: 38798564.
52. Parra Cuentas, ER, Zhang, J, Duose, D, Gonzalez-Kozlova, E, Redman, MW, Chen, H, Manyam, GC, Kumar, G, Zhang, J, Song, X, Segura Lazcano, R, Marques-Piubelli, ML, Laberiano Fernandez, C, Rojas Alvarez, F, Zhang, B, Taing, L, Jhaveri, A, Geisberg, J, Altreuter, J, Michor, F, Provencher, J, Yu, J, Cerami, E, Moravec, R, Kannan, KS, Luthra, R, Alatrash, G, Huang, HH, Xie, H, Patel, M, Nie, K, Harris, J, Argueta, K, Lindsay, J, Biswas, R, Van Nostrand, S, Kim-Schulze, S, Gray, J, Herbst, RS, Wistuba, II, Gettinger, S, Kelly, K, Bazhenova, LA, Gnjatic, S, Lee, JJ, Zhang, J, Haymaker, CL. Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial. Clinical Cancer Research 30(8):1655-1668, 2024. e-Pub 2024. PMID: 38277235.
53. Sujit SJ, Aminu M, Karpinets TV, Chen P, Saad MB, Salehjahromi M, Boom JD, Qayati M, George JM, Allen H, Antonoff MB, Hong L, Hu X, Heeke S, Tran HT, Le X, Elamin YY, Altan M, Vokes NI, Sheshadri A, Lin J, Zhang J, Lu Y, Behrens C, Godoy MCB, Wu CC, Chang JY, Chung C, Jaffray DA, Wistuba II, Lee JJ, Vaporciyan AA, Gibbons DL, Heymach J, Zhang J, Cascone T, Wu J. Enhancing NSCLC recurrence prediction with PET/CT habitat imaging, ctDNA, and integrative radiogenomics-blood insights. Nat Commun 15(1):3152, 2024. e-Pub 2024. PMID: 38605064.
54. Salehjahromi, M, Karpinets, T, Sujit, S, Qayati, M, Chen, P, Aminu, M, Saad, MB, Bandyopadhyay, R, Hong, L, Sheshadri, A, Lin, J, Antonoff, MB, Sepesi, B, Ostrin, EJ, Toumazis, I, Huang, P, Cheng, C, Cascone, T, Vokes, N, Behrens, C, Siewerdsen, JH, Hazle, JD, Chang, JY, Zhang, J, Lu, Y, Godoy, M, Chung, C, Jaffray, D, Wistuba, II, Lee, JJ, Vaporciyan, AA, Gibbons, DL, Gladish, G, Heymach, JV, Wu, CC, Zhang, J, Wu, J. Synthetic PET from CT improves diagnosis and prognosis for lung cancer. Cell Reports Medicine 5(3), 2024. e-Pub 2024. PMID: 38471502.
55. Qin, K, Wang, K, Li, S, Hong, L, Padmakumar, P, Waree, R, Hubert, SM, Le, X, Vokes, N, Rai, K, Vaporciyan, AA, Gibbons, DL, Heymach, JV, Lee, JJ, Woodman, SE, Chung, C, Jaffray, D, Altan, M, Lou, Y, Zhang, J. Clinical Benefit from Docetaxel +/− Ramucirumab Is Not Associated with Mutation Status in Metastatic Non-Small-Cell Lung Cancer Patients Who Progressed on Platinum Doublets and Immunotherapy. Cancers 16(5), 2024. e-Pub 2024. PMID: 38473297.
56. Nofal, S, Niu, J, Resong, PJ, Jin, J, Merriman, K, Le, X, Katki, HA, Heymach, JV, Antonoff, MB, Ostrin, EJ, Wu, J, Zhang, J, Toumazis, I. Personal history of cancer as a risk factor for second primary lung cancer. Cancer medicine 13(5), 2024. e-Pub 2024. PMID: 38466021.
57. Wang K, Du R, Myall NJ, Lewis WE, Uy N, Hong L, Skoulidis F, Byers LA, Tsao A, Cascone T, Pozadzides J, Tu J, Negrao MV, Gibbons DL, Park K, Rinsurongkawong W, Lee JJ, Gandara D, Behl D, Shu CA, Riess JW, Baik C, Wakelee HA, Vaporciyan AA, Heymach JV, Zhang J, Le X. Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC. J Thorac Oncol 19(3):500-506, 2024. e-Pub 2024. PMID: 38012986.
58. Heeke, S, Gay, CM, Estecio, MR, Tran, HT, Morris, BB, Zhang, B, Tang, X, Raso, G, Rocha, P, Lai, S, Arriola, E, Hofman, P, Hofman, V, Kopparapu, P, Lovly, CM, Concannon, K, Guimares de Sousa, L, Lewis, WE, Kondo, K, Hu, X, Tanimoto, A, Vokes, N, Nilsson, M, Stewart, C, Jansen, M, Horváth, I, Gaga, M, Panagoulias, V, Raviv, Y, Frumkin, D, Wasserstrom, A, Shuali, A, Schnabel, CA, Xi, Y, Diao, L, Wang, Q, Zhang, J, Van Loo, P, Wang, J, Wistuba, II, Byers, LA, Heymach, JV. Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypes. Cancer cell 42(2):225-237.e5, 2024. e-Pub 2024. PMID: 38278149.
59. Tran, HT, Heeke, S, Sujit, S, Vokes, N, Zhang, J, Aminu, M, Lam, VK, Vaporciyan, AA, Swisher, SG, Godoy, M, Cascone, T, Sepesi, B, Gibbons, DL, Wu, J, Heymach, JV. Circulating tumor DNA and radiological tumor volume identify patients at risk for relapse with resected, early-stage non-small-cell lung cancer. Annals of Oncology 35(2):183-189, 2024. e-Pub 2024. PMID: 37992871.
60. Wang, X, Bai, H, Zhang, J, Wang, Z, Duan, J, Cai, H, Cao, Z, Lin, Q, Ding, X, Sun, Y, Zhang, W, Xu, X, Chen, H, Zhang, D, Feng, X, Wan, J, Zhang, J, He, J, Wang, J. Genetic Intratumor Heterogeneity Remodels the Immune Microenvironment and Induces Immune Evasion in Brain Metastasis of Lung Cancer. Journal of Thoracic Oncology 19(2):252-272, 2024. e-Pub 2024. PMID: 37717855.
61. Zhang, B, Lewis, WE, Stewart, C, Morris, BB, Solis Soto, LM, Serrano, A, Xi, Y, Wang, Q, Lopez, ER, Concannon, K, Heeke, S, Tang, X, Raso, G, Cardnell, R, Vokes, N, Blumenschein, GR, Elamin, YY, Fosella, F, Tsao, A, Skoulidis, F, Hume, CB, Sasak, K, Lewis, J, Rinsurongkawong, W, Rinsurongkawong, V, Lee, JJ, Tran, HT, Zhang, J, Gibbons, DL, Vaporciyan, AA, Wang, J, Park, K, Heymach, JV, Byers, LA, Gay, CM, Le, X. Brief Report. JTO Clinical and Research Reports 5(2), 2024. e-Pub 2024. PMID: 38357092.
62. Li, H, Hu, X, Ning, M, Fuller, GN, Stewart, J, Gilliam, JC, Wu, J, Le, X, Vaporciyan, AA, Lee, JJ, Gibbons, DL, Heymach, JV, Futreal, A, Zhang, J. Case report : Molecular profiling facilitates the diagnosis of a challenging case of lung cancer with choriocarcinoma features. Frontiers in Oncology 14, 2024. e-Pub 2024. PMID: 38590653.
63. Li, C, Zhang, J, Cheng, C. TimiGP. STAR Protocols 4(4), 2023. e-Pub 2023. PMID: 38019649.
64. Chen, P, Rojas Alvarez, F, Hu, X, Serrano, A, Zhu, B, Chen, H, Hong, L, Bandyoyadhyay, R, Aminu, M, Kalhor, N, Lee, JJ, El Hussein, S, Khoury, J, Pass, HI, Moreira, AL, Velcheti, V, Sterman, DH, Fukuoka, J, Tabata, K, Su, D, Ying, L, Gibbons, DL, Heymach, JV, Wistuba, II, Fujimoto, J, Solis Soto, LM, Zhang, J, Wu, J. Pathomic Features Reveal Immune and Molecular Evolution From Lung Preneoplasia to Invasive Adenocarcinoma. Modern Pathology 36(12), 2023. e-Pub 2023. PMID: 37678674.
65. Altan M, Soto F, Zhong LL, Akhmedzhanov FO, Wilson NR, Zarifa A, Albittar AA, Yang V, Lewis J, Rinsurongkawong W, Jack Lee J, Rinsurongkawong V, Zhang J, Gibbons DL, Vaporciyan AA, Jennings K, Khawaja F, Faiz SA, Shannon VR, Shroff G, Godoy MCB, Daver NG, Gandhi S, Mendoza TR, Naing A, Daniel-MacDougall C, Heymach JV, Sheshadri A. Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A Single Center Experience. Oncologist, 2023. e-Pub 2023. PMID: 37156009.
66. Thummalapalli R, Ricciuti B, Bandlamudi C, Muldoon D, Rizvi H, Elkrief A, Luo J, Alessi JV, Pecci F, Lamberti G, Di Federico A, Hong L, Zhang J, Heymach JV, Gibbons DL, Plodkowski AJ, Ravichandran V, Donoghue MTA, Vanderbilt C, Ladanyi M, Rudin CM, Kris MG, Riely GJ, Chaft JE, Hellmann MD, Vokes NI, Awad MM, Schoenfeld AJ. Clinical and molecular features of long-term response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer. Clin Cancer Res, 2023. e-Pub 2023. PMID: 37432985.
67. Yang P, Hubert SM, Futreal PA, Song X, Zhang J, Lee JJ, Wistuba I, Yuan Y, Zhang J, Li Z. A novel Bayesian model for assessing intratumor heterogeneity of tumor infiltrating leukocytes with multi-region gene expression sequencing. bioRxiv, 2023. e-Pub 2023. PMID: 37961165.
68. Gan, J, Wang, H, Yu, H, He, Z, Zhang, W, Ma, K, Zhu, L, Bai, Y, Zhou, Z, Yullie, A, Bai, X, Wang, MW, Yang, D, Chen, Y, Chen, G, Lasenby, J, Cheng, C, Wu, J, Zhang, J, Wang, X, Chen, Y, Wang, G, Xia, T. Focalizing regions of biomarker relevance facilitates biomarker prediction on histopathological images. iScience 26(10), 2023. e-Pub 2023. PMID: 37767002.
69. Diao, S, Chen, P, Showkatian, E, Bandyopadhyay, R, Rojas Alvarez, F, Zhu, B, Hong, L, Aminu, M, Saad, MB, Salehjahromi, M, Muneer, A, Sujit, S, Behrens, MC, Gibbons, DL, Heymach, JV, Kalhor, N, Wistuba, II, Solis Soto, LM, Zhang, J, Qin, W, Wu, J. Automated Cellular-Level Dual Global Fusion of Whole-Slide Imaging for Lung Adenocarcinoma Prognosis. Cancers 15(19), 2023. e-Pub 2023. PMID: 37835518.
70. Ying, L, Zhang, C, Reuben, A, Tian, Y, Jin, J, Wang, C, Bai, J, Liu, X, Fang, J, Feng, T, Xu, C, Zhu, R, Huang, M, Lyu, Y, Lu, TT, Pan, X, Zhang, J, Su, D. Immune-active tumor-adjacent tissues are associated with favorable prognosis in stage I lung squamous cell carcinoma. iScience 26(9), 2023. e-Pub 2023. PMID: 37694148.
71. Chang JY, Lin SH, Dong W, Liao Z, Gandhi SJ, Gay CM, Zhang J, Chun SG, Elamin YY, Fossella FV, Blumenschein G, Cascone T, Le X, Pozadzides JV, Tsao A, Verma V, Welsh JW, Chen AB, Altan M, Mehran RJ, Vaporciyan AA, Swisher SG, Balter PA, Fujimoto J, Wistuba II, Feng L, Lee JJ, Heymach JV. Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet, 2023. e-Pub 2023. PMID: 37478883.
72. Konen, JM, Rodriguez, B, Wu, H, Fradette, JJ, Gibson, L, Diao, L, Wang, J, Schmidt, S, Wistuba, II, Zhang, J, Gibbons, DL. Autotaxin suppresses cytotoxic T cells via LPAR5 to promote anti-PD-1 resistance in non-small cell lung cancer. Journal of Clinical Investigation 133(17), 2023. e-Pub 2023. PMID: 37655662.
73. Wang, K, Kumar, T, Wang, J, Minussi, DC, Sei, E, Li, J, Tran, TM, Thennavan, A, Hu, M, Casasent, A, Xiao, Z, Bai, S, Yang, L, King, LM, Shah, V, Kristel, P, van der Borden, CL, Marks, JR, Zhao, Y, Zurita-Saavedra, A, Aparicio, A, Chapin, BF, Ye, J, Zhang, J, Gibbons, DL, Sawyer, EJ, Thompson, A, Futreal, A, Hwang, ES, Wesseling, J, Lips, EH, Navin, N. Archival single-cell genomics reveals persistent subclones during DCIS progression. Cell 186(18):3968-3982.e15, 2023. e-Pub 2023. PMID: 37586362.
74. Al Tashi, Q, Saad, MB, Sheshadri, A, Wu, CC, Chang, JY, Al-Lazikani, B, Gibbons, C, Vokes, N, Zhang, J, Lee, JJ, Heymach, JV, Jaffray, D, Mirjalili, S, Wu, J. SwarmDeepSurv: swarm intelligence advances deep survival network for prognostic radiomics signatures in four solid cancers. Patterns 4(8), 2023. e-Pub 2023. PMID: 37602223.
75. Wang, K, Du, R, Roy Chowdhuri, S, Li, ZT, Hong, L, Vokes, N, Elamin, YY, Bueno Hume, C, Skoulidis, F, Gay, CM, Blumenschein, GR, Fossella, FV, Tsao, A, Zhang, J, Karachaliou, N, O'Brate, A, Gann, CN, Lewis, J, Rinsurongkawong, W, Lee, JJ, Gibbons, DL, Vaporciyan, AA, Heymach, JV, Altan, M, Le, X. Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC. JTO Clinical and Research Reports 4(8), 2023. e-Pub 2023. PMID: 37649681.
76. Li R, Altan M, Reuben A, Lin R, Heymach JV, Tran H, Chen R, Little L, Hubert S, Zhang J, Li Z. A novel statistical method for decontaminating T-cell receptor sequencing data. Brief Bioinform, 2023. e-Pub 2023. PMID: 37337757.
77. Li C, Zhang B, Schaafsma E, Reuben A, Wang L, Turk MJ, Zhang J, Cheng C. TimiGP: Inferring cell-cell interactions and prognostic associations in the tumor immune microenvironment through gene pairs. Cell Rep Med 4(7):101121, 2023. e-Pub 2023. PMID: 37467716.
78. Xiao GY, Tan X, Rodriguez BL, Gibbons DL, Wang S, Wu C, Liu X, Yu J, Vasquez ME, Tran HT, Xu J, Russell WK, Haymaker C, Lee Y, Zhang J, Solis L, Wistuba II, Kurie JM. EMT activates exocytotic Rabs to coordinate invasion and immunosuppression in lung cancer. Proc Natl Acad Sci U S A 120(28):e2220276120, 2023. e-Pub 2023. PMID: 37406091.
79. Negrao MV, Araujo HA, Lamberti G, Cooper AJ, Akhave NS, Zhou T, Delasos L, Hicks JK, Aldea M, Minuti G, Hines J, Aredo JV, Dennis MJ, Chakrabarti T, Scott SC, Bironzo P, Scheffler M, Christopoulos P, Stenzinger A, Riess JW, Kim SY, Goldberg SB, Li M, Wang Q, Qing Y, Ni Y, Do MT, Lee R, Ricciuti B, Alessi JV, Wang J, Resuli B, Landi L, Tseng SC, Nishino M, Digumarthy SR, Rinsurongkawong W, Rinsurongkawong V, Vaporciyan AA, Blumenschein GR, Zhang J, Owen DH, Blakely CM, Mountzios G, Shu CA, Bestvina CM, Garassino MC, Marrone KA, Gray JE, Patel SP, Cummings AL, Wakelee HA, Wolf J, Scagliotti GV, Cappuzzo F, Barlesi F, Patil PD, Drusbosky L, Gibbons DL, Meric-Bernstam F, Lee JJ, Heymach JV, Hong DS, Heist RS, Awad MM, Skoulidis F. Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC. Cancer Discov 13(7):1556-1571, 2023. e-Pub 2023. PMID: 37068173.
80. Saad MB, Hong L, Aminu M, Vokes NI, Chen P, Salehjahromi M, Qin K, Sujit SJ, Lu X, Young E, Al-Tashi Q, Qureshi R, Wu CC, Carter BW, Lin SH, Lee PP, Gandhi S, Chang JY, Li R, Gensheimer MF, Wakelee HA, Neal JW, Lee HS, Cheng C, Velcheti V, Lou Y, Petranovic M, Rinsurongkawong W, Le X, Rinsurongkawong V, Spelman A, Elamin YY, Negrao MV, Skoulidis F, Gay CM, Cascone T, Antonoff MB, Sepesi B, Lewis J, Wistuba II, Hazle JD, Chung C, Jaffray D, Gibbons DL, Vaporciyan A, Lee JJ, Heymach JV, Zhang J, Wu J. Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study. Lancet Digit Health 5(7):e404-e420, 2023. e-Pub 2023. PMID: 37268451.
81. Silver A, Ho C, Ye Q, Zhang J, Janzen I, Li J, Martin M, Wu L, Wang Y, Lam S, MacAulay C, Melosky B, Yuan R. Prediction of Disease Progression to Upfront Pembrolizumab Monotherapy in Advanced Non-Small-Cell Lung Cancer with High PD-L1 Expression Using Baseline CT Disease Quantification and Smoking Pack Years. Curr Oncol 30(6):5546-5559, 2023. e-Pub 2023. PMID: 37366902.
82. Xia Y, Jin R, Li M, Lan F, Zhu H, Yu Y, Miao D, Wang Q, Zhou Y, Selvaggi G, Ying S, Zhang J, Shen H, Le X, Li W. Potent antitumor activity of ensartinib in MET exon 14 skipping-mutated non-small cell lung cancer. Cancer Lett 561:216140, 2023. e-Pub 2023. PMID: 36948240.
83. Frank ML, Lu K, Erdogan C, Han Y, Hu J, Wang T, Heymach JV, Zhang J, Reuben A. T-Cell Receptor Repertoire Sequencing in the Era of Cancer Immunotherapy. Clin Cancer Res 29(6):994-1008, 2023. e-Pub 2023. PMID: 36413126.
84. Huang J, Zhao G, Peng Q, Yi X, Ji L, Li J, Li P, Guan Y, Ge J, Chen L, Chen R, Hu X, Lee WC, Reuben A, Futreal PA, Xia X, Ma J, Zhang J, Chen Z. Analysis of genomic and immune intratumor heterogeneity in linitis plastica via multiregional exome and T-cell receptor sequencing. Mol Oncol, 2023. e-Pub 2023. PMID: 36703611.
85. Cascone T, Leung CH, Weissferdt A, Pataer A, Carter BW, Godoy MCB, Feldman H, William WN, Xi Y, Basu S, Sun JJ, Yadav SS, Rojas Alvarez FR, Lee Y, Mishra AK, Chen L, Pradhan M, Guo H, Sinjab A, Zhou N, Negrao MV, Le X, Gay CM, Tsao AS, Byers LA, Altan M, Glisson BS, Fossella FV, Elamin YY, Blumenschein G, Zhang J, Skoulidis F, Wu J, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Rajaram R, Antonoff MB, Fujimoto J, Solis LM, Parra ER, Haymaker C, Wistuba II, Swisher SG, Vaporciyan AA, Lin HY, Wang J, Gibbons DL, Jack Lee J, Ajami NJ, Wargo JA, Allison JP, Sharma P, Kadara H, Heymach JV, Sepesi B. Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial. Nat Med 29(3):593-604, 2023. e-Pub 2023. PMID: 36928818.
86. William WN, Zhang J, Zhao X, Parra ER, Uraoka N, Lin HY, Peng SA, El-Naggar AK, Rodriguez-Canales J, Song J, Gillenwater AM, Wistuba II, Myers JN, Gold KA, Ferrarotto R, Hwu P, Davoli T, Lee JJ, Heymach JV, Papadimitrakopoulou VA, Lippman SM. Spatial PD-L1, immune-cell microenvironment, and genomic copy-number alteration patterns and drivers of invasive-disease transition in prospective oral precancer cohort. Cancer 129(5):714-727, 2023. e-Pub 2023. PMID: 36597662.
87. Hong L, Aminu M, Li S, Lu X, Petranovic M, Saad MB, Chen P, Qin K, Varghese S, Rinsurongkawong W, Rinsurongkawong V, Spelman A, Elamin YY, Negrao MV, Skoulidis F, Gay CM, Cascone T, Gandhi SJ, Lin SH, Lee PP, Carter BW, Wu CC, Antonoff MB, Sepesi B, Lewis J, Gibbons DL, Vaporciyan AA, Le X, Jack Lee J, Roy-Chowdhuri S, Routbort MJ, Gainor JF, Heymach JV, Lou Y, Wu J, Zhang J, Vokes NI. Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer. Nat Commun 14(1):695, 2023. e-Pub 2023. PMID: 36755027.
88. Hu, Q, Frank, ML, Gao, Y, Ji, L, Peng, M, Chen, C, Wang, B, Hu, Y, Wu, Z, Li, J, Shu, L, He, Q, Zhang, Y, Xia, X, Zhang, J, Yi, X, Reuben, A, Yu, F. Spatial heterogeneity of T cell repertoire across NSCLC tumors, tumor edges, adjacent and distant lung tissues. OncoImmunology 12(1), 2023. e-Pub 2023. PMID: 37876834.
89. Li R, Zhang J, Li Z. EasyCellType: marker-based cell-type annotation by automatically querying multiple databases. Bioinform Adv 3(1):vbad029, 2023. e-Pub 2023. PMID: 36998720.
90. Vokes, N, Galan Cobo, A, Fernandez-Chas, M, Molkentine, D, Trevino, S, Druker, V, Qian, Y, Patel, S, Schmidt, S, Hong, L, Lewis, J, Rinsurongkawong, W, Rinsurongkawong, V, Lee, JJ, Vailati Negrao, M, Gibbons, DL, Vaporciyan, AA, Le, X, Wu, J, Zhang, J, Rigney, U, Iyer, S, Dean, E, Heymach, JV. ATM Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLC. Clinical Cancer Research 29(23):4958-4972, 2023. e-Pub 2023. PMID: 37733794.
91. De B, Farooqi AS, Mitchell KG, Ludmir EB, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Lee JJ, Swisher SG, Gibbons DL, Zhang J, Le X, Elamin YY, Gomez DR, Ning MS, Lin SH, Liao Z, Chang JY, Vaporciyan AA, Heymach JV, Antonoff MB, Gandhi SJ. Benchmarking Outcomes for Molecularly Characterized Synchronous Oligometastatic Non-Small-Cell Lung Cancer Reveals EGFR Mutations to Be Associated With Longer Overall Survival. JCO Precis Oncol 7:e2200540, 2023. e-Pub 2023. PMID: 36716413.
92. Qureshi, S, Arani, N, Parvathareddy, V, Tchakarov, A, Abdelrahim, M, Suarez-Almazor, M, Zhang, J, Gibbons, DL, Heymach, JV, Altan, M, Abudayyeh, A. Case Report. Frontiers in Nephrology 3, 2023. e-Pub 2023. PMID: 37675380.
93. Francisco-Cruz A, Rocha P, Reuben A, Krishnan SN, Das P, Chen R, Quek K, Li J, Parra ER, Solis LM, Barua S, Jiang M, Lazcano R, Chow CW, Behrens C, Gumb C, Little L, Fukuoka J, Kalhor N, Weissferdt A, Kadara H, Heymach JV, Swisher S, Sepesi B, Rao A, Moran C, Zhang J, Lee JJ, Fujimoto J, Futreal PA, Wistuba II, Peterson CB, Zhang J. Analysis of Immune Intratumor Heterogeneity Highlights Immunoregulatory and Coinhibitory Lymphocytes as Hallmarks of Recurrence in Stage I Non-Small Cell Lung Cancer. Mod Pathol 36(1):100028, 2023. e-Pub 2023. PMID: 36788067.
94. Altan M, Li QZ, Wang Q, Vokes NI, Sheshadri A, Gao J, Zhu C, Tran HT, Gandhi S, Antonoff MB, Swisher S, Wang J, Byers LA, Abdel-Wahab N, Franco-Vega MC, Wang Y, Lee JJ, Zhang J, Heymach JV. Distinct patterns of auto-reactive antibodies associated with organ-specific immune-related adverse events. Front Immunol 14:1322818, 2023. e-Pub 2023. PMID: 38152395.
95. Deboever N, Zhou N, McGrail DJ, Tomczak K, Oliva JL, Feldman HA, Parra E, Zhang J, Lee PP, Antonoff MB, Hofstetter WL, Mehran RJ, Rajaram R, Rice DC, Roth JA, Swisher SS, Vaporciyan AA, Altan M, Weissferdt A, Tsao AS, Haymaker CL, Sepesi B. Radiographic response to neoadjuvant therapy in pleural mesothelioma should serve as a guide for patient selection for cytoreductive operations. Front Oncol 13:1216999, 2023. e-Pub 2023. PMID: 37637041.
96. Aminu M, Yadav D, Hong L, Young E, Edelkamp P, Saad M, Salehjahromi M, Chen P, Sujit SJ, Chen MM, Sabloff B, Gladish G, de Groot PM, Godoy MCB, Cascone T, Vokes NI, Zhang J, Brock KK, Daver N, Woodman SE, Tawbi HA, Sheshadri A, Lee JJ, Jaffray D, D Code Team D, Wu CC, Chung C, Wu J. Habitat Imaging Biomarkers for Diagnosis and Prognosis in Cancer Patients Infected with COVID-19. Cancers (Basel) 15(1), 2022. e-Pub 2022. PMID: 36612278.
97. Zhou N, Bell CS, Feldman HA, Haymaker CL, Hofstetter WL, Tsao AS, Mehran RJ, Rice DC, Sepesi B, Mesothelioma Immune Genomic Group ( Zhang J ). Tumor thickness in mesothelioma predicts differential response to neoadjuvant therapy and survival, 2022. e-Pub 2022.
98. Das P, Peterson CB, Ni Y, Reuben A, Zhang J, Zhang J, Do KA, Baladandayuthapani V. Bayesian hierarchical quantile regression with application to characterizing the immune architecture of lung cancer. Biometrics, 2022. e-Pub 2022. PMID: 36239535.
99. Cao S, Wang JR, Ji S, Yang P, Dai Y, Guo S, Montierth MD, Shen JP, Zhao X, Chen J, Lee JJ, Guerrero PA, Spetsieris N, Engedal N, Taavitsainen S, Yu K, Livingstone J, Bhandari V, Hubert SM, Daw NC, Futreal PA, Efstathiou E, Lim B, Viale A, Zhang J, Nykter M, Czerniak BA, Brown PH, Swanton C, Msaouel P, Maitra A, Kopetz S, Campbell P, Speed TP, Boutros PC, Zhu H, Urbanucci A, Demeulemeester J, Van Loo P, Wang W. Estimation of tumor cell total mRNA expression in 15 cancer types predicts disease progression. Nat Biotechnol 40(11):1624-1633, 2022. e-Pub 2022. PMID: 35697807.
100. Lu T, Park S, Han Y, Wang Y, Hubert SM, Futreal PA, Wistuba I, Heymach JV, Reuben A, Zhang J, Wang T. Netie: inferring the evolution of neoantigen-T cell interactions in tumors. Nat Methods 19(11):1480-1489, 2022. e-Pub 2022. PMID: 36303017.
101. Tian Y, Li Q, Yang Z, Zhang S, Xu J, Wang Z, Bai H, Duan J, Zheng B, Li W, Cui Y, Wang X, Wan R, Fei K, Zhong J, Gao S, He J, Gay CM, Zhang J, Wang J, Tang F. Single-cell transcriptomic profiling reveals the tumor heterogeneity of small-cell lung cancer. Signal Transduct Target Ther 7(1):346, 2022. e-Pub 2022. PMID: 36195615.
102. Ricciuti, B, Alessi, JV, Elkrief, A, Wang, X, Cortellini, A, Li, YY, Vaz, VR, Gupta, H, Pecci, F, Barrichello, A, Lamberti, G, Nguyen, T, Lindsay, J, Sharma, B, Felt, K, Rodig, SJ, Nishino, M, Sholl, LM, Barbie, DA, Vailati Negrao, M, Zhang, J, Cherniack, AD, Heymach, JV, Meyerson, M, Ambrogio, C, Jänne, PA, Arbour, KC, Pinato, DJ, Skoulidis, F, Schoenfeld, AJ, Awad, MM, Luo, J. Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer. Annals of Oncology 33(10):1029-1040, 2022. e-Pub 2022. PMID: 35872166.
103. Akhave N, Zhang J, Bayley E, Frank M, Chiou SH, Behrens C, Chen R, Hu X, Parra ER, Lee WC, Swisher S, Solis L, Weissferdt A, Moran C, Kalhor N, Zhang J, Scheet P, Vaporciyan AA, Sepesi B, Gibbons DL, Heymach JV, Lee JJ, Wistuba II, Andrew Futreal P, Zhang J, Fujimoto J, Reuben A. Immunogenomic profiling of lung adenocarcinoma reveals poorly differentiated tumors are associated with an immunogenic tumor microenvironment. Lung Cancer 172:19-28, 2022. e-Pub 2022. PMID: 35973335.
104. Zhang B, Stewart CA, Wang Q, Cardnell RJ, Rocha P, Fujimoto J, Solis Soto LM, Wang R, Novegil V, Ansell P, He L, Fernandez L, Jendrisak A, Gilbertson C, Schonhoft JD, Byun J, Jones J, Anderson AKL, Aparicio A, Tran H, Negrao MV, Zhang J, Wang WL, Wistuba II, Wang J, Wenstrup R, Byers LA, Gay CM. Dynamic expression of Schlafen 11 (SLFN11) in circulating tumour cells as a liquid biomarker in small cell lung cancer. Br J Cancer 127(3):569-576, 2022. e-Pub 2022. PMID: 35440668.
105. Hong L, Lewis WE, Nilsson M, Patel S, Varghese S, Rivera MJ, Du RR, Chen P, Kemp HN, Rinsurongkawong W, Heeke S, Spelman AR, Elamin YY, Negrao MV, Sepesi B, Gibbons DL, Lee JJ, Wu J, Vokes NI, Heymach JV, Zhang J, Le X. Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung Adenocarcinoma. Cancers (Basel) 14(14), 2022. e-Pub 2022. PMID: 35884533.
106. Elamin YY, Robichaux JP, Carter BW, Altan M, Tran H, Gibbons DL, Heeke S, Fossella FV, Lam VK, Le X, Negrao MV, Nilsson MB, Patel A, Vijayan RSK, Cross JB, Zhang J, Byers LA, Lu C, Cascone T, Feng L, Luthra R, San Lucas FA, Mantha G, Routbort M, Blumenschein G, Tsao AS, Heymach JV. Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity. Cancer Cell 40(7):754-767.e6, 2022. e-Pub 2022. PMID: 35820397.
107. Schmidt ST, Akhave N, Knightly RE, Reuben A, Vokes N, Zhang J, Li J, Fujimoto J, Byers LA, Sanchez-Espiridion B, Diao L, Wang J, Federico L, Forget MA, McGrail DJ, Weissferdt A, Lin SY, Lee Y, Suzuki E, Kovacs JJ, Behrens C, Wistuba II, Futreal A, Vaporciyan A, Sepesi B, Heymach JV, Bernatchez C, Haymaker C, Cascone T, Zhang J, Bristow CA, Heffernan TP, Negrao MV, Gibbons DL, Team I. Shared Nearest Neighbors Approach and Interactive Browser for Network Analysis of a Comprehensive Non-Small-Cell Lung Cancer Data Set. JCO Clin Cancer Inform 6:e2200040, 2022. e-Pub 2022. PMID: 35944232.
108. Yuan B, Clowers MJ, Velasco WV, Peng S, Peng Q, Shi Y, Ramos-Castaneda M, Zarghooni M, Yang S, Babcock RL, Chang SH, Heymach JV, Zhang J, Ostrin EJ, Watowich SS, Kadara H, Moghaddam SJ. Targeting IL-1β as an immunopreventive and therapeutic modality for K-ras-mutant lung cancer. JCI Insight 7(11), 2022. e-Pub 2022. PMID: 35471938.
109. Liu Y, Zhang Z, Rinsurongkawong W, Gay CM, Le X, Ning MS, Lewis J, Rinsurongkawong V, Lee JJ, Roth J, Swisher S, Gandhi S, Lee PP, Gibbons DL, Vaporciyan AA, Heymach JV, Zhang J, Lin SH. Association of Driver Oncogene Variations With Outcomes in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Chemoradiation and Consolidative Durvalumab. JAMA Netw Open 5(6):e2215589, 2022. e-Pub 2022. PMID: 35666500.
110. Chen R, Li J, Fujimoto J, Hong L, Hu X, Quek K, Tang M, Mitra A, Behrens C, Chow CW, Jiang P, Little LD, Gumbs C, Song X, Zhang J, Tan D, Heymach JV, Wistuba I, Futreal PA, Gibbons DL, Byers LA, Zhang J, Reuben A. Immunogenomic intertumor heterogeneity across primary and metastatic sites in a patient with lung adenocarcinoma. J Exp Clin Cancer Res 41(1):172, 2022. e-Pub 2022. PMID: 35546239.
111. Altan M, Singhi EK, Worst M, Carter BW, Leung CH, Lee JJ, Presley CJ, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Zhang J, Gibbons DL, Vaporciyan AA, Heymach JV, Mott FE. Clinical Effectiveness and Safety of Anti-PD-(L)1 Therapy Among Older Adults With Advanced Non-Small Cell Lung Cancer. Clin Lung Cancer 23(3):236-243, 2022. e-Pub 2022. PMID: 35216923.
112. Alhalabi O, Chen J, Zhang Y, Lu Y, Wang Q, Ramachandran S, Tidwell RS, Han G, Yan X, Meng J, Wang R, Hoang AG, Wang WL, Song J, Lopez L, Andreev-Drakhlin A, Siefker-Radtke A, Zhang X, Benedict WF, Shah AY, Wang J, Msaouel P, Zhang M, Guo CC, Czerniak B, Behrens C, Soto L, Papadimitrakopoulou V, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Lee J, Roth J, Swisher S, Wistuba I, Heymach J, Wang J, Campbell MT, Efstathiou E, Titus M, Logothetis CJ, Ho TH, Zhang J, Wang L, Gao J. MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers. Nat Commun 13(1):1797, 2022. e-Pub 2022. PMID: 35379845.
113. Wang C, Chen L, Chen Y, Jia W, Cai X, Liu Y, Ji F, Xiong P, Liang A, Liu R, Guan Y, Cheng Z, Weng Y, Wang W, Duan Y, Kuang D, Xu S, Cai H, Xia Q, Yang D, Wang MW, Yang X, Zhang J, Cheng C, Liu L, Liu Z, Liang R, Wang G, Li Z, Xia H, Xia T. Abnormal global alternative RNA splicing in COVID-19 patients. PLoS Genet 18(4):e1010137, 2022. e-Pub 2022. PMID: 35421082.
114. Ricciuti B, Arbour KC, Lin JJ, Vajdi A, Vokes N, Hong L, Zhang J, Tolstorukov MY, Li YY, Spurr LF, Cherniack AD, Recondo G, Lamberti G, Wang X, Venkatraman D, Alessi JV, Vaz VR, Rizvi H, Egger J, Plodkowski AJ, Khosrowjerdi S, Digumarthy S, Park H, Vaz N, Nishino M, Sholl LM, Barbie D, Altan M, Heymach JV, Skoulidis F, Gainor JF, Hellmann MD, Awad MM. Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status. J Thorac Oncol 17(3):399-410, 2022. e-Pub 2022. PMID: 34740862.
115. Elamin YY, Robichaux JP, Carter BW, Altan M, Gibbons DL, Fossella FV, Lam VK, Patel AB, Negrao MV, Le X, Mott FE, Zhang J, Feng L, Blumenschein G, Tsao AS, Heymach JV. Poziotinib for Patients With HER2 Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II Trial. J Clin Oncol 40(7):JCO2101113, 2022. e-Pub 2022. PMID: 34550757.
116. Tian Y, Lai Q, Zheng Y, Ying L, Wang C, Jin J, Huang M, Wu Y, Li H, Zhang J, Su D. Oncogenic Alterations in Histologically Negative Lymph Nodes Are Associated with Prognosis of Patients with Stage I Lung Adenocarcinoma. Cancers (Basel) 14(3), 2022. e-Pub 2022. PMID: 35159091.
117. Jin Y, Chen Y, Tang H, Hu X, Hubert SM, Li Q, Su D, Xu H, Fan Y, Yu X, Chen Q, Liu J, Hong W, Xu Y, Deng H, Zhu D, Li P, Gong Y, Xia X, Gay CM, Zhang J, Chen M. Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer. Clin Cancer Res 28(3):526-539, 2022. e-Pub 2022. PMID: 34921019.
118. Shah P, Forget MA, Frank ML, Jiang P, Sakellariou-Thompson D, Federico L, Khairullah R, Neutzler CA, Wistuba I, Chow CB, Long Y, Fujimoto J, Lin SY, Maitra A, Negrao MV, Mitchell KG, Weissferdt A, Vaporciyan AA, Cascone T, Roth JA, Zhang J, Sepesi B, Gibbons DL, Heymach JV, Haymaker CL, McGrail DJ, Reuben A, Bernatchez C. Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes. J Immunother Cancer 10(2), 2022. e-Pub 2022. PMID: 35110355.
119. Deboever N, McGrail DJ, Lee Y, Tran HT, Mitchell KG, Antonoff MB, Hofstetter WL, Mehran RJ, Rice DC, Roth JA, Swisher SG, Vaporciyan AA, Walsh GL, Bernatchez C, Vailati Negrao M, Zhang J, Wistuba II, Heymach JV, Cascone T, Gibbons DL, Haymaker CL, Sepesi B. Surgical approach does not influence changes in circulating immune cell populations following lung cancer resection. Lung Cancer 164:69-75, 2022. e-Pub 2022. PMID: 35038676.
120. Nguyen TT, Lee HS, Burt BM, Wu J, Zhang J, Amos CI, Cheng C. A lepidic gene signature predicts patient prognosis and sensitivity to immunotherapy in lung adenocarcinoma. Genome Med 14(1):5, 2022. e-Pub 2022. PMID: 35016696.
121. Lin SH, Lin HY, Verma V, Xu-Welliver M, Thall PF, Yao L, Kim PY, Gombos DS, Kawedia JD, Komaki R, Gomez DR, Nguyen QN, O'Reilly MS, Lu C, Fossella FV, Skoulidis F, Zhang J, Tsao AS, Heymach JV, Blumenschein GR. Phase I Trial of Definitive Concurrent Chemoradiotherapy and Trametinib for KRAS-Mutated Non-Small Cell Lung Cancer. Cancer Treat Res Commun 30:100514, 2022. e-Pub 2022. PMID: 35051703.
122. Chen P, Zhang J, Wu J. Artificial Intelligence in Digital Pathology to Advance Cancer Immunotherapy. 21 Century Pathol 2(3), 2022. e-Pub 2022. PMID: 36282981.
123. Federico, L, McGrail, DJ, Bentebibel, SE, Haymaker, CL, Ravelli, A, Forget, MA, Karpinets, T, Jiang, P, Reuben, A, Vailati Negrao, M, Li, J, Khairullah, R, Zhang, J, Weissferdt, A, Vaporciyan, AA, Antonoff, MB, Walsh, GL, Lin, S, Futreal, A, Wistuba, II, Roth, JA, Byers, LA, Gaudreau, PO, Uraoka, N, Francisco-Cruz, A, Dejima, H, Segura Lazcano, R, Solis Soto, LM, Parra Cuentas, ER, Lee, JJ, Swisher, SG, Cascone, T, Heymach, JV, Sepesi, B, Gibbons, DL, Bernatchez, C. Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small-cell lung cancer. Annals of Oncology 33(1):42-56, 2022. e-Pub 2022. PMID: 34653632.
124. Bai X, Wang H, Ma L, Xu Y, Gan J, Fan Z, Yang F, Ma K, Yang J, Bai S, Shu C, Zou X, Huang R, Zhang C, Liu X, Tu D, Xu C, Zhang W, Wang X, Chen A, Zeng Y, Yang D, Wang MW, Holalkere N, Halin NJ, Kamel IR, Wu J, Peng X, Wang X, Shao J, Mongkolwat P, Zhang J, Liu W, Roberts M, Teng Z, Beer L, Sanchez LE, Sala E, Rubin DL, Weller A, Lasenby J, Zheng C, Wang J, Li Z, Schönlieb C, Xia T. Erratum: Author Correction: Advancing COVID-19 diagnosis with privacy-preserving collaboration in artificial intelligence. Nat Mach Intell 4(4):413, 2022. e-Pub 2022. PMID: 37520117.
125. Tang M, Abbas HA, Negrao MV, Ramineni M, Hu X, Hubert SM, Fujimoto J, Reuben A, Varghese S, Zhang J, Li J, Chow CW, Mao X, Song X, Lee WC, Wu J, Little L, Gumbs C, Behrens C, Moran C, Weissferdt A, Lee JJ, Sepesi B, Swisher S, Cheng C, Kurie J, Gibbons D, Heymach JV, Wistuba II, Futreal PA, Kalhor N, Zhang J. The histologic phenotype of lung cancers is associated with transcriptomic features rather than genomic characteristics. Nat Commun 12(1):7081, 2021. e-Pub 2021. PMID: 34873156.
126. Chen M, Chen R, Jin Y, Li J, Hu X, Zhang J, Fujimoto J, Hubert SM, Gay CM, Zhu B, Tian Y, McGranahan N, Lee WC, George J, Hu X, Chen Y, Wu M, Behrens C, Chow CW, Pham HHN, Fukuoka J, Wu J, Parra ER, Little LD, Gumbs C, Song X, Wu CJ, Diao L, Wang Q, Cardnell R, Zhang J, Wang J, Le X, Gibbons DL, Heymach JV, Jack Lee J, William WN, Cheng C, Glisson B, Wistuba I, Andrew Futreal P, Thomas RK, Reuben A, Byers LA, Zhang J. Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer. Nat Commun 12(1):6655, 2021. e-Pub 2021. PMID: 34789716.
127. Chen K, Bai J, Reuben A, Zhao H, Kang G, Zhang C, Qi Q, Xu Y, Hubert S, Chang L, Guan Y, Feng L, Zhang K, Zhang K, Yi X, Xia X, Cheng S, Yang F, Zhang J, Wang J. Multiomics Analysis Reveals Distinct Immunogenomic Features of Lung Cancer with Ground-Glass Opacity. Am J Respir Crit Care Med 204(10):1180-1192, 2021. e-Pub 2021. PMID: 34473939.
128. Lewis WE, Hong L, Mott FE, Simon G, Wu CC, Rinsurongkawong W, Lee JJ, Lam VK, Heymach JV, Zhang J, Le X. Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations. JTO Clin Res Rep 2(11):100237, 2021. e-Pub 2021. PMID: 34820641.
129. Stewart CA, Gay CM, Ramkumar K, Cargill KR, Cardnell RJ, Nilsson MB, Heeke S, Park EM, Kundu ST, Diao L, Wang Q, Shen L, Xi Y, Zhang B, Della Corte CM, Fan Y, Kundu K, Gao B, Avila K, Pickering CR, Johnson FM, Zhang J, Kadara H, Minna JD, Gibbons DL, Wang J, Heymach JV, Byers LA. Lung Cancer Models Reveal Severe Acute Respiratory Syndrome Coronavirus 2-Induced Epithelial-to-Mesenchymal Transition Contributes to Coronavirus Disease 2019 Pathophysiology. J Thorac Oncol 16(11):1821-1839, 2021. e-Pub 2021. PMID: 34274504.
130. Liu Y, Zhang Z, Rinsurongkawong W, Le X, Gay CM, Ning MS, Heymach JV, Zhang J, Lin SH. Toxicity and Local Control of Lung Stereotactic Body Radiation Therapy With or Without Concurrent Molecularly Targeted Therapies, 2021. e-Pub 2021. PMID: 34701473.
131. Sinjab A, Han G, Treekitkarnmongkol W, Hara K, Brennan PM, Dang M, Hao D, Wang R, Dai E, Dejima H, Zhang J, Bogatenkova E, Sanchez-Espiridion B, Chang K, Little DR, Bazzi S, Tran LM, Krysan K, Behrens C, Duose DY, Parra ER, Raso MG, Solis LM, Fukuoka J, Zhang J, Sepesi B, Cascone T, Byers LA, Gibbons DL, Chen J, Moghaddam SJ, Ostrin EJ, Rosen D, Heymach JV, Scheet P, Dubinett SM, Fujimoto J, Wistuba II, Stevenson CS, Spira A, Wang L, Kadara H. Resolving the spatial and cellular architecture of lung adenocarcinoma by multiregion single-cell sequencing. Cancer Discov 11(10):2506-2523, 2021. e-Pub 2021. PMID: 33972311.
132. Tian P, Zeng H, Ji L, Ding Z, Ren L, Gao W, Fan Z, Li L, Le X, Li P, Zhang M, Xia X, Zhang J, Li Y, Li W. Lung adenocarcinoma with ERBB2 exon 20 insertions: Comutations and immunogenomic features related to chemoimmunotherapy. Lung Cancer 160:50-58, 2021. e-Pub 2021. PMID: 34403912.
133. Zeng Z, Fu J, Cibulskis C, Jhaveri A, Gumbs C, Das B, Sanchez-Espiridion B, Janssens S, Taing L, Wang J, Lindsay J, Vilimas T, Zhang J, Tokheim C, Sahu A, Jiang P, Yan C, Duose DY, Cerami E, Chen L, Cohen D, Chen Q, Enos R, Huang X, Lee JJ, Liu Y, Neuberg DS, Nguyen C, Patterson C, Sarkar S, Shukla S, Tang M, Tsuji J, Uduman M, Wang X, Weirather JL, Yu J, Yu J, Zhang J, Zhang J, Meerzaman D, Thurin M, Futreal A, Karlovich C, Gabriel SB, Wistuba II, Liu XS, Wu CJ. Cross-site concordance evaluation of tumor DNA and RNA sequencing platforms for the CIMAC-CIDC network. Clin Cancer Res 27(18):5049-5061, 2021. e-Pub 2021. PMID: 33323402.
134. Robichaux JP, Le X, Vijayan RSK, Hicks JK, Heeke S, Elamin YY, Lin HY, Udagawa H, Skoulidis F, Tran H, Varghese S, He J, Zhang F, Nilsson MB, Hu L, Poteete A, Rinsurongkawong W, Zhang X, Ren C, Liu X, Hong L, Zhang J, Diao L, Madison R, Schrock AB, Saam J, Raymond V, Fang B, Wang J, Ha MJ, Cross JB, Gray JE, Heymach JV. Structure-based classification predicts drug response in EGFR-mutant NSCLC. Nature 597(7878):732-737, 2021. e-Pub 2021. PMID: 34526717.
135. Negrao MV, Skoulidis F, Montesion M, Schulze K, Bara I, Shen V, Xu H, Hu S, Sui D, Elamin YY, Le X, Goldberg ME, Murugesan K, Wu CJ, Zhang J, Barreto DS, Robichaux JP, Reuben A, Cascone T, Gay CM, Mitchell KG, Hong L, Rinsurongkawong W, Roth JA, Swisher SG, Lee J, Tsao A, Papadimitrakopoulou V, Gibbons DL, Glisson BS, Singal G, Miller VA, Alexander B, Frampton G, Albacker LA, Shames D, Zhang J, Heymach JV. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. J Immunother Cancer 9(8), 2021. e-Pub 2021. PMID: 34376553.
136. Tran HT, Lam VK, Elamin YY, Hong L, Colen R, Elshafeey NA, Hassan ISA, Altan M, Blumenschein GR, Rinsurongkawong W, Rivera MJ, Vasquez ME, Carter BW, Byers LE, Tsao AS, Gibbons DL, Fossella F, Glisson BS, Zhang J, Heymach JV. Clinical Outcomes in Non-Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling. JCO Precis Oncol 5, 2021. e-Pub 2021. PMID: 34377884.
137. Rocha P, Salazar R, Zhang J, Ledesma D, Solorzano JL, Mino B, Villalobos P, Dejima H, Douse DY, Diao L, Mitchell KG, Le X, Zhang J, Weissferdt A, Parra-Cuentas E, Cascone T, Rice DC, Sepesi B, Kalhor N, Moran C, Vaporciyan A, Heymach J, Gibbons DL, Lee JJ, Kadara H, Wistuba I, Behrens C, Solis LM. CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma. Cancer Immunol Immunother 70(7):1965-1976, 2021. e-Pub 2021. PMID: 33416944.
138. Rocha P, Salazar R, Zhang J, Ledesma D, Solorzano JL, Mino B, Villalobos P, Dejima H, Douse DY, Diao L, Mitchell KG, Le X, Zhang J, Weissferdt A, Parra-Cuentas E, Cascone T, Rice DC, Sepesi B, Kalhor N, Moran C, Vaporciyan A, Heymach J, Gibbons DL, Lee JJ, Kadara H, Wistuba I, Behrens C, Solis LM. Correction to: CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma. Cancer Immunol Immunother 70(7):1977-1978, 2021. e-Pub 2021. PMID: 33686493.
139. Hu X, Fujimoto J, Ying L, Fukuoka J, Ashizawa K, Sun W, Reuben A, Chow CW, McGranahan N, Chen R, Hu J, Godoy MC, Tabata K, Kuroda K, Shi L, Li J, Behrens C, Parra ER, Little LD, Gumbs C, Mao X, Song X, Tippen S, Thornton RL, Kadara H, Scheet P, Roarty E, Ostrin EJ, Wang X, Carter BW, Antonoff MB, Zhang J, Vaporciyan AA, Pass H, Swisher SG, Heymach JV, Lee JJ, Wistuba II, Hong WK, Futreal PA, Su D, Zhang J. Author Correction: Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma. Nat Commun 12(1):2888, 2021. e-Pub 2021. PMID: 33980839.
140. Dejima H, Hu X, Chen R, Zhang J, Fujimoto J, Parra ER, Haymaker C, Hubert SM, Duose D, Solis LM, Su D, Fukuoka J, Tabata K, Pham HHN, Mcgranahan N, Zhang B, Ye J, Ying L, Little L, Gumbs C, Chow CW, Estecio MR, Godoy MCB, Antonoff MB, Sepesi B, Pass HI, Behrens C, Zhang J, Vaporciyan AA, Heymach JV, Scheet P, Lee JJ, Wu J, Futreal PA, Reuben A, Kadara H, Wistuba II, Zhang J. Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features. Nat Commun 12(1):2722, 2021. e-Pub 2021. PMID: 33976164.
141. Behrens C, Rocha P, Parra ER, Feng L, Rodriguez-Canales J, Solis LM, Mino B, Zhang J, Gibbons DL, Sepesi B, Rice D, Heymach JV, Moran C, Creighton CJ, Lee JJ, Kadara H, Wistuba II. Female Gender Predicts Augmented Immune Infiltration in Lung Adenocarcinoma. Clin Lung Cancer 22(3):e415-e424, 2021. e-Pub 2021. PMID: 32763065.
142. Lee SH, Simoneau EB, Karpinets T, Futreal PA, Zhang J, Javle M, Zhang J, Vauthey JN, Lee JS, Estrella JS, Chun YS. Genomic Profiling of Multifocal Intrahepatic Cholangiocarcinoma Reveals Intraindividual Concordance of Genetic Alterations. Carcinogenesis 42(3):436-441, 2021. e-Pub 2021. PMID: 33200197.
143. Le X, Negrao MV, Reuben A, Federico L, Diao L, McGrail D, Nilsson M, Robichaux J, Munoz IG, Patel S, Elamin Y, Fan YH, Lee WC, Parra E, Solis Soto LM, Chen R, Li J, Karpinets T, Khairullah R, Kadara H, Behrens C, Sepesi B, Wang R, Zhu M, Wang L, Vaporciyan A, Roth J, Swisher S, Haymaker C, Zhang J, Wang J, Wong KK, Byers LA, Bernatchez C, Zhang J, Wistuba II, Gibbons DL, Akbay EA, Heymach JV. Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target. J Thorac Oncol 16(4):583-600, 2021. e-Pub 2021. PMID: 33388477.
144. Lam VK, Zhang J, Wu CC, Tran HT, Li L, Diao L, Wang J, Rinsurongkawong W, Raymond VM, Lanman RB, Lewis J, Roarty EB, Roth J, Swisher S, Lee JJ, Gibbons DL, Papadimitrakopoulou VA, Heymach JV. Genotype-Specific Differences in Circulating Tumor DNA Levels in Advanced NSCLC. J Thorac Oncol 16(4):601-609, 2021. e-Pub 2021. PMID: 33388476.
145. Sitthideatphaiboon P, Galan-Cobo A, Negrao MV, Qu X, Poteete A, Zhang F, Liu DD, Lewis WE, Kemp HN, Lewis J, Rinsurongkawong W, Giri U, Lee JJ, Zhang J, Roth JA, Swisher S, Heymach JV. STK11/LKB1 Mutations in NSCLC Are Associated with KEAP1/NRF2-Dependent Radiotherapy Resistance Targetable by Glutaminase Inhibition. Clin Cancer Res 27(6):1720-1733, 2021. e-Pub 2021. PMID: 33323404.
146. Han G, Sinjab A, Hara K, Treekitkarnmongkol W, Brennan P, Chang K, Bogatenkova E, Sanchez-Espiridion B, Behrens C, Solis LM, Gao B, Girard L, Zhang J, Sepesi B, Cascone T, Byers LA, Gibbons DL, Chen J, Moghaddam SJ, Ostrin EJ, Scheet P, Fujimoto J, Shay J, Heymach JV, Minna JD, Dubinett S, Wistuba II, Stevenson CS, Spira AE, Wang L, Kadara H. Single-Cell Expression Landscape of SARS-CoV-2 Receptor ACE2 and Host Proteases in Normal and Malignant Lung Tissues from Pulmonary Adenocarcinoma Patients. Cancers (Basel) 13(6), 2021. e-Pub 2021. PMID: 33809063.
147. Chiou SH, Tseng D, Reuben A, Mallajosyula V, Molina IS, Conley S, Wilhelmy J, McSween AM, Yang X, Nishimiya D, Sinha R, Nabet BY, Wang C, Shrager JB, Berry MF, Backhus L, Lui NS, Wakelee HA, Neal JW, Padda SK, Berry GJ, Delaidelli A, Sorensen PH, Sotillo E, Tran P, Benson JA, Richards R, Labanieh L, Klysz DD, Louis DM, Feldman SA, Diehn M, Weissman IL, Zhang J, Wistuba II, Futreal PA, Heymach JV, Garcia KC, Mackall CL, Davis MM. Global analysis of shared T cell specificities in human non-small cell lung cancer enables HLA inference and antigen discovery. Immunity 54(3):586-602.e8, 2021. e-Pub 2021. PMID: 33691136.
148. Schwalk AJ, Ost DE, Saltijeral SN, De La Garza H, Casal RF, Jimenez CA, Eapen GA, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Lee J, Elamin Y, Zhang J, Roth JA, Swisher S, Heymach JV, Grosu HB. Risk Factors for and Time to Recurrence of Symptomatic Malignant Pleural Effusion in Patients With Metastatic Non-Small Cell Lung Cancer with EGFR or ALK Mutations. Chest 159(3):1256-1264, 2021. e-Pub 2021. PMID: 33217413.
149. Cascone T, William WN, Weissferdt A, Leung CH, Lin HY, Pataer A, Godoy MCB, Carter BW, Federico L, Reuben A, Khan MAW, Dejima H, Francisco-Cruz A, Parra ER, Solis LM, Fujimoto J, Tran HT, Kalhor N, Fossella FV, Mott FE, Tsao AS, Blumenschein G, Le X, Zhang J, Skoulidis F, Kurie JM, Altan M, Lu C, Glisson BS, Byers LA, Elamin YY, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Roth JA, Antonoff MB, Kadara H, Haymaker C, Bernatchez C, Ajami NJ, Jenq RR, Sharma P, Allison JP, Futreal A, Wargo JA, Wistuba II, Swisher SG, Lee JJ, Gibbons DL, Vaporciyan AA, Heymach JV, Sepesi B. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med 27(3):504-514, 2021. e-Pub 2021. PMID: 33603241.
150. Hu X, Estecio MR, Chen R, Reuben A, Wang L, Fujimoto J, Carrot-Zhang J, McGranahan N, Ying L, Fukuoka J, Chow CW, Pham HHN, Godoy MCB, Carter BW, Behrens C, Zhang J, Antonoff MB, Sepesi B, Lu Y, Pass HI, Kadara H, Scheet P, Vaporciyan AA, Heymach JV, Wistuba II, Lee JJ, Futreal PA, Su D, Issa JJ, Zhang J. Evolution of DNA methylome from precancerous lesions to invasive lung adenocarcinomas. Nat Commun 12(1):687, 2021. e-Pub 2021. PMID: 33514726.
151. Stewart CA, Gay CM, Ramkumar K, Cargill KR, Cardnell RJ, Nilsson MB, Heeke S, Park EM, Kundu ST, Diao L, Wang Q, Shen L, Xi Y, Zhang B, Della Corte CM, Fan Y, Kundu K, Gao B, Avila K, Pickering CR, Johnson FM, Zhang J, Kadara H, Minna JD, Gibbons DL, Wang J, Heymach JV, Byers LA. SARS-CoV-2 infection induces EMT-like molecular changes, including ZEB1-mediated repression of the viral receptor ACE2, in lung cancer models. bioRxiv, 2021. e-Pub 2021. PMID: 32577652.
152. Gaudreau PO, Negrao MV, Mitchell KG, Reuben A, Corsini EM, Li J, Karpinets TV, Wang Q, Diao L, Wang J, Federico L, Parra-Cuentas ER, Khairullah R, Behrens C, Correa AM, Gomez D, Little L, Gumbs C, Kadara HN, Fujimoto J, McGrail DJ, Vaporciyan AA, Swisher SG, Walsh G, Antonoff MB, Weissferdt A, Tran H, Roarty E, Haymaker C, Bernatchez C, Zhang J, Futreal PA, Wistuba II, Cascone T, Heymach JV, Sepesi B, Zhang J, Gibbons DL. Neoadjuvant Chemotherapy Increases Cytotoxic T Cell, Tissue Resident Memory T Cell, and B Cell Infiltration in Resectable NSCLC. J Thorac Oncol 16(1):127-139, 2021. e-Pub 2021. PMID: 33096269.
153. Liu X, Wang F, Xu C, Chen X, Hou X, Li Q, Li P, Xie Z, Liu Y, Chang L, Guan Y, Zhang X, Yang L, Wang H, Yi X, Zhang J, Xia X, Moran C, Chen L. Genomic origin and intratumor heterogeneity revealed by sequencing on carcinomatous and sarcomatous components of pulmonary sarcomatoid carcinoma. Oncogene 40(4):821-832, 2021. e-Pub 2021. PMID: 33273725.
154. Le X, Hong L, Hensel C, Chen R, Kemp H, Coleman N, Ciunci CA, Liu SV, Negrao MV, Yen J, Xia X, Scheuenpflug J, Stroh C, Juraeva D, Tsao A, Hong D, Raymond V, Paik P, Zhang J, Heymach JV. Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non-Small-Cell Lung Cancer Harboring MET Exon 14 Skipping. JCO Precis Oncol 5, 2021. e-Pub 2021. PMID: 34957368.
155. Welsh JW, Heymach JV, Guo C, Menon H, Klein K, Cushman TR, Verma V, Hess KR, Shroff G, Tang C, Skoulidis F, Jeter M, Comeaux N, Patel RR, Chen D, Ozgen T, Nguyen QN, Chang JY, Altan M, Zhang J, Papadimitrakopoulou VA, Simon GR, Byers LA, Glisson B. Phase 1/2 Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage SCLC. J Thorac Oncol 15(12):1919-1927, 2020. e-Pub 2020. PMID: 32916308.
156. Lee WC, Reuben A, Hu X, McGranahan N, Chen R, Jalali A, Negrao MV, Hubert SM, Tang C, Wu CC, Lucas AS, Roh W, Suda K, Kim J, Tan AC, Peng DH, Lu W, Tang X, Chow CW, Fujimoto J, Behrens C, Kalhor N, Fukumura K, Coyle M, Thornton R, Gumbs C, Li J, Wu CJ, Little L, Roarty E, Song X, Lee JJ, Sulman EP, Rao G, Swisher S, Diao L, Wang J, Heymach JV, Huse JT, Scheet P, Wistuba II, Gibbons DL, Futreal PA, Zhang J, Gomez D, Zhang J. Multiomics profiling of primary lung cancers and distant metastases reveals immunosuppression as a common characteristic of tumor cells with metastatic plasticity. Genome Biol 21(1):271, 2020. e-Pub 2020. PMID: 33148332.
157. Liu X, Hong L, Nilsson M, Hubert SM, Wu S, Rinsurongkawong W, Lewis J, Spelman A, Roth J, Swisher S, He Y, Jack Lee J, Fang B, Heymach JV, Zhang J, Le X. Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancer. Lung Cancer 149:33-40, 2020. e-Pub 2020. PMID: 32956986.
158. Chen R, Lee WC, Fujimoto J, Li J, Hu X, Mehran R, Rice D, Swisher SG, Sepesi B, Tran HT, Chow CW, Little LD, Gumbs C, Haymaker C, Heymach JV, Wistuba II, Lee JJ, Futreal PA, Zhang J, Reuben A, Tsao AS, Zhang J. Evolution of Genomic and T-cell Repertoire Heterogeneity of Malignant Pleural Mesothelioma Under Dasatinib Treatment. Clin Cancer Res 26(20):5477-5486, 2020. e-Pub 2020. PMID: 32816946.
159. Whisenant MS, Williams LA, Garcia Gonzalez A, Mendoza T, Shi Q, Cleeland C, Zhang J, Heymach J, Simon G. What Do Patients With Non-Small-Cell Lung Cancer Experience? Content Domain for the MD Anderson Symptom Inventory for Lung Cancer. JCO Oncol Pract 16(10):e1151-e1160, 2020. e-Pub 2020. PMID: 32539654.
160. Cao S, Wang J, Ji S, Yang P, Chen J, Montierth M, Shen J, Lee J, Guerrero P, Yu K, Livingstone J, Bhandari V, Hubert S, Daw N, Futreal PA, Efstathiou E, Lim B, Viale A, Zhang J, Maitra A, Kopetz S, Campbell P, Speed T, Boutros P, Urbanucci A, Zhu H, Demeulemeester J, Loo P, Wang W. Differing total mRNA expression shapes the molecular and clinical phenotype of cancer. bioRxiv, 2020. e-Pub 2020.
161. Hong L, Negrao MV, Dibaj SS, Chen R, Reuben A, Bohac JM, Liu X, Skoulidis F, Gay CM, Cascone T, Mitchell KG, Tran HT, Le X, Byers LA, Sepesi B, Altan M, Elamin YY, Fossella FV, Kurie JM, Lu C, Mott FE, Tsao AS, Rinsurongkawong W, Lewis J, Gibbons DL, Glisson BS, Blumenschein GR, Roarty EB, Futreal PA, Wistuba II, Roth JA, Swisher SG, Papadimitrakopoulou VA, Heymach JV, Lee JJ, Simon GR, Zhang J. Programmed Death Ligand 1 Heterogeneity and its Impact on Benefit from Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer. J Thorac Oncol 15(9):1449-1459, 2020. e-Pub 2020. PMID: 32389639.
162. Tian Y, Xu J, Chu Q, Duan J, Zhang J, Bai H, Yang Z, Fang W, Cai L, Wan R, Fei K, He J, Gao S, Zhang L, Wang Z, Wang J. A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients. BMC Med 18(1):232, 2020. e-Pub 2020. PMID: 32843031.
163. Wang D, Xu Y, Goldstein JB, Ye K, Hu X, Xiao L, Li L, Chang L, Guan Y, Long G, He Q, Yi X, Zhang J, Wang Z, Xia X, Zhou L. Preoperative evaluation of microvascular invasion with circulating tumour DNA in operable hepatocellular carcinoma. Liver Int 40(8):1997-2007, 2020. e-Pub 2020. PMID: 32279416.
164. Corsini EM, Wang Q, Tran HT, Mitchell KG, Antonoff MB, Hofstetter WL, Mehran RJ, Rice DC, Roth JA, Swisher SG, Vaporciyan AA, Walsh GL, Reuben A, Vasquez ME, Bernatchez C, Wang J, Cascone T, Zhang J, Heymach JV, Gibbons DL, Haymaker CL, Sepesi B. Peripheral cytokines are not influenced by the type of surgical approach for non-small cell lung cancer by four weeks postoperatively. Lung Cancer 146:303-309, 2020. e-Pub 2020. PMID: 32619781.
165. Cascone T, Sepesi B, Lin H, Kalhor N, Parra ER, Jiang M, Godoy MCB, Zhang J, Fossella F, Tsao AS, Lam VK, Lu C, Mott FE, Simon GR, Antonoff MB, Reza MJ, Rice D, Behren C, Weissferdt A, Moran C, Vaporciyan AA, Lee JJ, Swisher SG, Gibbons DL, Wistuba II, William WN, Heymach JV. A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel and Nintedanib for Resectable Non-Small Cell Lung Cancer. Clin Cancer Res, 2020. e-Pub 2020. PMID: 32193228.
166. Tang Z, Chen H, Hong L, Tang G, Toruner GA, Wang W, Roy Chowdhuri S, Yin W, Jung HS, Gu J, Routbort MJ, Zhang J, Khoury JD, Medeiros LJ. Inconsistent Intersample ALK FISH Results in Patients with Lung Cancer: Analysis of Potential Causes. Cancers (Basel) 12(7), 2020. e-Pub 2020. PMID: 32674491.
167. Xie F, Zhang J, Wang J, Reuben A, Xu W, Yi X, Varn FS, Ye Y, Cheng J, Yu M, Wang Y, Liu Y, Xie M, Du P, Ma K, Ma X, Zhou P, Yang S, Chen Y, Wang G, Xia X, Liao Z, Heymach JV, Wistuba II, Futreal PA, Ye K, Cheng C, Xia T. Multifactorial Deep Learning Reveals Pan-Cancer Genomic Tumor Clusters with Distinct Immunogenomic Landscape and Response to Immunotherapy. Clin Cancer Res 26(12):2908-2920, 2020. e-Pub 2020. PMID: 31911545.
168. Xu Y, Ma L, Yang F, Chen Y, Ma K, Yang J, Yang X, Chen Y, Shu C, Fan Z, Gan J, Zou X, Huang R, Zhang C, Liu X, Tu D, Xu C, Zhang W, Yang D, Wang MW, Wang X, Xie X, Leng H, Holalkere N, Halin NJ, Kamel IR, Wu J, Peng X, Wang X, Shao J, Mongkolwat P, Zhang J, Rubin DL, Wang G, Zheng C, Li Z, Bai X, Xia T. A collaborative online AI engine for CT-based COVID-19 diagnosis. medRxiv, 2020. e-Pub 2020. PMID: 32511484.
169. Yang J, Gong Y, Lam VK, Shi Y, Guan Y, Zhang Y, Ji L, Chen Y, Zhao Y, Qian F, Chen J, Li P, Zhang F, Wang J, Zhang X, Yang L, Kopetz S, Futreal PA, Zhang J, Yi X, Xia X, Yu P. Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer. Cell Death Dis 11(5):346, 2020. e-Pub 2020. PMID: 32393783.
170. Corsini EM, Wang J, Wu CC, Fujimoto J, Negrao MV, Chen R, Quek K, Mitchell KG, Chow CB, Little L, Gumbs C, Song X, Behrens C, Correa AM, Antonoff MB, Swisher SG, Heymach JV, Zhang J, Wistuba II, Futreal PA, Sepesi B, Zhang J. Genomic assessment distinguishes intrapulmonary metastases from synchronous primary lung cancers. J Thorac Dis 12(5):1952-1959, 2020. e-Pub 2020. PMID: 32642098.
171. Ferranti CS, Cheng J, Thompson C, Zhang J, Rotolo JA, Buddaseth S, Fuks Z, Kolesnick RN. Fusion of lysosomes to plasma membrane initiates radiation-induced apoptosis. J Cell Biol 219(4), 2020. e-Pub 2020. PMID: 32328634.
172. Mitchell KG, Diao L, Karpinets T, Negrao MV, Tran HT, Parra ER, Corsini EM, Reuben A, Federico L, Bernatchez C, Dejima H, Francisco-Cruz A, Wang J, Antonoff MB, Vaporciyan AA, Swisher SG, Cascone T, Wistuba II, Heymach JV, Gibbons DL, Zhang J, Haymaker CL, Sepesi B. Neutrophil expansion defines an immunoinhibitory peripheral and intratumoral inflammatory milieu in resected non-small cell lung cancer: a descriptive analysis of a prospectively immunoprofiled cohort. J Immunother Cancer 8(1), 2020. e-Pub 2020. PMID: 32350118.
173. Stewart CA, Gay CM, Xi Y, Sivajothi S, Sivakamasundari V, Fujimoto J, Bolisetty M, Hartsfield PM, Balasubramaniyan V, Chalishazar MD, Moran C, Kalhor N, Stewart J, Tran H, Swisher SG, Roth JA, Zhang J, de Groot J, Glisson B, Oliver TG, Heymach JV, Wistuba I, Robson P, Wang J, Byers LA. Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer. Nat Cancer 1:423-436, 2020. e-Pub 2020. PMID: 33521652.
174. Mitchell KG, Farooqi A, Ludmir EB, Corsini EM, Sepesi B, Gomez DR, Antonoff MB, MD Anderson Cancer Center Oligometastatic Lung Cancer Working Group MD. Pulmonary resection is associated with long-term survival and should remain a therapeutic option in oligometastatic lung cancer. J Thorac Cardiovasc Surg, 2020. e-Pub 2020. PMID: 32331820.
175. Liu Y, Fan J, Xu T, Ahmadinejad N, Hess K, Lin SH, Zhang J, Liu X, Liu L, Ning B, Liao Z, Hu TY. Extracellular vesicle tetraspanin-8 level predicts distant metastasis in non-small cell lung cancer after concurrent chemoradiation. Sci Adv 6(11):eaaz6162, 2020. e-Pub 2020. PMID: 32195353.
176. Nelson DB, Mitchell KG, Wang J, Fujimoto J, Godoy M, Behrens C, Zheng X, Zhang J, Sepesi B, Vaporciyan AA, Hofstetter WL, Mehran RJ, Rice DC, Walsh GL, Swisher SG, Moran CA, Kalhor N, Weissferdt A, Wistuba II, Roth JA, Antonoff MB. Immune regulatory markers of lepidic-pattern adenocarcinomas presenting as ground glass opacities. J Thorac Dis 12(3):329-337, 2020. e-Pub 2020. PMID: 32274099.
177. Gainor JF, Rizvi H, Jimenez Aguilar E, Skoulidis F, Yeap BY, Naidoo J, Khosrowjerdi S, Mooradian M, Lydon C, Illei P, Zhang J, Peterson R, Ricciuti B, Nishino M, Zhang J, Roth JA, Grishman J, Anderson D, Little BP, Carter BW, Arbour K, Sauter JL, Mino-Kenudson M, Heymach JV, Digumarthy S, Shaw AT, Awad MM, Hellmann MD. Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression =50. Ann Oncol 31(3):404-411, 2020. e-Pub 2020. PMID: 32067682.
178. Zhuo M, Guan Y, Yang X, Hong L, Wang Y, Li Z, Chen R, Abbas HA, Chang L, Gong Y, Wu N, Zhong J, Chen W, Chen H, Dong Z, Zhu X, Li J, Wang Y, An T, Wu M, Wang Z, Wang J, Roarty EB, Rinsurongkawong W, Lewis J, Roth JA, Swisher SG, Lee JJ, Heymach JV, Wistuba II, Kalhor N, Yang L, Yi X, Futreal PA, Glisson BS, Xia X, Zhang J, Zhao J. The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma. Clin Cancer Res 26(4):892-901, 2020. e-Pub 2020. PMID: 31694833.
179. Jin Y, Bao H, Le X, Fan X, Tang M, Shi X, Zhao J, Yan J, Xu Y, Quek K, Elamin YY, Zhang J, Futreal PA, Wistuba II, Heymach JV, Lou G, Shao L, He Q, Lin C, Wu X, Shao YW, Wang X, He J, Chen Y, Stebbing J, Chen M, Zhang J, Yu X. Correction: Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation. Oncogene 39(9):2027, 2020. e-Pub 2020. PMID: 31831835.
180. Tang C, Lee WC, Reuben A, Chang L, Tran H, Little L, Gumbs C, Wargo J, Futreal A, Liao Z, Xia X, Yi X, Swisher SG, Heymach JV, Gomez D, Zhang J. Immune and Circulating Tumor DNA Profiling After Radiation Treatment for Oligometastatic Non-Small Cell Lung Cancer: Translational Correlatives from a Mature Randomized Phase II Trial. Int J Radiat Oncol Biol Phys 106(2):349-357, 2020. e-Pub 2020. PMID: 31678224.
181. Mitchell KG, Negrao MV, Parra ER, Li J, Zhang J, Dejima H, Vaporciyan AA, Swisher SG, Weissferdt A, Antonoff MB, Cascone T, Roarty E, Wistuba II, Heymach JV, Gibbons DL, Zhang J, Sepesi B. Lymphovascular Invasion Is Associated with Mutational Burden and PD-L1 in Resected Lung Cancer. Ann Thorac Surg 109(2):358-366, 2020. e-Pub 2020. PMID: 31550464.
182. Chen F, Shen C, Pang X, Zhang Z, Deng Y, Han L, Chen X, Zhang J, Xia Q, Qian Y. Effectiveness of tigecycline in the treatment of infections caused by carbapenem-resistant gram-negative bacteria in pediatric liver transplant recipients: A retrospective study. Transpl Infect Dis 22(1):e13199, 2020. e-Pub 2020. PMID: 31627248.
183. Ruiz-Cordero R, Ma J, Khanna A, Lyons G, Rinsurongkawong W, Bassett R, Guo M, Routbort MJ, Zhang J, Skoulidis F, Heymach J, Roarty EB, Tang Z, Medeiros LJ, Patel KP, Luthra R, Roy-Chowdhuri S. Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations. BMC Cancer 20(1):83, 2020. e-Pub 2020. PMID: 32005111.
184. Reuben A, Zhang J, Chiou SH, Gittelman RM, Li J, Lee WC, Fujimoto J, Behrens C, Liu X, Wang F, Quek K, Wang C, Kheradmand F, Chen R, Chow CW, Lin H, Bernatchez C, Jalali A, Hu X, Wu CJ, Eterovic AK, Parra ER, Yusko E, Emerson R, Benzeno S, Vignali M, Wu X, Ye Y, Little LD, Gumbs C, Mao X, Song X, Tippen S, Thornton RL, Cascone T, Snyder A, Wargo JA, Herbst R, Swisher S, Kadara H, Moran C, Kalhor N, Zhang J, Scheet P, Vaporciyan AA, Sepesi B, Gibbons DL, Robins H, Hwu P, Heymach JV, Sharma P, Allison JP, Baladandayuthapani V, Lee JJ, Davis MM, Wistuba II, Futreal PA, Zhang J. Comprehensive T cell repertoire characterization of non-small cell lung cancer. Nat Commun 11(1):603, 2020. e-Pub 2020. PMID: 32001676.
185. Mitchell KG, Farooqi A, Ludmir EB, Corsini EM, Zhang J, Sepesi B, Vaporciyan AA, Swisher SG, Heymach JV, Zhang J, Gomez DR, Antonoff MB. Improved Overall Survival With Comprehensive Local Consolidative Therapy in Synchronous Oligometastatic Non-Small-Cell Lung Cancer. Clin Lung Cancer 21(1):37-46.e7, 2020. e-Pub 2020. PMID: 31447303.
186. Lv Z, Wu K, Qin X, Yuan J, Yan M, Zhang J, Wang L, Ji T, Cao W, Chen W. A Novel Tumor Suppressor SPINK5 Serves as an Independent Prognostic Predictor for Patients with Head and Neck Squamous Cell Carcinoma. Cancer Manag Res 12:4855-4869, 2020. e-Pub 2020. PMID: 32606974.
187. Wang Y, Zheng Q, Jia B, An T, Zhao J, Wu M, Zhuo M, Li J, Zhong J, Chen H, Yang X, Chi Y, Dong Z, Sepesi B, Zhang J, Gay CM, Wang Z. Effects of Surgery on Survival of Early-Stage Patients With SCLC: Propensity Score Analysis and Nomogram Construction in SEER Database. Front Oncol 10:626, 2020. e-Pub 2020. PMID: 32391280.
188. Hillman RT, Cardnell R, Fujimoto J, Lee WC, Zhang J, Byers LA, Ramalingam P, Leitao M, Swisher E, Futreal PA, Frumovitz M. Comparative genomics of high-grade neuroendocrine carcinoma of the cervix. PLoS One 15(6):e0234505, 2020. e-Pub 2020. PMID: 32544169.
189. Su D, Zhang D, Jin J, Ying L, Han M, Chen K, Li B, Wu J, Xie Z, Zhang F, Lin Y, Cheng G, Li JY, Huang M, Wang J, Wang K, Zhang J, Li F, Xiong L, Futreal A, Mao W. Identification of predictors of drug sensitivity using patient-derived models of esophageal squamous cell carcinoma. Nat Commun 10(1):5076, 2019. e-Pub 2019. PMID: 31700061.
190. Kadara H, Sivakumar S, Jakubek Y, San Lucas FA, Lang W, McDowell T, Weber Z, Behrens C, Davies GE, Kalhor N, Moran C, El-Zein R, Mehran R, Swisher SG, Wang J, Zhang J, Fujimoto J, Fowler J, Heymach JV, Dubinett S, Spira AE, Ehli EA, Wistuba II, Scheet P. Driver Mutations in Normal Airway Epithelium Elucidate Spatiotemporal Resolution of Lung Cancer. Am J Respir Crit Care Med, 2019. e-Pub 2019. PMID: 30896962.
191. Kudo Y, Haymaker C, Zhang J, Reuben A, Duose DY, Fujimoto J, Roy-Chowdhuri S, Solis Soto LM, Dejima H, Parra ER, Mino B, Abraham R, Ikeda N, Vaporcyan A, Gibbons D, Zhang J, Lang FF, Luthra R, Lee JJ, Moran C, Huse JT, Kadara H, Wistuba II. Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small-cell lung cancer. Ann Oncol 30(9):1521-1530, 2019. e-Pub 2019. PMID: 31282941.
192. Zhang C, Zhang J, Xu FP, Wang YG, Xie Z, Su J, Dong S, Nie Q, Shao Y, Zhou Q, Yang JJ, Yang XN, Zhang XC, Li Z, Wu YL, Zhong WZ. Genomic Landscape and Immune Microenvironment Features of Preinvasive and Early-Invasive Lung Adenocarcinoma. J Thorac Oncol, 2019. e-Pub 2019. PMID: 31446140.
193. Hu X, Fujimoto J, Ying L, Fukuoka J, Ashizawa K, Sun W, Reuben A, Chow CW, McGranahan N, Chen R, Hu J, Godoy MC, Tabata K, Kuroda K, Shi L, Li J, Behrens C, Parra ER, Little LD, Gumbs C, Mao X, Song X, Tippen S, Thornton RL, Kadara H, Scheet P, Roarty E, Ostrin EJ, Wang X, Carter BW, Antonoff MB, Zhang J, Vaporciyan AA, Pass H, Swisher SG, Heymach JV, Lee JJ, Wistuba II, Hong WK, Futreal PA, Su D, Zhang J. Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma. Nat Commun 10(1):2978, 2019. e-Pub 2019. PMID: 31278276.
194. Ma F, Guan Y, Yi Z, Chang L, Li Q, Chen S, Zhu W, Guan X, Li C, Qian H, Xia X, Yang L, Zhang J, Husain H, Liao Z, Futreal A, Huang J, Yi X, Xu B. Assessing tumor heterogeneity using ctDNA to predict and monitor therapeutic response in metastatic breast cancer. Int J Cancer, 2019. e-Pub 2019. PMID: 31241775.
195. Wang J, Yi Y, Xiao Y, Dong L, Liang L, Teng L, Ying JM, Lu T, Liu Y, Guan Y, Pang J, Zhou L, Lu J, Zhang Z, Liu X, Liang X, Zeng X, Yi X, Zhou W, Xia X, Yang L, Zhang J, Kopetz S, Futreal PA, Wu H, Liang Z. Prevalence of recurrent oncogenic fusion in mismatch repair-deficient colorectal carcinoma with hypermethylated MLH1 and wild-type BRAF and KRAS. Mod Pathol 32(7):1053-1064, 2019. e-Pub 2019. PMID: 30723297.
196. Gomez DR, Tang C, Zhang J, Blumenschein GR, Hernandez M, Lee JJ, Ye R, Palma DA, Louie AV, Camidge DR, Doebele RC, Skoulidis F, Gaspar LE, Welsh JW, Gibbons DL, Karam JA, Kavanagh BD, Tsao AS, Sepesi B, Swisher SG, Heymach JV. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. J Clin Oncol 37(18):1558-1565, 2019. e-Pub 2019. PMID: 31067138.
197. Simon G, DiNardo CD, Takahashi K, Cascone T, Powers C, Stevens R, Allen J, Antonoff MB, Gomez D, Keane P, Suarez Saiz F, Nguyen Q, Roarty E, Pierce S, Zhang J, Hardeman Barnhill E, Lakhani K, Shaw K, Smith B, Swisher S, High R, Futreal PA, Heymach J, Chin L. Applying Artificial Intelligence to Address the Knowledge Gaps in Cancer Care. Oncologist 24(6):772-782, 2019. e-Pub 2019. PMID: 30446581.
198. Negrao MV, Lam VK, Reuben A, Rubin ML, Landry LL, Roarty EB, Rinsurongkawong W, Lewis J, Roth JA, Swisher SG, Gibbons DL, Wistuba II, Papadimitrakopoulou V, Glisson BS, Blumenschein GR, Lee JJ, Heymach JV, Zhang J. PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer. J Thorac Oncol 14(6):1021-1031, 2019. e-Pub 2019. PMID: 30780001.
199. Fischer GM, Jalali A, Kircher DA, Lee WC, McQuade JL, Haydu LE, Joon AY, Reuben A, de Macedo MP, Carapeto FCL, Yang C, Srivastava A, Ambati CR, Sreekumar A, Hudgens CW, Knighton B, Deng W, Ferguson SD, Tawbi HA, Glitza IC, Gershenwald JE, Vashisht Gopal YN, Hwu P, Huse JT, Wargo JA, Futreal PA, Putluri N, Lazar AJ, DeBerardinis RJ, Marszalek JR, Zhang J, Holmen SL, Tetzlaff MT, Davies MA. Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases. Cancer Discov 9(5):628-645, 2019. e-Pub 2019. PMID: 30787016.
200. Sivakumar S, San Lucas FA, Jakubek YA, McDowell TL, Lang W, Kallsen N, Peyton S, Davies GE, Fukuoka J, Yatabe Y, Zhang J, Futreal PA, Fowler J, Fujimoto J, Ehli EA, Hawk ET, Wistuba II, Kadara H, Scheet P. Genomic landscape of allelic imbalance in premalignant atypical adenomatous hyperplasias of the lung. EBioMedicine 42:296-303, 2019. e-Pub 2019. PMID: 30905849.
201. Nong J, Gong Y, Guan Y, Yi X, Yi Y, Chang L, Yang L, Lv J, Guo Z, Jia H, Chu Y, Liu T, Chen M, Byers L, Roarty E, Lam VK, Papadimitrakopoulou VA, Wistuba I, Heymach JV, Glisson B, Liao Z, Lee JJ, Futreal PA, Zhang S, Xia X, Zhang J, Wang J. Author Correction: Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer. Nat Commun 10(1):552, 2019. e-Pub 2019. PMID: 30696827.
202. Elamin YY, Gomez DR, Antonoff MB, Robichaux JP, Tran H, Shorter MK, Bohac JM, Negrao MV, Le X, Rinsurogkawong W, Lewis J, Lacerda L, Roarty EB, Swisher SG, Roth JA, Zhang J, Papadimitrakopoulou V, Heymach JV. Local Consolidation Therapy (LCT) After First Line Tyrosine Kinase Inhibitor (TKI) for Patients With EGFR Mutant Metastatic Non-small-cell Lung Cancer (NSCLC). Clin Lung Cancer 20(1):43-47, 2019. e-Pub 2019. PMID: 30343004.
203. Lam VK, Tran HT, Banks KC, Lanman RB, Rinsurongkawong W, Peled N, Lewis J, Lee JJ, Roth J, Roarty EB, Swisher S, Talasaz A, Futreal PA, Papadimitrakopoulou V, Heymach JV, Zhang J. Targeted Tissue and Cell-Free Tumor DNA Sequencing of Advanced Lung Squamous-Cell Carcinoma Reveals Clinically Significant Prevalence of Actionable Alterations. Clin Lung Cancer 20(1):30-36.e3, 2019. e-Pub 2019. PMID: 30279110.
204. Le X, Puri S, Negrao MV, Nilsson MB, Robichaux J, Boyle T, Hicks JK, Lovinger KL, Roarty E, Rinsurongkawong W, Tang M, Sun H, Elamin Y, Lacerda LC, Lewis J, Roth JA, Swisher SG, Lee JJ, William WN, Glisson BS, Zhang J, Papadimitrakopoulou VA, Gray JE, Heymach JV. Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC. Clin Cancer Res 24(24):6195-6203, 2018. e-Pub 2018. PMID: 30228210.
205. Ferguson SD, Zheng S, Xiu J, Zhou S, Khasraw M, Brastianos PK, Kesari S, Hu J, Rudnick J, Salacz ME, Piccioni D, Huang S, Davies MA, Glitza IC, Heymach JV, Zhang J, Ibrahim NK, DeGroot JF, McCarty J, O'Brien BJ, Sawaya R, Verhaak RGW, Reddy SK, Priebe W, Gatalica Z, Spetzler D, Heimberger AB. Profiles of brain metastases: Prioritization of therapeutic targets. Int J Cancer 143(11):3019-3026, 2018. e-Pub 2018. PMID: 29923182.
206. Nong J, Gong Y, Guan Y, Yi X, Yi Y, Chang L, Yang L, Lv J, Guo Z, Jia H, Chu Y, Liu T, Chen M, Byers L, Roarty E, Lam VK, Papadimitrakopoulou VA, Wistuba I, Heymach JV, Glisson B, Liao Z, Lee JJ, Futreal PA, Zhang S, Xia X, Zhang J, Wang J. Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer. Nat Commun 9(1):3114, 2018. e-Pub 2018. PMID: 30082701.
207. Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, Awad MM, Gainor JF, Schrock AB, Hartmaier RJ, Trabucco SE, Gay L, Ali SM, Elvin JA, Singal G, Ross JS, Fabrizio D, Szabo PM, Chang H, Sasson A, Srinivasan S, Kirov S, Szustakowski J, Vitazka P, Edwards R, Bufill JA, Sharma N, Ou SI, Peled N, Spigel DR, Rizvi H, Aguilar EJ, Carter BW, Erasmus J, Halpenny DF, Plodkowski AJ, Long NM, Nishino M, Denning WL, Galan-Cobo A, Hamdi H, Hirz T, Tong P, Wang J, Rodriguez-Canales J, Villalobos PA, Parra ER, Kalhor N, Sholl LM, Sauter JL, Jungbluth AA, Mino-Kenudson M, Azimi R, Elamin YY, Zhang J, Leonardi GC, Jiang F, Wong KK, Lee JJ, Papadimitrakopoulou VA, Wistuba II, Miller VA, Frampton GM, Wolchok JD, Shaw AT, Jänne PA, Stephens PJ, Rudin CM, Geese WJ, Albacker LA, Heymach JV. STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. Cancer Discov 8(7):822-835, 2018. e-Pub 2018. PMID: 29773717.
208. Parra ER, Villalobos P, Behrens C, Jiang M, Pataer A, Swisher SG, William WN, Zhang J, Lee J, Cascone T, Heymach JV, Forget MA, Haymaker C, Bernatchez C, Kalhor N, Weissferdt A, Moran C, Zhang J, Vaporciyan A, Gibbons DL, Sepesi B, Wistuba II. Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches. J Immunother Cancer 6(1):48, 2018. e-Pub 2018. PMID: 29871672.
209. Lee WC, Diao L, Wang J, Zhang J, Roarty EB, Varghese S, Chow CW, Fujimoto J, Behrens C, Cascone T, Peng W, Kalhor N, Moran CA, Weissferdt A, Johnson FM, William WN, Swisher SG, Lee JJ, Hong WK, Heymach JV, Wistuba II, Futreal PA, Zhang J. Multiregion gene expression profiling reveals heterogeneity in molecular subtypes and immunotherapy response signatures in lung cancer. Mod Pathol 31(6):947-955, 2018. e-Pub 2018. PMID: 29410488.
210. Parra ER, Villalobos P, Zhang J, Behrens C, Mino B, Swisher S, Sepesi B, Weissferdt A, Kalhor N, Heymach JV, Moran C, Zhang J, Lee J, Rodriguez-Canales J, Gibbons D, Wistuba II. Immunohistochemical and Image Analysis-Based Study Shows That Several Immune Checkpoints are Co-expressed in Non-Small Cell Lung Carcinoma Tumors. J Thorac Oncol 13(6):779-791, 2018. e-Pub 2018. PMID: 29526824.
211. Tang Z, Zhang J, Lu X, Wang W, Chen H, Robinson MK, Cheng J, Tang G, Medeiros LJ. Coexistent genetic alterations involving ALK, RET, ROS1 or MET in 15 cases of lung adenocarcinoma. Mod Pathol 31(2):307-312, 2018. e-Pub 2018. PMID: 28914263.
212. Sivakumar S, Lucas FAS, McDowell TL, Lang W, Xu L, Fujimoto J, Zhang J, Futreal PA, Fukuoka J, Yatabe Y, Dubinett SM, Spira AE, Fowler J, Hawk ET, Wistuba II, Scheet P, Kadara H. Genomic Landscape of Atypical Adenomatous Hyperplasia Reveals Divergent Modes to Lung Adenocarcinoma. Cancer Res 77(22):6119-6130, 2017. e-Pub 2017. PMID: 28951454.
213. Liu B, Mitani Y, Rao X, Zafereo M, Zhang J, Zhang J, Futreal PA, Lozano G, El-Naggar AK. Spatio-Temporal Genomic Heterogeneity, Phylogeny, and Metastatic Evolution in Salivary Adenoid Cystic Carcinoma. J Natl Cancer Inst 109(10), 2017. e-Pub 2017. PMID: 29117356.
214. Schvartsman G, Peng SA, Bis G, Lee JJ, Benveniste MFK, Zhang J, Roarty EB, Lacerda L, Swisher S, Heymach JV, Fossella FV, William WN. Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer. Lung Cancer 112:90-95, 2017. e-Pub 2017. PMID: 29191606.
215. Reuben A, Gittelman R, Gao J, Zhang J, Yusko EC, Wu CJ, Emerson R, Zhang J, Tipton C, Li J, Quek K, Gopalakrishnan V, Chen R, Vence LM, Cascone T, Vignali M, Fujimoto J, Rodriguez-Canales J, Parra ER, Little LD, Gumbs C, Forget MA, Federico L, Haymaker C, Behrens C, Benzeno S, Bernatchez C, Sepesi B, Gibbons DL, Wargo JA, William WN, Swisher S, Heymach JV, Robins H, Lee JJ, Sharma P, Allison JP, Futreal PA, Wistuba II, Zhang J. TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. Cancer Discov 7(10):1088-1097, 2017. e-Pub 2017. PMID: 28733428.
216. Quek K, Li J, Estecio M, Zhang J, Fujimoto J, Roarty E, Little L, Chow CW, Song X, Behrens C, Chen T, William WN, Swisher S, Heymach J, Wistuba I, Zhang J, Futreal A, Zhang J. DNA methylation intratumor heterogeneity in localized lung adenocarcinomas. Oncotarget 8(13):21994-22002, 2017. e-Pub 2017. PMID: 28423542.
217. Logan JK, Tang C, Liao Z, Lee JJ, Heymach JV, Swisher SG, Welsh JW, Zhang J, Lin SH, Gomez DR. Analysis of Factors Affecting Successful Clinical Trial Enrollment in the Context of Three Prospective, Randomized, Controlled Trials. Int J Radiat Oncol Biol Phys 97(4):770-777, 2017. e-Pub 2017. PMID: 28244413.
218. Reddy JP, Tang C, Shih T, Kim B, Kim C, Nguyen QN, Welsh J, Benveniste M, Zhang J, Liao Z, Gomez DR. Influence of Surveillance PET/CT on Detection of Early Recurrence After Definitive Radiation in Stage III Non-small-cell Lung Cancer. Clin Lung Cancer 18(2):141-148, 2017. e-Pub 2017. PMID: 27913215.
219. Gomez DR, Blumenschein GR, Lee JJ, Hernandez M, Ye R, Camidge DR, Doebele RC, Skoulidis F, Gaspar LE, Gibbons DL, Karam JA, Kavanagh BD, Tang C, Komaki R, Louie AV, Palma DA, Tsao AS, Sepesi B, William WN, Zhang J, Shi Q, Wang XS, Swisher SG, Heymach JV. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol 17(12):1672-1682, 2016. e-Pub 2016. PMID: 27789196.
220. Liu Y, Zhang J, Li L, Yin G, Zhang J, Zheng S, Cheung H, Wu N, Lu N, Mao X, Yang L, Zhang J, Zhang L, Seth S, Chen H, Song X, Liu K, Xie Y, Zhou L, Zhao C, Han N, Chen W, Zhang S, Chen L, Cai W, Li L, Shen M, Xu N, Cheng S, Yang H, Lee JJ, Correa A, Fujimoto J, Behrens C, Chow CW, William WN, Heymach JV, Hong WK, Swisher S, Wistuba II, Wang J, Lin D, Liu X, Futreal PA, Gao Y. Genomic heterogeneity of multiple synchronous lung cancer. Nat Commun 7:13200, 2016. e-Pub 2016. PMID: 27767028.
221. Fan Y, Xi L, Hughes DS, Zhang J, Zhang J, Futreal PA, Wheeler DA, Wang W. MuSE: accounting for tumor heterogeneity using a sample-specific error model improves sensitivity and specificity in mutation calling from sequencing data. Genome Biol 17(1):178, 2016. e-Pub 2016. PMID: 27557938.
222. Parra ER, Behrens C, Rodriguez-Canales J, Lin HY, Mino B, Blando J, Zhang J, Gibbons DL, Heymach JV, Sepesi B, Swisher SG, Weissferdt A, Kalhor N, Izzo J, Kadara H, Moran C, Lee JJ, Wistuba II. Image Analysis-Based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non-Small Cell Lung Carcinoma Patients. Clin Cancer Res, 2016. e-Pub 2016. PMID: 27252415.
223. Y* X, J* Z, Lin H, Gold KA, Sturgis EM, Garden AS, Lee JJ, William WN. Relationship between level of lymph node metastasis and survival in locally advanced head and neck squamous cell carcinoma. Cancer 122(4):534-45, 2016. e-Pub 2016. PMID: 26554754.
224. Skoulidis F, Byers LA, Diao L, Papadimitrakopoulou VA, Tong P, Izzo J, Behrens C, Kadara H, Parra ER, Canales JR, Zhang J, Giri U, Gudikote J, Cortez MA, Yang C, Fan Y, Peyton M, Girard L, Coombes KR, Toniatti C, Heffernan TP, Choi M, Frampton GM, Miller V, Weinstein JN, Herbst RS, Wong KK, Zhang J, Sharma P, Mills GB, Hong WK, Minna JD, Allison JP, Futreal A, Wang J, Wistuba II, Heymach JV. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles and therapeutic vulnerabilities. Cancer Discov 5(8):860-77, 2015. e-Pub 2015. PMID: 26069186.
225. Zhang J, Gold KA, Lin HY, Swisher SG, Xing Y, Lee JJ, Kim ES, William WN. Relationship between tumor size and survival in non-small cell lung cancer (NSCLC): an analysis of the Surveillance, Epidemiology, and End Results (SEER) registry. J Thorac Oncol 10(4):682-690, 2015. e-Pub 2015. PMID: 25590605.
226. Buganoa D, Kalhor N, Zhang J, Neskey M, William Jr W. Squamous-cell transformation in a patient with lung adenocarcinoma receiving erlotinib: Co-occurrence with T790M mutation. Cancer Treatment Communications 4:34-36, 2015. e-Pub 2015.
227. Zhang J, Fujimoto J, Zhang J, Wedge DC, Song X, Zhang J, Seth S, Chow CW, Cao Y, Gumbs C, Gold KA, Kalhor N, Little L, Mahadeshwar H, Moran C, Protopopov A, Sun H, Tang J, Wu X, Ye Y, William WN, Lee JJ, Heymach JV, Hong WK, Swisher S, Wistuba II, Futreal PA. Intra-tumor Heterogeneity in Localized Lung Adenocarcinomas Delineated by Multi-region Sequencing. Science 346(6206):256-259, 2014. e-Pub 2014. PMID: 25301631.
228. Rotolo J, Stancevic B, Zhang J, Hua G, Fuller J, Yin X, Haimovitz-Friedman A, Kim K, Qian M, Cardó-Vila M, Fuks Z, Pasqualini R, Arap W, Kolesnick R. Anti-ceramide antibody prevents the radiation gastrointestinal syndrome in mice. J Clin Invest 122(5):1786-90, 2012. e-Pub 2012. PMID: 22466649.
229. Feng XL, Li L, Gao YN, Zhang JJ, Xiao T, Ying JM, Gao JD, Sun YT, Cheng SJ. Overexpression of c-erbB-2 and loss of p16 have molecular diagnostic relevance but no prognostic value in lung cancer. Med Oncol 28(1):336-341, 2011. e-Pub 2011. PMID: 20237870.
230. Rotolo JA, Stancevic B, Lu SX, Zhang J, Suh D, King CG, Kappel LW, Murphy GF, Liu C, Fuks Z, van den Brink MR, Kolesnick R. Cytolytic T cells induce ceramide-rich platforms in target cell membranes to initiate graft-versus-host disease. Blood 114(17):3693-706, 2009. e-Pub 2009. PMID: 19666872.
231. Zhang J, Zafrullah M, Yang X, Yin X, Zhang Z, Fuks Z, Kolesnick R. Downregulation of KSR1 in pancreatic cancer xenografts by antisense oligonucleotide correlates with tumor drug uptake. Cancer Biol Ther 7(9):1490-1495, 2008. e-Pub 2008. PMID: 18719367.
232. Jin X, Zhang J, Gao Y, Ding K, Wang N, Zhou D, Jen J, Cheng S. Relationship between mitochondrial DNA mutations and clinical characteristics in human lung cancer. Mitochondrion 7(5):347-353, 2007. e-Pub 2007. PMID: 17707697.
233. Feng X, Li L, Gao Y, Zhang J, Ying J, Xiao T, Gao J, Liu X, Sun Y, Cheng S. Fhit protein expression in lung cancer studied by high-throughput tissue microarray. Bull Cancer 94(3):E8-11, 2007. e-Pub 2007. PMID: 17371765.
234. Rotolo JA, Zhang J, Donepudi M, Lee H, Fuks Z, Kolesnick R. Caspase-dependent and -independent activation of acid sphingomyelinase signaling. J Biol Chem 280(28):26425-26434, 2005. e-Pub 2005. PMID: 15849201.
235. Ch'ang HJ, Maj JG, Paris F, Xing HR, Zhang J, Truman JP, Cardon-Cardo C, Haimovitz-Friedman A, Kolesnick R, Fuks Z. ATM regulates target switching to escalating doses of radiation in the intestines. Nat Med 11(5):484-490, 2005. e-Pub 2005. PMID: 15864314.
236. Liu JY, An Q, Zhang JJ, Lei WD, Cheng SJ, Gao YN. [Screening of hypermethylated DNA fragments in tumor tissue derived from patients with lung cancer]. Yi Chuan Xue Bao 31(4):389-94, 2004. e-Pub 2004. PMID: 15487509.
237. Zhang J, Zheng S, Gao Y, Rotolo JA, Xiao Z, Li C, Cheng S. A partial allelotyping of urothelial carcinoma of bladder in the Chinese. Carcinogenesis 25(3):343-247, 2004. e-Pub 2004. PMID: 14604888.
238. An Q, Pacyna-Gengelbach M, Schlüns K, Deutschmann N, Guo S, Gao Y, Zhang J, Cheng S, Petersen I. Identification of differentially expressed genes in immortalized human bronchial epithelial cell line as a model for in vitro study of lung carcinogenesis. Int J Cancer 103(2):194-204, 2003. e-Pub 2003. PMID: 12455033.
239. An Q, Liu Y, Gao Y, Huang J, Fong X, Liu L, Zhang D, Zhang J, Cheng S. Deletion of tumor suppressor genes in Chinese non-small cell lung cancer. Cancer Lett 184(2):189-195, 2002. e-Pub 2002. PMID: 12127691.
240. Xiao Z, Zhang J, Zheng S, Li C, He Z, Cheng S, Gao Y. [Loss of heterozygosity of tumor suppressor genes at chromosome 3p in transitional cell carcinoma of urinary bladder]. Zhonghua Yi Xue Za Zhi 82(20):1375-7, 2002. e-Pub 2002. PMID: 12509916.
241. Xu X, Li L, Zhang J, Gao Y, Zhang R, Tang P, Cheng S. Loss of heterozygosity of tumor suppressor genes on chromosome 3p in laryngeal squamous cell carcinoma by microsatellite analysis. J Otorhinolaryngology and Head-Neck Surg 9(4):231-236, 2002. e-Pub 2002.
242. Jin XJ, Zhang J, Song Y, Gao YN, Cheng SJ. [Mitochondrial DNA mutations in lung cancer]. Ai Zheng 21(7):715-8, 2002. e-Pub 2002. PMID: 12479093.
243. Shao S, Sun W, Zhang J, An Q, Xiao T, Yang P, Cheng S, Gao Y. Fine deletion mapping on chromosome 8p21 - 8p22 in adenocarcinoma of lung. Zhonghua Yi Xue Za Zhi 82(11):740-2, 2002. e-Pub 2002. PMID: 12126542.
244. Shao S, Xu X, Zhang J, Yang P, Cheng S, Gao Y. Loss of heterozygosity on chromosome 9p21.3-23 in laryngeal squamous cell carcinoma. J Dalian Med Univ 24(2):81-83, 2002. e-Pub 2002.
245. Zheng S, Zhang J, Di X, Xiao Z, Wang D, Li C, He Z, Han N, Guo S, Cheng S, Gao Y. Loss of heterozygosity fine mapping of chromosome 17p13 in transitional cell carcinoma of human urinary bladder. Zhonghua Yi Xue Za Zhi 82(3):161-3, 2002. e-Pub 2002. PMID: 11953150.
246. Zhang J, Zheng S, Fan Z, Gao Y, Di X, Wang D, Xiao Z, Li C, An Q, Cheng S. A comparison between microsatellite analysis and cytology of urine for the detection of bladder cancer. Cancer Lett 172(1):55-58, 2001. e-Pub 2001. PMID: 11595129.
247. Xu X, An Q, Zhang J, Tang P, Cheng S. Loss of heterozygosity analysis of chromosome 9p13-23 in microdissected laryngeal squamous cell carcinoma. Chin J Otorhinolaryngol 36(5):367-371, 2001. e-Pub 2001.
248. Zhang J, Zheng S, Di X, Xiao Z, Wang D, An Q, Li C, Guo S, Han N, Cheng S, Gao Y. A further study on potential of microsatellite analysis of urine in detection of bladder cancer. Natl Med J China 81(20):1224-1227, 2001. e-Pub 2001.
249. An Q, Dong X, Zhang J, Huang J, Li L, Cheng S, Gao Y. Studies on inactivation of p16/CDKN2 gene in non-small-cell lung cancer. Chin Journal Cancer 20(6):591-594, 2001. e-Pub 2001.
250. Li L, An Q, Feng X, Zhang J, Huang J, Liu L, Cheng S, Gao Y. Abnormalities of tumor suppressor genes at chromosome 3p in lung cancer. Natl Med J China 81(7):399-401, 2001. e-Pub 2001.
251. Fan Z, Zhang J, Bai J, Xiao Z, Cheng S. Deletion mapping of 18q and Smad proteins expression analysis in bladder carcinomas. Chin J Oncol 23(2):135-137, 2001. e-Pub 2001.
252. Zhang J, Fan Z, Gao Y, Xiao Z, Li C, An Q, Cheng S. Detecting bladder cancer in the Chinese by microsatellite analysis: ethnic and etiologic considerations. J Natl Cancer Inst 39(1):45-50, 2001. e-Pub 2001. PMID: 11136841.
253. Fan Z, Zhang J, Bai J, Xiao Z, Cheng S. Alterations of microsatellites on 9p in tumor tissue and urine sediments from patients with transitional cell carcinoma. Natl Med J China 80(1):44-45, 2001. e-Pub 2001.
254. Zhang J, Gao Y, Cheng S. Whole genome amplification: golden key for minute DNA analysis. Chin J Pathol 29(6):447-449, 2000. e-Pub 2000.
255. Zhang J, An Q, Gao Y, Cheng S. Microsatellites and human tumors. Chin J Cancer 19(10):948-950, 2000. e-Pub 2000.
256. Zhang J, Fan Z, Bai J, Xiao Z, An Q, Gao Y, Cheng S. Potential of microsatellite analysis in detection of bladder cancer in the Chinese. Chin J Cancer 19(6):512-516, 2000. e-Pub 2000.

Invited Articles

1. Zhang J, Gold KA, Kim E. Sorafenib in Non-Small Cell Lung Cancer. Expert Opin Investig Drugs 21(9):1417-1426, 2012. e-Pub 2012. PMID: 22725255.

Review Articles

1. Wang Y, Rosell R, Hirsch FR, Lu S, Govindan R, Park K, Peters S, Zhang JJ. Emerging Options and Future Strategies in Immunotherapy for Advanced Lung Squamous Cell Carcinoma. Ann Oncol, 2025. e-Pub 2025. PMID: 41260258.
2. Zhu E, Muneer A, Zhang J, Xia Y, Li X, Zhou C, Heymach JV, Wu J, Le X. Progress and challenges of artificial intelligence in lung cancer clinical translation. NPJ Precis Oncol 9(1):210, 2025. e-Pub 2025. PMID: 40595378.
3. Mascaux C, Sen T, Sanchez-Cespedes M, Ortiz-Cuaran S, Bosse Y, Dammeijer F, Cavic M, Barr MP, Arulananda S, Armisen R, Berger AH, Bianchi F, Carbone DP, Cerciello F, Lockwood WW, Mitsudomi T, Ohara S, Politi K, Qin S, Roisman LC, Samstein R, Skoulidis F, Tan AC, Thomas A, Zhang J, Wynes MW, John T, Tsao MS. Advances in Lung Cancer Basic and Translational Research in 2025 - Overview and Perspectives Focusing on NSCLC. J Thorac Oncol, 2025. e-Pub 2025. PMID: 40473107.
4. Qin K, Gay CM, Byers LA, Zhang J. The current and emerging immunotherapy paradigm in small-cell lung cancer. Nat Cancer 6(6):954-966, 2025. e-Pub 2025. PMID: 40473974.
5. Wang Y, Safi M, Hirsch FR, Lu S, Peters S, Govindan R, Rosell R, Park K, Zhang J. Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions. Nat Rev Clin Oncol, 2025. e-Pub 2025. PMID: 39762577.
6. Zhang, J, Vokes, N, Li, M, Xu, J, Bai, H, Wang, J, Wang, Z, Zhang, J. Overcoming EGFR-TKI resistance by targeting the tumor microenvironment. Chinese Medical Journal Pulmonary and Critical Care Medicine 2(3):151-161, 2024. e-Pub 2024. PMID: 39403414.
7. Al-Danakh, A, Safi, M, Jian, Y, Yang, L, Zhu, X, Chen, Q, Yang, K, Wang, S, Zhang, J, Yang, D. Aging-related biomarker discovery in the era of immune checkpoint inhibitors for cancer patients. Frontiers in immunology 15, 2024. e-Pub 2024. PMID: 38590525.
8. Pan, K, Concannon, K, Li, J, Zhang, J, Heymach, JV, Le, X. Emerging therapeutics and evolving assessment criteria for intracranial metastases in patients with oncogene-driven non-small-cell lung cancer. Nature Reviews Clinical Oncology 20(10):716-732, 2023. e-Pub 2023. PMID: 37592034.
9. Al-Tashi Q, Saad MB, Muneer A, Qureshi R, Mirjalili S, Sheshadri A, Le X, Vokes NI, Zhang J, Wu J. Machine Learning Models for the Identification of Prognostic and Predictive Cancer Biomarkers: A Systematic Review. Int J Mol Sci 24(9), 2023. e-Pub 2023. PMID: 37175487.
10. Qin K, Hong L, Zhang J, Le X. MET Amplification as a Resistance Driver to TKI Therapies in Lung Cancer: Clinical Challenges and Opportunities. Cancers (Basel) 15(3), 2023. e-Pub 2023. PMID: 36765572.
11. Vokes NI, Zhang J. The Role of Whole Exome Sequencing in Distinguishing Primary and Secondary Lung Cancers. Lung Cancer (Auckl) 12:139-149, 2021. e-Pub 2021. PMID: 34880699.
12. Hong L, Zhang J, Heymach JV, Le X. Current and future treatment options for MET exon 14 skipping alterations in non-small cell lung cancer. Ther Adv Med Oncol 13:1758835921992976, 2021. e-Pub 2021. PMID: 33643443.
13. Zhang R, Zhang J, He ZG, Cheng SJ, Gao YN. [Research advances on bladder cancer associated genes]. Ai Zheng 22(1):104-7, 2003. e-Pub 2003. PMID: 12561447.

Other Articles

1. Skoulidis, F, Araujo, HA, Do, MT, Qian, Y, Sun, X, Cobo, AG, Le, JT, Montesion, M, Palmer, R, Jahchan, NS, Juan, J, Min, C, Yu, Y, Pan, X, Arbour, KC, Vokes, N, Schmidt, S, Molkentine, D, Owen, D, Memmott, R, Patil, P, Marmarelis, ME, Awad, MM, Murray, J, Hellyer, JA, Gainor, J, Dimou, A, Bestvina, CM, Shu, CA, Riess, JW, Blakely, CM, Pecot, CV, Mezquita, L, Tabbò, F, Scheffler, M, Digumarthy, S, Mooradian, MJ, Sacher, A, Lau, SC, Saltos, A, Rotow, JK, Johnson, RP, Liu, C, Stewart, TF, Goldberg, SB, Killam, J, Walther, Z, Schalper, K, Davies, KD, Woodcock, MG, Anagnostou, V, Marrone, KA, Forde, PM, Ricciuti, B, Venkatraman, D, Van Allen, EM, Cummings, AL, Goldman, JW, Shaish, H, Kier, M, Katz, S, Aggarwal, C, Ni, Y, Azok, J, Segal, J, Ritterhouse, LL, Neal, JW, Lacroix, L, Elamin, YY, Vailati Negrao, M, Le, X, Lam, VK, Lewis, WE, Kemp, HN, Carter, B, Roth, JA, Swisher, S, Lee, R, Zhou, T, Poteete, A, Kong, Y, Takehara, T, Paula, AG, Parra Cuentas, ER, Behrens, MC, Wistuba, II, Zhang, J, Blumenschein, GR, Gay, CM, Byers, LA, Gibbons, DL, Tsao, A, Lee, JJ, Bivona, T, Camidge, DR, Gray, JE, Leighl, NB, Levy, BP, Brahmer, JR, Garassino, MC, Gandara, D, Garon, EB, Rizvi, NA, Scagliotti, G, Wolf, J, Planchard, D, Besse, B, Herbst, RS, Wakelee, HA, Pennell, N, Shaw, AT, Jänne, PA, Carbone, DP, Hellmann, MD, Rudin, CM, Albacker, LA, Mann, H, Zhu, Z, Lai, Z, Stewart, RA, Peters, S, Johnson, M, Wong, KK, Huang, A, Winslow, MM, Rosen, MJ, Winters, IP, Papadimitrakopoulou, VA, Cascone, T, Jewsbury, P, Heymach, JV Correction to. Nature 639(8054):E19, 2025. PMID: 40016449.
2. Han, J, Dong, Y, Zhu, X, Reuben, A, Zhang, J, Xu, J, Bai, H, Duan, J, Wan, R, Zhao, J, Bai, J, Xia, X, Yi, X, Cheng, C, Wang, J, Wang, Z Author Correction. Nature communications 16(1), 2025. PMID: 39994256.
3. Jin, Y, Wu, Y, Reuben, A, Zhu, L, Gay, CM, Wu, Q, Zhou, X, Mo, H, Zheng, Q, Ren, J, Fang, Z, Peng, T, Wang, N, Ma, L, Fan, Y, Song, H, Zhang, J, Chen, M Correction to. Cell Discovery 10(1), 2024. PMID: 39702462.
4. Deboever, N, Zhang, J The opportunities and challenges of perioperative therapy of localized non-small cell lung cancer-thoughts from the KEYNOTE-671 trial. Translational Lung Cancer Research 12(11):2347-2352, 2023. PMID: 38090518.

Editorials

1. Le X, Elamin YY, Zhang J. New Actions on Actionable Mutations in Lung Cancers. Cancers (Basel) 15(11), 2023. PMID: 37296880.
2. Deboever N, Zhang J. Neoadjuvant chemo-immunotherapy for lung cancer: how much is too much?. Transl Lung Cancer Res 11(12):2360-2363, 2022. PMID: 36636418.
3. Lam VK, Zhang J. Blood-based tumor mutation burden: continued progress toward personalizing immunotherapy in non-small cell lung cancer. J Thorac Dis 11(6):2208-2211, 2019. PMID: 31372254.
4. Zhao L, Zhang J, Xu L, Abbas HA. Novel Cancer Immunotherapies and Antitumor Immunity. J Immunol Res 2019:3742061, 2019. PMID: 31428655.
5. Negrao MV, Quek K, Zhang J, Sepesi B. TRACERx: Tracking tumor evolution to impact the course of lung cancer. J Thorac Cardiovasc Surg 155(3):1199-1202, 2018. PMID: 29331175.
6. Lee W, Kopetz S, Wistuba I, Zhang J. Metastasis of cancer: when and how?. Ann Oncol 28(9):2045-2047, 2017.

Abstracts

1. Hui Xu, Xinyan Xu, Kai Zhang, Julie Lin, Maliazurina Saad, George Eapen, Jianjun Zhang, Don Gibbons, John Heymach, Ara Vaporciyan, Jack Roth, Reza Mehran, Peter Balter, Julianne Pollard, David Qian, Steven Lin, Saumil Gandhi, Zhongxing Liao, Jia Wu, Joe Chang. Vision-Language AI Model for Detecting PET/CT-Occult Lymph Node Metastasis in Early-Stage NSCLC Treated with SABR to Prevent Regional Recurrence. ASTRO's 2025 Annual Meeting, 2025. e-Pub 2025.
2. Zhang J, Cai J, Wang H, Yu Y, Bosch-Barrera J, Bernabe R, Andric Z, Badin F, Okuma Y, Paik P, Naidoo J, Kalofonos H, Wang B, Jotte R, Pennell N, Riess J, Doroshow D, Nishio M, Alatorre-Alexander J, Lu S. A randomized phase 3 study of ivonescimab plus chemotherapy versus pembrolizumab plus chemotherapy for the first-line treatment of metastatic non–small cell lung cancer: HARMONi-3. ASCO Annual Meeting, 2025. e-Pub 2025.
3. Boiarsky D, Hong L, Cooper A, Ricciuti B, Saad M, Elkrief A, Di Federico A, Aminu M, Rinsurongkawong W, Gibbons D, Vaporciyan A, Le X, Lee J, Heymach JV, Wu J, Awad M, Schoenfeld A, Zhang J, Vokes N. Molecular profiling of metastatic lung squamous cell carcinoma (mLUSC) to identify patients with differential response to immune checkpoint inhibitor (ICI) therapy. ASCO Annual Meeting, 2025. e-Pub 2025.
4. King N, Hong L, Rinsurongkawong W, Young E, Sui D, McNeill L, Rinsurongkawong V, Lewis J, Lee J, Altan M, Zhang B, Vokes N, Le X, Tran H, Araujo H, Gibbons D, Heymach JV, Zhang J, Lin J. Race-associated clinicogenomic correlates of outcomes to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer (NSCLC). ASCO Annual Meeting, 2025. e-Pub 2025.
5. Parma M, Singhi E, Solis L, Wang W, Altan M, Franco-Vega M, Halliday A, Jacome J, Zhang J, Heymach JV, Byers L, Gay C, Zhang B. Real-world efficacy and safety of tarlatamab in patients with relapsed extensive-stage small cell lung cancer. ASCO Annual Meeting, 2025. e-Pub 2025.
6. Wang X, Zhang Z, Li J, Zhang J, Cheng C. Genomic aberration-derived signature in lung adenocarcinoma improves patient prognosis and therapy stratification. AACR Annual Meeting, 2025. e-Pub 2025.
7. Chen H, Zhang B, Serrano A, Hernandez S, Lu W, Trevino S, Vokes N, Liu X, Tian Y, Zhu B, Nilsson M, Heymach JV, Zhang J, Solis Soto L, Gay C, Byers L, Le X. Spatially resolved protein profiling of tumor and immune microenvironment in EGFR mutant NSCLC with transformation to SCLC. AACR Annual Meeting, 2025. e-Pub 2025.
8. Liu X, Stamboulian M, Borgeaud M, Ravichandran A, Weipert C, Nilsson M, Zhu E, Chen H, Lewis C, Heeke S, He J, Lawson J, Zhang J, Alfredo A, Heymach JV, Le X. EGFR PACC mutations occur more frequently as compound mutations with better responses to EGFR TKIs. AACR Annual meeting, 2025. e-Pub 2025.
9. Rahal Z, Zhou T, Serrano A, Feng J, Vaccaro A, Sinjab A, Le J, Sun X, Wang M, Hu W, Zhang J, Bruno T, Tran H, Swisher S, Leung C, Lee J, Wang J, Heymach JV, Gibbons D, Wistuba I, Weissferdt A, Burks J, Solis Soto L, Kadara H, Cascone T. Spatial and cellular immune landscapes of non-small cell lung cancer in association with response to neoadjuvant chemoimmunotherapy. AACR Annual Meeting, 2025. e-Pub 2025.
10. Grippin A, Marconi C, Copling S, Gupta P, Young E, Sharma P, Gibbons D, Tran H, Kim Y, Zhang J, Wargo J, Heymach JV, Mendez-Gomez H, Jiang W, Sayour E, Lin S. SARS-CoV-2 mRNA vaccines sensitize tumors to immune checkpoint blockade. AACR Annual Meeting, 2025. e-Pub 2025.
11. Chen H, Zhu B, Fujimoto J, Tian Y, Li J, Li C, Chen P, Reuben A, Nilsson M, Le X, Poteete A, Hubert S, Gibbons D, Wistuba I, Wu J, Cheng C, Heymach JV, Zhang J. Dynamic crosstalk between endothelial and epithelial cells drives tumor progression in lung adenocarcinoma. AACR Annual Meeting, 2025. e-Pub 2025.
12. Morris B, Zhang Z, Lynch A, Heeke S, Concannon K, Stewart A, Wang R, Halliday A, Rinsurongkawong W, Rinsurongkawong V, Lee J, Zhang J, Gibbons D, Vaporciyan A, Gay C, Tran H, Heymach JV, Byers L, Van Loo P. Reconstructing small cell lung cancer evolution using deep whole genome sequencing of circulating tumor DNA. AACR Annual Meeting, 2025. e-Pub 2025.
13. Bandyopadhyay R, Rojas F, Hong L, Saad M, Showkatian E, Vokes N, Kalhor N, Haymaker C, Wu C, Carter B, Chang J, Le X, Cascone T, Jaffray D, Gibbons D, Vaporciyan A, Lee J, Wistuna I, Heymach JV, Solis Soto L, Zhang J, Wu J. Deep learning-driven pathomics signatures enhance stratification and prognosis in mNSCLC treated with immune checkpoints inhibitors. SITC Annual meeting 2024, 2024. e-Pub 2024.
14. Aminu M, Zhu B, Vokes N, Chen H, Hong L, Jian-Rong L, Fujimoto J, Poteete A, Nilsson M, Le X, Cascone T, Jaffray D, Nocholas N, Byers L, Gibbons D, Heymach JV, Chen K, Cheng C, Zhang J, Wu J. Unvelining immune evolution in lung pre-cancer through graph contrastive learning of spatial transcriptomics. SITC Annual meeting 2024, 2024. e-Pub 2024.
15. Muneer A, Showkatian S, Saad M, Hong L, Aminu M, Salehjahromi M, Sujit S, Waqas M, Li W, Vokes N, Wu C, Carter B, Chang J, Cascone T, Le X, Wistuba I, Chung C, Jaffray D, Gibbons D, Vaporciyan A, Lee J, Heymach JV, Zhang J, Wu J. Predicting PD-L1 expression from CT scans using deep learning to guide immunotherapy in metastatic non-small-cell lung cancer. SITC Annual meeting, 2024. e-Pub 2024.
16. Grippin A, Copling S, Kim A, Young E, Lohray R, Chang E, Kouzy R, Lewis J, Dennis W, Liang R, Gupta P, Lee J, Gibbons D, Vaporciyan A, Mendez-Gomez H, Tran H, Kim Y, Heymach JV, Zhang J, Sayour E, Jiang W, Lin S. SAR-COV-2 mRNA vaccines are associated with type I interaction signaling and improved clinical responses to immune checkpoints inhabitation. SITC Annual meeting 2024, 2024. e-Pub 2024.
17. Trevino S, Chen H, Halliday A, Ren X, Du R, Hong L, Poteete A, Zhu B, Nilsson M, Aminu M, Rinsurongkawong W, Rinsurongkawong V, Lee J, Blumenschein G, Gay C, Negrao MV, Altan M, Cascone T, Elamin Y, Skoulidis F, Tran H, Antonoff M, Vaporciyan A, Wu J, Kurie J, Gibbons D, Zhang J, Heymach JV, Le X, Vokes N. Defining immune and tumor resistant cell stated to targeted vs immune therapy in non-small cell lung cancer (NSCLC). SITC annual meeting, 2024. e-Pub 2024.
18. Ozirmak N, Molina M, Hernandez S, Serrano A, Tomczak K, Wei L, Khan K, Barnes S, Dou J, Liang Q, Jiang M, Sanchez-Espiridion B, Weissferdt A, Heymch JV, Zhang J, Sepesi B, Cascone T, Tsao A, Altan M, Mehran R, Gibbons D, Wistuba I, Haymaker C, Chen K, Solis Soto L. Comparison of Spatial transcriptomic platforms in FFPE TMA samples. SITC 2024, 2024. e-Pub 2024.
19. Salehjahromi M, Hong L, Li H, Kitsel Y, Godoy M, Wu CC, Antonoff M, Toumazis L, Osterin E, Heeke S, Vokes N, Le X, Vaporciyan A,, Lee JJ, Heymach J, Zhang J, Wu J. Predicting lung cancer risk with CT radiomics: implications for immunoprevention. SITC 2024, 2024. e-Pub 2024.
20. Zhou N, Leung C, William JR W, Weissferdt A, Pataer A, Godoy M, Carter B, Fossella F, Tsao A, Blumenschein G, Le X, Zhang J, Skoulidis F, Kurie J, Altan M, Lu C, Glisson B, Byers L, Elamin Y, Mehran R, Rice D, Walsh G, Hofstetter W, Roth J, Tran H, Wu J, Solis Soto L, Kadara H, Swisher S, Vaporciyan A, Gibbons D, Lin H, Lee J, Heymach JV, Negrao MV, Sepsei B, Cascone T. Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in respectable non-small cell lung cancer. SITC Annual meeting 2024, 2024. e-Pub 2024.
21. Koksoy A, Oliva-Ramirez J, Tomczak K, Stanford M, Deboever N, Pandurengan R, Medina Rosales M, Ozirmak Lermi N, Strange C, Parra Cuentas E, Weissferdt A, Chen K, Rice D, Zhang J, Solis Soto L, Mehran R, Altan M, Tsao A, Haymaker C. Analysis of PD1+ T Cells and LS Presence in Pleural Mesothelioma Using Spatial and Machine Learning Approaches. SITC 2024, 2024. e-Pub 2024.
22. Von Itztein M, Liu J, Mu-Mosley H, Fattah F, Park J, SoRelle J, Farrar JD, Gwin M, Hsienchen D, Gloria-McCutchen Y, Wakeland E, Cole S, Bhalla Sh, Kainthla R, Puzanov I, Switzer B, Daniels G, Zakharia Y, Shaheen M, Zhang J, Xie Y, Gerber D. Racial differences in Systemic Immune Parameters in individuals with Lung cancer. IASLC Annual meeting, 2024. e-Pub 2024.
23. Hong L, Di Federico A, Aminu M, Ricciuti B, Machado Alessi J, Rinsurongkawong W, Elamin Y, Sepesi B, Lewis J, Gibbons D, Vaporciyan A, Lee J, Le X, Heymach JV, Wu J, Awad M, Zhang J, Vokes N. PD-L1 expression in pulmonary sarcomatoid carcinoma and response to immunotherapy. ASCO Annual Meeting 2024, 2024. e-Pub 2024.
24. Boiarsky D, Hong L, Ricciuti B, Cooper A, Saad M, Elkrief A, Di Federico A, Aminu M, Rinsurongkawong W, Lewis J, Gibbons D, Vaporciyan A, Le X, Lee J, Heymach JV, Wu J, Schoenfeld A, Awad M, Zhang J, Vokes N. Efficacy and clinicogenomic biomarkers of response to dual versus single agent checkpoint inhibitor therapy in untreated metastatic non-small cell lung cancer. ASCO Annual Meeting 2024, 2024. e-Pub 2024.
25. Li C, Zhang J, Cheng C. ssTimiGP: Equip the TimiGP system with a single-sample module, facilitating the cell-cell interaction inference of the tumor microenvironment in any sample. AACR Annual Conference 2024, 2024. e-Pub 2024.
26. Heeke S, Nilsson M, Gibbons D, Zhang J, Wistuba I, Park K, Heymach JV, Le X. Tumor transcriptional identity as a key predictor of clinical outcome in EGFR-Mutant non-small cell lung cancer. AACR Annual Conference 2024, 2024. e-Pub 2024.
27. Morris B, Zhang Z, Heeke S, Cancannon K, Zhang B, Rinsurongkawong W, Rinsurongkawong V, Lee J, Zhang J, Gibbons D, Vaporciyan A, Gay C, Tran H, Heymach JV, Byers L, Van Loo P. Dissecting patterns of small cell lung cancer evolution using deep whole genome sequencing of circulating tumor DNA. AACR Annual Conference 2024, 2024. e-Pub 2024.
28. Zhu B, Chen P, Li J, Aminu M, Li C, Chen H, Tian Y, Rojas F, Edwin Roger P, Shi O, Nilsson M, Poteete A, Hubert S, Khan K, Lu W, Song X, Zhang J, Gibbons D, Solis Soto L, Wistuba I, Heymach JV, Cheng C, Wu J, Zhang J. Spatial analysis revealed distinct molecular and immune landscape in genetic versus carcinogen-induced lung adenocarcinoma precancer mouse models. AACR Annual Conference 2024, 2024. e-Pub 2024.
29. Tian Y, Li J, Zhu B, Fradette J, Chen H, Li C, Rodriguez L, Kraushaar D, Solis Soto L, Reuben A, Wistuba I, Gibbons D, Chang C, Zhang J. Deciphering the spatial and temporal dynamics of premetastatic niche in lung mediated by Treg and myeloid cell interactions. AACR Annual Conference, 2024. e-Pub 2024.
30. Chen H, Zhu B, Fujimoto J, Tian Y, Li J, Li C, Chen P, Reuben A, Nilsson M, Le X, Poteete A, Hubert S, Gibbons D, Wistuba I, Wu J, Cheng C, Heymach JV, Zhang J. Single-cell profiling reveals dynamic epithelial and immune cell interactions in the progression of lung adenocarcinoma. AACR Annual Conference 2024, 2024. e-Pub 2024.
31. Oliva-Ramirez J, Stanford S, Lu H, Lee Y, Tomczak K, Medina Rosales M, Zhou X, Ravi V, Conley A, Ingram D, Deboever N, Strange C, Weissferdt A, Rice D, Zhang J, Ludwig J, Amaria R, Livingston J, Altan M, Mehran R, Somaiah, Tsao A, Haymaker C. Identification of metabolic profiles from expanded tumor infiltrating lymphocytes across multiple cancer types. SITC Metabolism at the hub, 2024. e-Pub 2024.
32. Di Federico A, Hong L, Elkrief A, Thummalapalli R, Ricciuti B, Alessi J, Gogia P, Pecci F, Gandhi M, Ladanyi M, Zhang J, Gibbons D, Heymach JV, Nishino M, Sholl L, Awad M, Arbour K, Schoenfeld A, Vokes N, Luo J. Clinicopathologic and genomic features of patients with mucinous lung adenocarcinoma and response to systemic therapies. ESMO 2024, 2024. e-Pub 2024.
33. Rojas F, Chen P, Serrano A, Fujimoto J, Hong L, Zhu B, Hu X, Salehjahromi M, Bandyopadhyay R, Aminu M, Kalhor N, Wistuba I, Gibbons D, Heymach JV, Zhang J, Wu J, Solis Soto L. Artificial Intelligence-Assisted Tissue Morphology Analysis Reveals the Lymphocytes Infiltration Progression from Lung Preneoplasia to Invasive Adenocarcinoma. USCAP Annual Conference, 2024. e-Pub 2024.
34. Oliva-Ramirez J, Tomczak K, Stanford M, Deboever N, Zhou N, Medina Rosales M, Kumar G, Ozirmak Lermi N, Strange C, Weissferd A, Chen K, Rice D, Mehran R, Zhang J, Altan M, Tsao A, Sepesi B, Haymaker C. Relation of Granulocyte-mediated immune suppression in epithelioid malignant pleural mesothelioma and chronic obstructive pulmonary disease. 1st Translational Molecular Pathology-Immunoprofiling Lab, 2024. e-Pub 2024.
35. Li C, Hong W, Zhang B, Reuben A, Wang L, Zhang J, Cheng C. Utilizing TimiGP for in-depth analysis of the tumor immune microenvironment and its association with clinical outcomes of various cancers after immunotherapy. ASHG Annual Conference, 2023. e-Pub 2023.
36. Kwang Chae Y, Lu Y, Patel S, Rodriguez C, Onitilo A, Mattour A, Rybkin I, Fenton S, Chung L, Kim H, Othus M, Parra E, Zhang J, Gomez Bolanos L, Laberiano Fernandez C, Solis Soto L, Chen H, Manyam G, Duose D, Luthra R, Zhang J, Al-Atrash G, Wistuba I, Lee J, Zhang J, Haymaker C, McLeod C, Chen H, Sharon E, Ryan C, Plets M, Lopez G, Blanke C, Kurzrock R. Clinical outcomes and translational analysis of DART S1609: the thyroid cancer cohort; PD-1+ PD-L1+ TIL correlated with favorable survival. SITC 2023, 2023. e-Pub 2023.
37. Chang J, Lin S, Dong W, Liao Z, Gandhi L, Chun S, Gay C, Zhang J, Fossella F, Blumenschein G, Cascone T, Le X, Pozadzides J, Tsao A, Altan M, Welsh J, Verma V, Wistuba I, Lee J, Heymach JV. Nivolumab After Stereotactic Ablative Radiotherapy for Early-Stage Non-Small Cell Lung Cancer: Randomized I-SABR Trial. World Conference on Lung Cancer 2023, 2023. e-Pub 2023.
38. Wang K, Rojas Alvarez F, Leung C, Kemp H, Lewis W, Arrechedera C, Solis Soto L, Blumenschein G, Sepesi B, Skoulidis F, Heymach JV, Gibbons D, Zhang J, Wistuba I, Lee J, Weissferd A, Swisher S, Pataer A, Cascone T, Negrao MV. Neoadjuvant Chemotherapy or Chemo-IO in Resectable KRAS-Mutated Non-small Cell Lung Cancer (NSCLC) Patients: Single Center Experience. World Conference on Lung Cancer 2023, 2023. e-Pub 2023.
39. Zhang J, Salehjahromi M, Godoy M, Antonoff M, Ostrin E, Le X, Gay C, Negrao MV, Byers L, Lu C, Blumenschein G, Rice D, Walsh G, Rajaram R, Sepesi B, Lin S, Hofstetter W, Mehran R, Vaporciyan A, Moghaddam S, Lee J, Wu J, Heymach JV. The interim analysis of Can-Prevent-Lung Trial: canakinumab for the prevention of lung cancer. World Conference on Lung Cancer 2023, 2023. e-Pub 2023.
40. Oliva-Ramirez J, Tomczak K, Stanford M, Deboever N, Zhou N, Kumar G, Ozirmak Lermi N, Strange C, Weissferd A, Chen K, Rice D, Mehran R, Zhang J, Altan M, Tsao A, Sepesi B, Haymaker C. Relation of chronic obstructive pulmonary disease in malignant pleural mesothelioma tumor microenvironment. Translational Molecular Pathology Annual Retreat, 2023. e-Pub 2023.
41. Wang K, Fossella FV, Vailati Negrao M, Cascone T, Gay CM, Le X, Vokes NI, Hume CB, Hassan AA, Gibbons DL, Lee JJ, Heymach JV, ZhangJ. Clinical outcomes of chemotherapy rechallenge in patients with metastatic non-small cell lung (NSCLC) who progressed on immunotherapy maintenance after front line platinum doublets and immunotherapy, 2023. e-Pub 2023.
42. Tomczak K, Ozirmak Lermi N, Deboever N, Zhou N, Jiang X, Ramos C, Oliva-Ramirez J, Kumar G, Stanford M, Wu C, Strange C, Weissferd A, Chen C, Rice D, Mehran R, Zhang J, Altan M, Tsao A, Sepesi B, Haymaker C. Diversity of Tumor Immune Microenvironment landscape of epithelioid Malignant Pleural Mesothelioma in patients with primary surgically resected tumors. 16th International Conference of the international Mesothelioma interest group, 2023. e-Pub 2023.
43. Li H, Qin K, Zhang Z, Hong L, Wu C, Cobos Barco Godoy M, Antonoff M, Ostrin E, Toumazis L, Gibbons D, Heymach JV, Lee J, Wu J, Zhang J. Cancer risk assessment in patients with persistent pulmonary nodules and its correlation with cancer-free survival. ASCO Annual Meeting 2023, 2023. e-Pub 2023.
44. Qin K, Wang K, Li S, Hong L, Rinsurongkawong W, Hubert S, Le X, Vokes N, Altan M, Gibbons D, Heymach JV, Lee J, Lou Y, Zhang J. Association of docetaxel efficacy with cancer gene mutation status in patients with metastatic non-small-cell lung cancer who progressed on platinum doublets and immunotherapy. ASCO Annual Meeting 2023, 2023. e-Pub 2023.
45. Wang K, Fossella F, Negrao MV, Cascone T, Gay C, Le X, Vokes N, Bueno Hume C, Hassan A, Gibbons D, Lee J, Heymach JV, Zhang J. Clinical outcomes of chemotherapy rechallenge in patients with metastatic non-small cell lung (NSCLC) who progressed on immunotherapy maintenance after front line platinum doublets and immunotherapy. ASCO Annual Meeting 2023, 2023. e-Pub 2023.
46. Liu Y, Rinsurongkawong W, Gay C, Lewis W, Rinsurongkawong V, Lee J, Lee P, Zhang J, Gibbons D, Vaporciyan A, Heymach JV, Lin S. Timing of Salvage Tyrosine Kinase Inhibitors for Patients with Progressive Locally Advanced Non-Small Cell Lung Cancer Initially Treated with Chemoradiation and Consolidative Durvalumab. ASCO Annual Meeting 2023, 2023. e-Pub 2023.
47. Hong L, Aminu M, Lu X, Saad M, Chen P, Rinsurongkawong W, Spelman A, Elamin Y, Negrao MV, Skoulidis F, Gay C, Cascone T, Antonoff M, Sepesi B, Lewis J, Gibbons D, Vaporciyan A, Le X, Lee J, Roy-Chowdhuri S, Routbort M, Heymach JV, Wu J, Zhang J, Vokes N. Genomic and clinical predictors of early disease progression and chemoimmunotherapy benefit in advanced NSCLC. AACR Annual Conference 2023, 2023. e-Pub 2023.
48. Zhu B, Li J, Chen H, Chen H, Chen P, Fujimoto J, Tian Y, Aminu M, Li C, Hong L, Reuben A, Parra Cuentas E, Shi O, Nilsson M, Poteete A, Hubert S, Khan K, Lu W, Kraushaar D, Song X, Zhang J, Gibbons D, Solis Soto L, Wistuba I, Wu J, Heymach JV, Cheng C, Zhang J. Single cell and spatial profiling reveal molecular and immune evolution from precancers to invasive lung adenocarcinomas in genetic and carcinogen-induced mouse models. AACR Annual Conference 2023, 2023. e-Pub 2023.
49. Tian T, Li J, Zhu B, Fradette J, Chen H, Li C, Cui S, Kraushaar D, Fujimoto J, Rodriguez L, Solis Soto L, Reuben A, Wistuba I, Gibbons D, Zhao C, Zhang J. Single-cell and spatial transcriptomic profiling reveal the cascade of immune events during progression and metastasis of non-small cell lung cancer. AACR Annual Conference 2023, 2023. e-Pub 2023.
50. Chen C, Zhu B, Fujimoto J, Tian Y, Li J, Chen P, Reuben A, Nilsson M, Le X, Poteete A, Hubert S, Gibbons D, Wistuba I, Wu J, Cheng C, Heymach JV, Zhang J. Single-cell transcriptomic analysis reveals immune landscape in the malignant transformation of normal lung to lung adenocarcinoma in genetic murine models. AACR Annual Conference 2023, 2023. e-Pub 2023.
51. Morris B, Nabet B, Shames D, Heeke S, Gay C, Wang J, Zhang J, Heymach JV, Byers L. Comprehensive DNA repair landscape analysis reveals novel small cell lung cancer biology. AACR Annual Conference 2023, 2023. e-Pub 2023.
52. Hernandez SD, Lu W, Serrano AG, Arrechedera C, Sanchez-Espiridion B, Ozirmak N, Molina M, Kostousov L, Khan K, Tang X, Fujimoto J, Parra E, Raso G, Schmidt S, Behrens C, Heymach JV, Zhang J, Chen K, Sepesi B, Cascone T, Gibbons D, Wistuba I, Haymaker C, Solis L. Spatial profiling of immune biomarkers in resected treatment-naïve early stage lung adenocarcinoma. AACR Annual Conference 2023, 2023. e-Pub 2023.
53. Hong L, Drusbosky L, Wang Y, Xiong Y, Chen R, Heeke S, Nilsson M, Zhang J, Heymach JV, Le X. Mutation and co-mutation landscape ofERBB2 alterations in advanced NSCLC. AACR Annual Conference 2023, 2023. e-Pub 2023.
54. Chen P, Rojas F, Hu X, Fujimoto J, Serrano A, Zhu B, Hong L, Bandyopadhyay R, Aminu M, Saad M, Salehjahromi M, Sujit S, Kalhor N, Pass H, Moreira A, Wistuba I, Gibbons D, Heymach JV, Solis Soto L, Zhang J, Wu J. Pathomics reveals the molecular and immune evolution from lung preneoplasia to invasive adenocarcinoma. AACR Annual Conference 2023, 2023. e-Pub 2023.
55. Aminu M, Vokes N, Saad M, Li H, Hong L, Mohamed M, Boom J, Chen P, Altan M, Grandhi S, Swisher S, Antonoff M, Pozadzides J, Blumenschein Jr G, Gibbons D, Cascone T, Elamin Y, Le X, Negrao MV, Skoulidis F, Tsao A, Tu J, Lee J, Zhang J, Heymach JV, Wu J. Tumor volumetric analysis to correlate disease burden with response to dual immune checkpoint blockade in metastatic NSCLC. AACR Annual Conference 2023, 2023. e-Pub 2023.
56. Al Khalaf T, Heeke S, Feng L, Drusbosky L, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Lee J, Zhang J, Gibbons D, Vaporciyan A, Lam V, Subbiah V, Heymach JV, Elmain Y. The genomic landscape of RET fusions in non-small cell lung cancer and the impact of co-occurring genomic alterations on the efficacy of selective RET inhibitors. AACR Annual Conference, 2023. e-Pub 2023.
57. Rojas F, Chen P, Serrano A, Fujimoto J, Hong L, Zhu B, Hu X, Salehjahromi M, Bandyopadhyay R, Aminu M, Kalhor N, Wistuba I, Gibbons D, Heymach J, Zhang J, Wu J, Solis Soto L. Artificial Intelligence-Assisted Tissue Morphology Analysis Reveals the Lymphocytes Infiltration Progression from Lung Preneoplasia to Invasive Adenocarcinoma. 2023 USCAP Annual Meeting,, 2023. e-Pub 2023.
58. Tomczak K, Ramos C, Deboever N, Zhou N, Oliva J, Wu C, Strange C, Weissferd A, Rice D, Mehran R, Zhang J, Altan M, Tsao A, Sepesi B, Haymaker C. Single cell transcriptome and epigenome profiling reveals the diversity of T cell states in ex vivo grown tumor-infiltrating lymphocytes from malignant pleural mesothelioma. SITC 37th Annual Meeting & Pre-Conference Programs, 2022. e-Pub 2022.
59. Tomczak K, Oliva J, Zhou N, Ramos C, Deboeve N, Feldman H, Lee P, Strange C, Weissferdt A, Rice D, Mehran R, Zhang J, Tsao A, Sepesi B, Haymaker C. The Impact of Radiographic Tumor Thickness on the Complexity of the Tumor Immune Microenvironment in Malignant Pleural Mesothelioma. Virtual POSTER presentation at SITC 36th Annual Meeting & Pre-Conference Programs, 2022. e-Pub 2022.
60. Byers L, Heymach JV, Gibbons D, Zhang J, Chiappori A, Rasmussen E, Decato B, Smit M, Hashemi Sadraei N. A phase 1 study of AMG 119, a DLL3-targeting, chimeric antigen receptor (CAR) T cell therapy, in relapsed/refractory small cell lung cancer (SCLC). The 37th SITC Annual Conference, 2022. e-Pub 2022.
61. FranK M, Shah P, Forget A, Federico L, Jiang P, Khairullah R, Wistuba I, Chow C, Long Y, Fujimoto J, Lin S, Maitra A, Negrao M, Mitchell K, Weissferdt A, Vaporciyan A, Cascone T, Roth J, Zhang J, Sepesi B, Gibbons JV, Haymaker C, McGrai D, Bernatchez B, Reuben A. Combined IL-2, agonistic CD3 and 4–1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes. The 36th SITC Annual Conference, 2022. e-Pub 2022.
62. Schmidt S, Lee Y, Leung C, Federico L, Lin H, Weissferdt A, Pataer A, Dejima H, Francisco-Cruz A, Rojas F, Solis L, Parra E, Pradhan M, Guo H, William W, Reuben A, Kadara H, Wistuba I, Zhang J, Swisher S, Vaporciyan A, Negrao M, Bristow C, Heffernan T, Bernatchez C, Lee J, Heymach JV, Sepesi B, Gibbons D, Haymaker C, Cascone T. Integrative immunomics highlight the immunomodulatory impact of neoadjuvant chemotherapy and immune-based treatments in resected non-small-cell lung cancer. The 36th SITC Annual Conference, 2022. e-Pub 2022.
63. Singhi E, Mott F, Worst M, Leung C, Lee J, Carter B, Presley C, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Zhang J, Gibbons D, Vaporciyan A, Heymach JV, Altan M. Clinical outcomes of immunotherapy continued beyond radiographic progression in older adults with advanced non-small cell lung cancer. The 36th SITC Annual Conference, 2022. e-Pub 2022.
64. Luo Q, Parra E, Negrao M, Akhave N, Bayley E, Mitchell K, Zhang J, Heymach JV, Sepesi B, Wistuba I, Gibbons D, Reuben A. Proximity between cytotoxic antigen-experienced T cells and tumor cells is associated with improved clinical outcomes in early-stage NSCLC. The 36th SITC Annual Conference, 2022. e-Pub 2022.
65. Heeke S, Gay M, Estecio M, Stewart A, Tran H, Zhang B, Tran X, Raso M, Concannon K, Guimaraes De Sousa L, Lewis W, Kondo K, Xi Y, Diao L, Wang Q, Zhang J, Wang J, Wistuba I, Byers L, Heymach JV. Exploiting DNA methylation for classification of SCLC subtypes from liquid biopsies using a robust machine learning approach. World Conference on Lung Cancer 2022, 2022. e-Pub 2022.
66. Wang K, Du R, Roy S, Vokes N, Elamin Y, Bueno Hume C, Skoulidis F, Gay C, Blumenschein G, Fossella F, Tsao A, Lee J, Rinsurongkawong W, Rinsurongkawong V, Gibbons D, Vaporciyan A, Zhang J, Heymach JV, Altan M, Le X. Resistance mechanisms to dual EGFR and MET inhibition in patients with EGFR-mutant MET-amplified non-small cell lung cancer. The ESMO Congress 2022, 2022. e-Pub 2022.
67. Le X, Lewis W, Hong L, Skoulidis F, Byers L, Tsao A, Cascone T, Pozadzides J, Tu J, Negrao MV, Baik C, Zhang J, Heymach JV. Real-World Case Series on Efficacy and Safety of Amivantamab for EGFR-mutant Non-small Cell Lung Cancer. World Conference on Lung Cancer 2022, 2022. e-Pub 2022.
68. Oezkan F, Hilz S, Grindheim J, Wallace A, Seweryn M, Reuben A, Zhang J, Owen D, Nicholas A, Yadav M, Nagarkar D, De Almeida P, Ebert P, Osborne E, Johnson A, Lee J, Bunn P, Johnson B, Zhaft J, Kris M, Rusch V, Schulze K, Kwiatkowski D, Wistua I. . T-Cell Dynamics in Response to Neoadjuvant Atezolizumab in Early NSCLC by Antigen Response and T-Cell Receptor Sequencing. World Conference on Lung Cancer 2022, 2022. e-Pub 2022.
69. Bandyopadhyay R, Chen P, El Hussein S, Rojas F, Ebare K, Wistuba I, Solis Soto L, Medeiros J, Zhang J, Khoury J, Wu J. Is More Always Better? Effects of Patch Sampling in Distinguishing Chronic Lymphocytic Leukemia from Transformation to Diffuse Large B-Cell Lymphoma. International Workshop on Computational Mathematics Modeling in Cancer Analysis, 2022. e-Pub 2022.
70. Saad M, Hong L, Aminu M, Vokes N, Chen P, Wu C, Rinsurongkawong W, Spelman A, Negrao MV, Cascone T, Lin S, Lee P, Sepesi B, Gibbons D, Vaporciyan A, Lee J, Le X, Zhang J, Wu J, Heymach JV. Deep learning signature from chest CT and association with immunotherapy outcomes in EGFR/ALK-negative NSCLC. ASCO Annual Meeting, 2022. e-Pub 2022.
71. Hong L, Rinsurongkawong W, Saad M, Chene P, Aminu M, Spelman A, Negrao MV, Cascone T, Lin S, Lee P, Sepesi B, Lewis J, Gibbons D, Vaporciyan A, Lee J, Le X, Wu J, Heymach JV, Zhang J, Vokes N. Real-world effectiveness of immune checkpoint inhibitors alone or in combination with chemotherapy in metastatic non–small cell lung cancer. ASCO Annual Meeting, 2022. e-Pub 2022.
72. Mehmet A, Wang Q, Li Q, Zhu C, Tran H, Sheshadri A, Gandhi S, Antonoff M, Swisher S, Vokes N, Spelman A, Lee J, Zhang J, Heymach JV. Auto-reactive antibodies as predictive markers for immune checkpoint–induced pneumonitis, 2022. e-Pub 2022.
73. Elamin Y, Negrao MV, Fossella F, Byers L, Zhang J, Gay C, Tu J, Vu Pozadzides J, Tran H, Lu C, Feng L, Spelman A, Blumenschein GR, Tsao A, Heymach JV. Results of a phase 1b study of osimertinib plus sapanisertib or alisertib for osimertinib-resistant, EGFR-mutant non–small cell lung cancer (NSCLC). ASCO Annual Meeting, 2022. e-Pub 2022.
74. Parra E, Duose D, Zhang J, Weber Redman M, Lazcano Segura R, Marques-Piubelli M, Laberiano Fernandez C, Zhang B, Lindsay J, Moravec R, Kannan K, Luthra R, Alatrash G, Herbst R, Wistuba I, Gettinger S, Bazhenova L, Lee J, Zhang J, Haymaker C. Multiomics profiling and association with molecular and immune features in association with benefits from immunotherapy for patients with previously treated stage IV or recurrent squamous cell lung cancer from the phase III SWOG LungMAP S1400I trial. ASCO Annual Meeting, 2022. e-Pub 2022.
75. Li Z, Hubert S, Zhang R, Song X, Karpinets T, Weissferdt A, Little L, Mohammad M, Gumbs C, Negrao MV, Zhang J, Pataer A, Swisher S, Vaporciyan A, Roth J, Heymach JV, Sepesi B, Gibbons D, Fang B, Zhang J. Molecular parameters impacting the success rate of a lung cancer PDX model. ASCO Annual Meeting, 2022. e-Pub 2022.
76. Altan M, Sui D, Gandhi S, Swisher S, Vokes N, Antonoff M, Zhang J, Blumenschein GR, Cascone T, Elamin Y, Gay C, Gibbons D, Le X, Negrao MV, Skoulidis F, Tsao A, Tu J, Spelman A, Lee J, Heymach JV. Clinical outcome and potential benefits of post-progression immunotherapy for patients with metastatic NSCLC with primary resistance to ipilumumab and nivolumab in the LONESTAR phase III study. ASCO Annual Meeting, 2022. e-Pub 2022.
77. Hong L, Lewis W, Varghese S, Rivera M, Du R, Chen P, Kemp H, Rinsurongkawong W, Rehmani S, Spelman A, Elamin Y, Negrao MV, Sepesi B, Gibbons D, Lee J, Wu J, Vokes N, Heymach JV, Zhang J, Le X. Limited benefit from the addition of immunotherapy to chemotherapy in TKI-refractory EGFR-mutant lung adenocarcinoma. ASCO Annual Conference 2022, 2022. e-Pub 2022.
78. Roger Parra E, Zhang J, Redman M, Lazcano R, Mario P, Laberiano Fernandez C, Krishna R, Zhang S, Chen H, Manyam G, Moravec R, Cerami E, Lindsay J, Yu J, Biswas R, Van Nostrand S, Duose D, Zhang J, Herbst R, Al-Atrash G, Kannan K, Wistuba I, Gettinger S, Bazhenova L, Lee J, Zhang J, Haymaker. Infiltration and spatial distribution of immune cells are associated clinical benefit from Nivolumab and Ipilimumab for previously treated patients with stage IV squamous cell lung cancer: an immune biomarker analysis of Phase III SWOG LungMAP S1400I trial. AACR Annual Meeting 2022, 2022. e-Pub 2022.
79. Duose D, Zhang J, Redman M, Zhang B, Cerami E, Lindsay J, Yu J, Biswas R, Van Nostrand S, Moravec R, Luthra R, Al-Atrash G, Kelly K, Herbst R, Wistuba I, Gettinger S, Bazhenova L, Lee J, Zhang J, Haymaker C. Immune gene expression signatures associated clinical benefit from nivolumab and ipilimumab for previously treated patients with stage IV squamous cell lung cancer: An immune biomarker analysis of phase III SWOG LungMAP S1400I trial. AACR Annual Meeting, 2022. e-Pub 2022.
80. Heeke S, Gay C, Estecio M, Stewart A, Tran H, Zhang B, Tang X, Raso G, Concannon K, Guimaraes De Sousa L, Lewis W, Nilsson M, Xi Y, Diao L, Wang Q, Zhang J, Wang J, Wistuba I, Byers L, Heymach JV. Use of DNA methylation from tumor and plasma to identify four major small cell lung cancer subtypes with distinct biology and therapeutic vulnerabilities. AACR Annual Meeting 2022, 2022. e-Pub 2022.
81. Le X, Wang R, Vokes N, Elamin Y, Kalhor N, McGrail D, Xi Y, Treviño III S, Hong L, Du R, Blumenschein G, Gay C, Negrao MV, Altan M, Tran H, Hu L, Wang J, Heeke S, Nilsson M, Robichaux J, Dang M, Han G, Byers L, Tsao A, Sepesi B, Bernatchez C, Zhang j, Wang L, Heymach JV. Enhanced lineage plasticity in RTK-independent TKI-resistant EGFR-mutant NSCLC. AACR Annual Meeting 2022, 2022. e-Pub 2022.
82. Lazcano R, Rocha P, Hernandez S, Mehta J, Kang A, Kannan K, Lu W, Powell S, Khan K, Parra E, Zhou J, Pandurengan R, Zhang J, Cascone T, Behrens C, Haymaker C, Wang L, Wistuba I, Kadara H, Solis Soto L. Immune Programs Associated to Tumoral Tertiary Lymphoid Structures at Different Maturation Stages in Early-Stage Lung Adenocarcinoma. USCAP 2022 Pathology Annual Meeting, 2022. e-Pub 2022.
83. Schmidt ST, Akhave N, Reuben A, Cascone T, Zhang J, Li J, Fujimoto J, Byers L, Sanchez-Espiridion B, Diao L, Wang J, Federico L, Forget MN, McGrail D, Weissferdt A, Lin Sh, Lee Y, Vokes N, Behrens C, Wistuba I, Futreal A, Vaporciyan A, Sepesi B, Heymach JV, Bernatchez C, Haymaker C, Zhang J, Bristow C, Heffernan T, Negrao MV, Gibbons D. A shared nearest neighbors approach for integrated, multi-platform networks and its application to the exploration of multiomics data from early-stage non-small cell lung cancers. AACR Molecular Cancer Therapeutics meeting, 2021. e-Pub 2021.
84. Rocha P, Salazar R, Solorzano J, Zhang J, Mino B, Parra E, Ledesma D, Kadara H, Vaporciyan A, Rice D, Kalhor N, Moran C, Gibbons D, Weissferdt A, Sepesi B, Wistuba I, Behrens C, Solis L. CD73 Expression in Lung Adenocarcinomas and Immunological and Molecular Associations. The 20th World Conference on Lung Cancer, 2021. e-Pub 2021.
85. Hong L, Rinsurongkawong W, Rinsurongkawong V, Spelman AR, Lewis J, Gandhi SJ, Antonoff MB, Gibbons DL, Vaporciyan AA, Lee JJ, Heymach JV, Zhang J, Vokes NI. Outcomes from local consolidative therapy and immune checkpoint inhibitors in metastatic non-small cell lung cancer. ESMO Conference, 2021. e-Pub 2021.
86. Akhave A, Schmidt S, Reuben A, Cascone T, Zhang J, Li J, Fujimoto J, Byers L, Sanchez-Espiridion B, Diao L, Wang J, Federico L, Forget L, McGrail D, Weissferdt A, Lin S, Lee Y, Behrens C, Wistuba I, Futreal A, Vaporciyan A, Sepesi B, Heymach JV, Bernatchez C, Haymaker C, Zhang J, Bristow C, Negrao M, Gibbons D. Integrated multi-platform profiling of early-stage non-small cell lung cancer identifies relationship between disease recurrence and decreased native immune response in treatment-naïve resected NSCLC. AACR Annual Conference, 2021. e-Pub 2021.
87. Lee Y, McGrail D, Tran H, Vasquez M, Ramos C, Reuben A, Vaporciyan A, Weissferdt A, Bernatchez C, Cascone T, Wistuba I, Zhang J, Heymach JV, Negrao M, Gibbons D, Sepesi, Haymaker C. Circulating biomarkers are associated with recurrence following complete resection of non-small cell lung cancer. AACR Annual Conference, 2021. e-Pub 2021.
88. Han G, Sinjab A, Hara K, Treekitkarnmongkol W, Brennan P, Chang K, Bokatenkova E, Sanchez-Espiridion B, Behrens C, Solis L, Gao B, Girard L, Zhang J, Sepesi B, Cascone T, Byers L, Gibbons D, Chen J, Moghaddam S, Ostrin E, Scheet P, Fujimoto J, Shay J, Heymach JV, Minna J, Dubinett S, Wistuba I, Stevenson C, Spira A, Wang L, Kadara H. Single-cell expression landscape of SARS-CoV-2 receptor ACE2 and host proteases in human lung adenocarcinoma. AACR Annual Conference, 2021. e-Pub 2021.
89. Rocha P, Salazar R, Zhang J, Ledesma D, Solorzano J, Mino B, Villalobos P, Dejima H, Douse D, Diao L, Mitchell K, Le X, Zhang J, Weissferdt A, Parra-Cuentas E, Cascone T, Rice D, Sepesi B, Kalhor N, Moran C, Vaporciyan A, Heymach JV, Gibbons D, Lee J, Kadara H, Wistuba I, Behrens C, Solis L. CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma. AACR Annual Conference, 2021. e-Pub 2021.
90. Rocha, Stewart A, Parra E, Solis L, Gay C, Cardnell R, Uraoka N, Francisco-Cruz A, Dejima H, Xi Y, Diao L, Wang J, Negrao M, Zhang J, Wistuba I, Gibbons D, Byers L. Multiplex immunofluorescence (mIF) reveals differences in tumor immune microenvironment between molecularly-defined subsets of small cell lung cancer. AACR Annual Conference, 2021. e-Pub 2021.
91. Liu Y, Zhang Z, Rinsurongkawong W, Le X, Gay C, Ning M, Heymach JV, Zhang J, Lin S. Driver mutations to predict for poorer outcomes in non-small cell lung cancer patients treated with concurrent chemoradiation and consolidation durvalumab. 2021 ASCO Annual Meeting, 2021. e-Pub 2021.
92. Ying L, Su D, Chunliu Z, Tian Y, Bai J, Wang C, Fang J, Futreal A, Zhang J. Multiomics analysis reveals high-immune infiltration in tumor-adjacent lung tissues affects the prognosis of stage I NSCLC. 2021 ASCO Annual Meeting, 2021. e-Pub 2021.
93. Dong X, Chen L, Tong F, Wei C, Wang H, Xia X, Xu Y, Liu P, Liao X, Zhang J, Carbone D. Longitudinal sequencing of TCR and circulating tumor DNA revealing radiotherapeutic efficacy and prognosis for non-small cell lung cancer patients with brain metastasis. 2021 ASCO Annual Meeting, 2021. e-Pub 2021.
94. Zhou N, Sepesi B, Leung C, Lin H, William WN, Weissferdt A, Pataer A, Godoy M, Fossella F, Blumenschein G, Le X, Tsao A, Zhang J, Hofstetter W, Swisher S, Vaporciyan A, Lee J, Gibbons D, Heymach JV, Cascone T. Impact of genomic aberrations and additional therapies on survival outcomes of patients with operable non-small cell lung cancer (NSCLC) from the NEOSTAR study. 2021 ASCO Annual Meeting, 2021. e-Pub 2021.
95. Frank M, Yu F, Reuben A, Peng M, Yang G, Chen X, Ji L, Li P, Xia X, Guan Y, Zhang J. Spatial analysis of the T-cell repertoire in non-small cell lung cancer reveals a clonality gradient from the tumor to the distal lung. 2021 ASCO Annual Meeting, 2021. e-Pub 2021.
96. Chen M, Jin Y, Chen Y, Hu X, Tang H, Li Q, Li P, Ly X, Xia X, Zhang J. PI3K-AKT pathway alterations are revealed as a potential mechanism of chemoradiation resistance in small cell lung cancer by whole-exome sequencing. 2021 ASCO Annual Meeting, 2021. e-Pub 2021.
97. Le X, Hong L, Kemp H, Saam J, Hensel C, Raymond V, Zhang J, Heymach JV. Circulating Tumor DNA Analysis in NSCLC with MET exon 14 Skipping Alterations. World Conference on Lung Cancer, 2021. e-Pub 2021.
98. Zhou, Rice D, Mehran R, Feldman H, Tomczak K, Hofstetter W, Vaporciyan A, Correa A, Zhang J, Haymaker C, Tsao A, Sepesi B. Association between Baseline Tumor Thickness and Response to Neoadjuvant Chemotherapy in Malignant Pleural Mesothelioma. World Conference on Lung Cancer, 2021. e-Pub 2021.
99. Farooqi A, Mitchell K, Ludmir E, Boyce-Fappiano D, Vaporciyan A, Swisher, Zhang J, Le X, Antonoff M, Gomez G, Elamin Y, Heymach JV, Gandhi S. EGFR Mutations Predict Superior Survival of NSCLC Patients with Oligometastatic Disease Treated with Local Consolidative Therapy. World Conference on Lung Cancer, 2021. e-Pub 2021.
100. Robichaux J, Le X, Vijayan R, Hicks K, Elamin Y, Tran H, Varghese S, He J, Zhang F, Hu L, Poteete A, Rinsurongkawong W, Zhang X, Nilsson M, Liu X, Diao L, Zhang J, Madison R, Schrock A, Saam J, Fang B, Wang J, Cross J, Gray J, Heymach JV. Structural Classification of Atypical EGFR Mutations Identifies 4 Major Subgroups With Distinct Patterns of Drug Sensitivity. World Conference on Lung Cancer, 2021. e-Pub 2021.
101. Li J, Zhang J, Ho C, Myers R, Mar C, Martin, Melosly, Lam V, Yuan R. Regression of the Ground Glass Component in Patients with Multifocal Primary Lung Cancers (MPLCs) Receiving Pembrolizumab. World Conference on Lung Cancer, 2021. e-Pub 2021.
102. Sepesi B, Corsini E, Weissferdt A, Pataer A, Altan M, Antonoff M, Blumenschein G, Elamin Y, Fossella F, Glisson B, Hofstetter W, Kurie J, Le X, Leung C, Lin H, Lu C, Mehran R, Mott F, Rice D, Roth J, Skoulidis F, Swisher S, Tsao A, Vaporciyan A, Walsh G, Zhang J, Gibbons D, Heymach JV, Cascone T. Combined neoadjuvant chemo-immunotherapy therapy achieves superior downstaging of resectable non-small cell lung cancer as compared to chemotherapy, mono or dual immunotherapy. The 34th SITC Annual Conference, 2020. e-Pub 2020.
103. Mitchell KG, Diao L, Karpinets T, Negrao M, Tran H, Parra ER, Corsini EM, Reuben A, Federico L, Bernatchez C, Dejima H, Francisco-Cruz A, Wang J, Antonoff M, Vaporciyan A, Swisher S, Cascone T, Wistuba I, Heymach JV, Gibbons D, Zhang J, Haymaker C, Sepesi B. Neutrophil expansion defines an immunoinhibitory peripheral and intratumoral inflammatory milieu in resected non-small cell lung cancer: a descriptive analysis of a prospectively immunoprofiled cohort. The 33th SITC Annual Conference, 2020. e-Pub 2020.
104. Stewart A, Gay C, Xi Y, Sivajothi S, Fujimoto J, Hartsfield H, Tran H, Swisher S, Roth J, Zhang J, Glisson B, Heymach JV, Wistuba I, Robson P, Wang J, Byers L. Paired, single-cell profiling of circulating tumor cell-derived xenograft models of small cell lung cancer reveals intratumoral heterogeneity and emergence of new cell clusters following treatment relapse. AACR Annual Conference, 2020. e-Pub 2020.
105. Tran H, Lam V, Vasquez M, Elamin Y, Raymond V, Hong L, Blumenschein G, Carter B, Lanman R, Altan M, Tsao A, Byers L, Gibbons D, Zhang J, Heymach JV. Comparable clinical benefits between low and high variant allelic frequency in NSCLC patients treated with targeted therapies based on molecular alterations from ctDNA NGS. AACR Annual Conference, 2020. e-Pub 2020.
106. Lazcano Segura RN, Catao A, Solis LM, Jiang M, Tamegnon A, Fujimoto J, Rodriguez-Canales J, Chow CB, Behrens C, Kalhor N, Weissferdt A, Heymach JV, Swisher S, Sepesi B, Lee J, Moran C, Futreal A, Zhang J, Parra ER, Wistuba I, Tetzlaff M, Francisco-Cruz A. Tertiary lymphoid structures features associate with outcome in non-small cell lung carcinoma. AACR Annual Conference, 2020. e-Pub 2020.
107. Sinjab A, Han G, Treekitkarnmongkol W, Brennan P, Hara K, Chang K, Bogatenkova E, Sanchez-Espiridion B, Behrens C, Zhang J, Sepesi B, Cascone T, Gibbons D, Chen J, Eapen G, Ostrin E, Fujimoto J, Spira A, Scheet P, Wistuba I, Wang L, Kadara H. A single-cell transcriptomic atlas of lung adenocarcinoma and adjacent normal-appearing tissue. AACR Annual Conference, 2020. e-Pub 2020.
108. Cascone T, Sepesi B, Lin H, Kalhor N, Parra ER, Jiang M, Godoy M, Zhang J, Fossella F, Tsao A, Lam V, Lu C, Mott F, Simon G, Antonoff MB, Moran C, Vaporciyan A, Lee J, Swisher S, Gibbons D, Wistuba I, William Jr W, Heymach JV. A phase I/II study of neoadjuvant cisplatin, docetaxel, and nintedanib for resectable non–small cell lung cancer. AACR Annual Conference, 2020. e-Pub 2020.
109. Jin Y, Chen Y, Tang H, Li Q, Li P, Hu X, Guan YF, Xia X, Yi X, Zhang J, Chen M. Clinical potential of ctDNA-based TMB in small cell lung cancer recieving chemoradiotherapy. ASCO Annual Meeting 2020, 2020. e-Pub 2020.
110. Liu X, Wang F, Chen X, Hou X, Chang L, Xie Z, Liu Y, Li Q, Li P, Guan YF, Zhang X, Wang Sh, Xu Ch, Wang H, Yi X, Zhang J, Xia X, Moran C, Chen L. Genomic origin and immune-related status of pulmonary sarcomatoid carcinoma. ASCO Annual Meeting 2020, 2020. e-Pub 2020.
111. Huang J, Zhao G, Peng Q, Ma J, Li P, Chang L, Guan YF, Reuben A, Xia X, Yi X, Zhang J, Chen Z. Genomic and immune intratumor heterogeneity in gastric linitis plastica. ASCO Annual Meeting 2020, 2020. e-Pub 2020.
112. Tseng D, Chiou Sh, Yang X, Reuben A, Wilhelmy J, McSween A, Conley S, Sinha R, Nabet B, Wang Ch, Shrager JB, Berry MF, Backhus LM, Lui N, Wakelee HA, Neal JW, Zhang J, Garcia KC, Mackall K, Davis M. Discovery of a novel shared tumor antigen in human lung cancer. ASCO Annual Meeting, 2020. e-Pub 2020.
113. Soto F, Zhong L, Shannon V, Wilson N, Zarifa A, Akhmedzhano F, Heymach JV, Arain MH, Lewis J, Rinsurongkawong W, Lee JJ, Zhang J, Swisher S, Mendoza TR, Naing A, Sheshadri A, Altan M. Incidence and risk factors for pneumonitis associated with immune checkpoint inhibitors in advanced-stage non-small cell lung cancer: A single center experience. ASCO Annual Meeting 2020, 2020. e-Pub 2020.
114. Sepesi B, Corsini EM, Weissferdt A, Pataer A, Leung CH, Lin H, Le X, Mott F, Fossella F, Altan M, Tsao A, Skoulidis F, Blumenschein G, Kurie J, Zhang J, Glisson B, Lu C, Elamin Y, Antonoff MB, Hofstetter WL, Mehran RJ, Rice DC, Roth JA, Swisher SG, Vaporciyan AA, Walsh GL, Gibbons DL, Heymach JV, Cascone T. Combined Neoadjuvant Chemo-Immunotherapy Therapy Achieves Superior Downstaging of Resectable Non-Small Cell Lung Cancer as Compared to Chemotherapy, Mono Or Dual Immunotherapy. European Society of Thoracic Surgeons Annual Meeting, 2020. e-Pub 2020.
115. Chiou S, Tseng D, Yang X, Reuben A, McSween A, Wilhelmy J, Wang Ch, Shrager J, Zhang J, Garcia Ch, Mackall C, Davis M. Towards the identification of novel tumor antigens in human lung cancer. Cancer Immunology Research, 2020. e-Pub 2020.
116. Gaudreau P, Ajami N, Sepesi B, Karpinets T, Reuben A, Wong M, Parra E, Federico L, Gopalakrishnan V, Mitchell K, Negrao M, Spencer C, Vaporciyan A, Weissferdt A, Haymaker C, Tran H, Bernatchez C, Landry L, Roarty E, Cascone T, Heymach JV, Zhang J, Wistuba I, Wargo J, Gibbons D. Depicting the Intra-Tumoral Viral and Microbial Landscape of Localized NSCLC Using Standard Next Generation Sequencing Data. The 20th World Conference on Lung Cancer, 2019. e-Pub 2019.
117. Gaudreau P, Negrao M, Mitchell K, Corsini E, Karpinets T, Wang Q, Diao L, Wang J, Federico L, Parra E, Behrens C, Correa A, Vaporciyan A, Weissferdt A, Tran H, Roarty E, Wistuba I, Reuben A, Haymaker C, Bernatchez C, Cascone T, Heymach J, Sepesi B, Zhang J, Gibbons D, ICON collaborators. Neoadjuvant Chemotherapy is Associated to an Inflamed Immune Tumor Microenvironment in Localized NSCLC. The 20th World Conference on Lung Cancer, 2019. e-Pub 2019.
118. Reuben A, Zhang J, Gittelman R, Chiou S, Li J, Fujimoto J, Behrens C, Kheradmand F, Chow C, Bernatchez C, Eterovic AK, Benzeno S, Vignali M, Wu X, Ye Y, Cascone T, Herbst R, Swisher S, Kadara H, Moran C, Scheet P, Vaporciyan A, Sepesi B, Gibbons D, Robins H, Hwu P, Heymach JV, Sharma P, Allison J, Lee J, Davis M, Wistuba I, Futreal PA. Increased Frequency of Bystander T Cells in the Lungs Is Associated With Recurrence in Localized Non-Small Cell Lung Cancer. The 20th World Conference on Lung Cancer, 2019. e-Pub 2019.
119. Sepesi B, Cascone T, William W, Lin H, Leung C, Weissferdt A, Walsh G, Rice D, Roth J, Mehran R, Hofstetter W, Antonoff M, Fossella F, Mott F, Le X, Skoulidis F, Zhang J, Byers L, Lam V, Glisson B, Kurie J, Blumenschein G, Tsao A, Lu C, Altan M, Elamin Y, Gibbons D, Papadimitrakopolou V, Lee J, Heymach J, Vaporciyan A, Swisher S. Surgical Outcomes Following Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab In Non-Small Cell Lung Cancer - NEOSTAR study. The 20th World Conference on Lung Cancer, 2019. e-Pub 2019.
120. Skoulidis F, Arbour K, Hellmann M, Patil P, Marmarelis M, Owen D, Awad M, Murray J, Levy B, Hellyer J, Gainor J, Stewart T, Goldberg S, Dimou A, Bestvina C, Cummings A, Elamin Y, Lam V, Zhang J, Shu C, Riess J, Blakely C, Pecot C, Mezquita L, Tabbò F, Sacher A, Scheffler M, Ricciuti B, Venkatraman D, Rizvi H, Liu C, Johnston R, Ni Y, Azok J, Kier M, Katz S, Davies K, Segal J, Ritterhouse L, Shaish H, Lacroix L, Memmott R, Madrigal J, Goldman J, Lau S, Killam J, Walther Z, Carter B, Woodcock M, Roth J, Swisher S, Leighl N, Digumarthy S, Mooradian M, Rotow J, Wolf J, Scagliotti G, Planchard D, Besse B, Bivona T, Gandara D, Garon E, Rizvi N, Camidge DR, Schalper K, Herbst R, Shaw A, Neal J, Wakelee H, Brahmer J, Jänne P, Carbone D, Aggarwal C, Pennell N, Rudin C, Papadimitrakopoulou V, Heymach JV. STK11/LKB1 genomic alterations are associated with inferior clinical outcomes with chemo-immunotherapy in non-squamous NSCLC. The 20th World Conference on Lung Cancer, 2019. e-Pub 2019.
121. Jin Y, Bao H, Le X, Fan X, Yang M, Fan Y, Zhang Y, Shi X, Zhao J, Lou G, Shao L, He Q, Lin C, Zhang J, Futreal PA, Wistuba I, Heymach JV, Wu X, Shao YW, Yan J, Chen Y, Chen M, Yu X, Xu Y. Genomic Evolution During TKI Treatment in Non-Small Cell Lung Cancer Patients With or Without Acquired T790M Mutation. The 20th World Conference on Lung Cancer, 2019. e-Pub 2019.
122. Kudo Y, Haymaker C, Zhang J, Reuben A, Fujimoto J, Roy-Chowdhuri S, Solis L, Dejima H, Parra Cuentas E, Mino B, Ikeda N, Luthra R, Gibbons D, Lang F, Lee JJ, Huse J, Kadara H, Wistuba I. Immune Suppressive Microenvironment and Highly Clonal Concordance of TCR Repertoire in Brain Metastases from Non-Small Cell Lung Cancer. The 20th World Conference on Lung Cancer, 2019. e-Pub 2019.
123. Williams L, Shi Q, El Ferjani B, Hirschmann M, Ponce D, Dibaj S, Chandwani S, Roarty E, Rinsurongkawong W, Lewis J, Burke T, Cleeland C, Lee J, Roth R, Swisher S, Heymach JV, Zhang J, Simon G. Differences in Symptom Burden Between Responsive and Progressive Disease in Advanced Non-Small Cell Lung Cancer (aNSCLC). The 20th World Conference on Lung Cancer, 2019. e-Pub 2019.
124. Negrao M, Skoulidis F, Montesion M, Schulze K, Bara I, Shen V, Hu S, Elamin Y, Le X, Goldberg M, Wu C, Zhang J, Barreto D, Rinsurongkawong W, Simon G, Roth J, Swisher S, Lee J, Tsao A, Papadimitrakopoulou V, Gibbons D, Glisson B, Miller V, Alexander B, Frampton G, Albacker L, Shames D, Heymach JV. BRAF Mutations Are Associated with Increased Benefit from PD1/PDL1 Blockade Compared with Other Oncogenic Drivers in Non-Small Cell Lung Cancer. The 20th World Conference on Lung Cancer, 2019. e-Pub 2019.
125. Tran H, Lam V, Vasquez M, Hong L, Colen R, Elshafeey N, Hassan I, Papadimitrakopoulou V, Blumenschein G, Carter B, Simon G, Lanman R, Raymond V, Elamin Y, Altan M, Tsao A, Gibbons D, Zhang J, Heymach J. Outcomes in Advanced NSCLC Patients Treated with 1st Line EGFR-TKI Based on Mutation Detection from Tissue or cfDNA-Based Genomic Sequencing. The 20th World Conference on Lung Cancer, 2019. e-Pub 2019.
126. Reuben A, Zhang J, Gittelman R, Chiou S, Li J, Fujimoto J, Behrens C, Kheradmand F, Chow C, Bernatchez C, Eterovic K, Benzeno S, Vignali M, Wu X, Ye Y, Cascone T, Herbst R, Swisher S, Kadara H, Moran C, Zhang JH, Scheet P, Vaporciyan A, Sepesi B, Gibbons D, Robins H, Hwu P, Heymach JV, Sharma P, Allison J, Lee J, Davis M, Wistuba I, Futreal PA, Zhang J. Comprehensive characterization of the T cell repertoire in non-small cell lung cancer (PROSPECT). The 20th World Conference on Lung Cancer, 2019. e-Pub 2019.
127. Chen R, Jin Y, Li J, Zhang JX, Fujimoto J, Hu X, Chen Y, Behrens C, Chow C, Parra E, Little L, Gumbs C, Song X, Zhang JH, Gibbons D, Heymach JV, Lee J, William W, Glisson B, Wistuba I, Futreal PA, Byers L, Reuben A, Chen M, Zhang J. Genomic and T cell repertoire intratumor heterogeneity of small-cell lung cancer by multiregion exome and TCR sequencing: an association with survival. The 20th World Conference on Lung Cancer, 2019. e-Pub 2019.
128. Lewis W, Simon G, Mott F, Papadimitrakopoulou V, Rinsurongkawong W, Lewis J, Lee J, Roth J, Swisher S, Heymach J, Zhang J, Lam V. Clinical Outcomes in Metastatic Squamous Lung Cancer with Targetable Driver Alterations. The 20th World Conference on Lung Cancer, 2019. e-Pub 2019.
129. Mitchell K, Farooqi A, Ludmir E, Corsini E, Sepesi B, Vaporciyan A, Swisher S, Heymach J, Zhang J, Gomez D, Antonoff M. Pulmonary Resection Is Associated with Durable Overall Survival in Synchronous Oligometastatic Non-Small Cell Lung Cancer. AATS International Thoracic Surg Onc Summit, 2019. e-Pub 2019.
130. Shi Q, Williams L, Ferjani B, Hirschmann M, Ponce D, Dibaj S, Chandwani S, Roarty E, Rinsurongkawong W, Lewis J, Burke T, Cleeland C, Lee J, Roth J, Swisher S, Heymach J, Zhang J, Simon G. Body Mass Index Relating to Patient-Reported Symptoms in First-Line Treatment of Metastatic Non-Small Cell Lung Cancer. The 20th World Conference on Lung Cancer, 2019. e-Pub 2019.
131. Mitchell K, Negrao M, Parra E, Li J, Zhang J, Dejima H, Vaporciyan A, Swisher S, Weissferdt A, Antonoff M, Cascone T, Roarty E, Wistuba I, Heymach J, Gibbons D, Zhang J, Sepesi B. Lymphovascular Invasion Is Associated with Mutational Burden and PD-L1 in Resected Lung Cancer. The 20th World Conference on Lung Cancer, 2019. e-Pub 2019.
132. Mitchell K, Farooqi A, Ludmir E, Corsini E, Zhang JX, Sepesi B, Vaporciyan A, Swisher S, Heymach J, Zhang J, Gomez D, Antonoff M. Improved Overall Survival With Comprehensive Local Consolidative Therapy in Synchronous Oligometastatic Non–Small-Cell Lung Cancer. The 20th World Conference on Lung Cancer, 2019. e-Pub 2019.
133. Tang C, Lee W, Tran H, Reuben A, Swisher S, Heymach J, Zhang J, Gomez D. Radiation induced changes in the circulating t-cell repertoire and circulating tumor DNA in oligometastatic NSCLC: translational correlatives from a mature randomized phase II trial. ASTRO Annual meeting, 2019. e-Pub 2019.
134. Le X, Negrao M, Reuben A, Lee W, Parra E, Li J, Karpinets T, Behrens C, Sepesi B, Vaporiciyan A, Roth J, Haymaker C, Roarty E, Zhang JH, Bernatchez C, Zhang J, Wistuba I, Gibbons D, Heymach J. Characterization of the tumor immune microenvironment in treatment-naïve EGFR-mutant NSCLC uncovers a low IFN-gamma suppressed immune phenotype. AACR annual meeting, 2019. e-Pub 2019.
135. Negrao M, Karpinets T, Li J, Reuben A, Haymaker C, Mitchel K, Fujimoto J, Chow C, Parra E, Federico L, Zhang JH, Vaporciyan A, Bernatchez C, Cascone T, Roarty E, Sepesi B, Wistuba I, Heymach J, Zhang J, Gibbons D. Immune-genomic profiling identifies a subgroup of squamous cell lung cancers with immunosuppressed tumor microenvironment and correlates TGF-beta and Wnt-beta-catenin signaling as predictive of low PD-L1 expression. AACR annual meeting, 2019. e-Pub 2019.
136. Stewart A, Gay C, Xi Y, Siva V, Fujimoto J, Bolisetty M, Kalhor N, Hartsfield P, Tran H, Zhang J, Swisher S, Roth J, Oliver T, Heymach J, Wistuba I, Glisson B, Robson P, Wang J, Byers L. Single-cell analyses reveal increasing intratumoral heterogeneity as an essential component of treatment resistance in small cell lung cancer. AACR annual meeting, 2019. e-Pub 2019.
137. Stewart CA, Gay C, Xi Y, Fujimoto J, Kalhor N, Hartsfield P, Tran H, Fernandez L, Lu D, Wang Y, Dittamore W, Zhang J, Swisher S, Roth JA, Oliver T, Heymach JV, Wistuba I, Glisson B, Robson P, Wang J, Byers L. Single-cell analyses reveal increasing intratumoral heterogeneity as an essential component of treatment resistance in small cell lung cancer. ASCO Annual meeting, 2019. e-Pub 2019.
138. Gomez DR, Tang Ch, Zhang J, Blumenschein Jr GR, Hernandez M, Lee J, Ye R, Palma DA, Louie AV, Camidge DR, Doebele RC, Skoulidis F, Gaspar L, Welsh JW, Gibbons D, Karam JA, Kavanagh B, Tsao AS, Sepesi B, Swisher S, Heymach JV. Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non–small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study. ASCO Annual Meeting, Chicago, 2019. e-Pub 2019.
139. Peng W, Wu L, Chang L, Li J, Bai J, Zhang J, Guan Y, Jiang M, Pu X, Xu L, Wang Q, Xu F, Chen B, Cao J, Yi X, Yang L, Xia X, Zhang J. Pathogenic germline mutation profile in Chinese lung cancers and related-driver mutation pattern. ASCO Annual Meeting, 2019. e-Pub 2019.
140. Jin Y, Bao H, Le X, Fan X, Tang M, Fan Y, Zhang Y, Xu Y, Wu X, Shao Y, Yan J, He J, Chen M, Zhang J, Yu X. Distinct resistant mechanism and genomic evolution during TKI treatment in non-small cell lung cancer patients with or without acquired T790M mutation. ASCO Annual Meeting, 2019. e-Pub 2019.
141. Hong L, Dibaj S, Negrao MV, Reuben A, Roarty E, Rinsurongkawong W, Lewis J, Gibbons D, Sepesi B, Papadimitrakopoulou V, Glisson B, Blumenschein Jr GR, Futreal A, Wistuba I, Roth J, Swisher S, Heymach J, Simon G, Lee J, Zhang J. Spatial and temporal heterogeneity of PD-L1 and its impact on benefit from immune checkpoint blockade in non-small cell lung cancer (NSCLC). ASCO Annual Meeting, 2019. e-Pub 2019.
142. Yang J, Gong Y, Lam V, Shi Y, Guan YF, Zhang Y, Ji L, Chen Y, Zhao Y, Qian F, Chen J, Li P, Zhang F, Wang J, Yang L, Futreal A, Zhang J, Yi X, Xia X, Yu P. Tracking circulating cell-free tumor DNA in gastric cancer to detect early disease recurrence. ASCO Annual Meeting, 2019. e-Pub 2019.
143. Mitchell KG, Diao L, Tran H, Negrao MV, Karpinets T, Wang J, Parra Cuentas ER, Corsini E, Reuben A, Federico L, Bernatchez Ch, Vaporciyan A, Swisher S, Cascone T, Wistuba I, Heymach J, Zhang J, Gibbons D, Haymaker C, Sepesi B. Association of relative neutrophilia with a distinct immunoinhibitory milieu in non-small cell lung cancer. ASCO Annual Meeting, 2019. e-Pub 2019.
144. Reuben A, Zhang J, Lin H, Little L, Gumbs C, Tran H, Wang L, Haymaker C, Mehran R, Rice D, Walsh G, Lee J, Wistuba I, Swisher S, Vaporciyan A, Futreal A, Sepesi B, Heymach J, Gibbons D, Cascone T, NEOSTAR Study Group. T cell repertoire analysis of non-small cell lung cancer patients treated with neoadjuvant nivolumab alone or in combination with ipilimumab (NEOSTAR trial). ASCO Annual Meeting, Chicago, 2019. e-Pub 2019.
145. William WN, Lee WC, Lee J, Lin HY, Eterovic AK, El-Naggar AK, Gillenwater AM, Pisegna M, Tong P, Li L, Tian X, Tran H, Saintigny P, Wang J, Papadimitrakopoulou V, Lippman S, Futreal PA, Heymach J, Zhang J. Genomic and transcriptomic landscape of oral pre-cancers (OPCs) and risk of oral cancer (OC). ASCO Annual Meeting, 2019. e-Pub 2019.
146. Zhuo M, Guan YF, Yang X, Hong L, Wang Y, Li Z, Chen R, Abbas H, Zhong J, Chen H, Dong Z, Zhu X, Li J, Roarty E, Rinsurongkawong W, Lewis J, Futreal A, Xia X, Zhang J, Zhao J. cfDNA analysis to reveal association of genomic features with chemotherapy response and survival in patients with pulmonary large-cell neuroendocrine carcinoma. ASCO Annual Meeting, 2019. e-Pub 2019.
147. Yang J, Gong Y, Lam V, Shi Y, Guan Y, Zhang Y, Ji Y, Chen Y, Zhao Y, Qian F, Chen J, Li P, Zhang F, Wang J, Yang L, Futreal PA, Zhang J, Yi X, Xia X, Yu P. Tracking circulating cell-free tumor DNA in gastric cancer to detect early disease recurrence. ASCO Annual Meeting, 2019. e-Pub 2019.
148. Francisco-Cruz A, Parra E, Krishnan S, Barua S, Jiang M, Fujimoto F, Peterson C, Das P, Chow C, Rodriguez-Canales J, Behrens C, Kalhor N, Weissferdt A, Heymach J, Swisher S, Sepesi B, Rao A, Lee J, Moran C, Futreal PA, Zhang J, Wistuba I. Impact of the spatial analysis of tumor-associated lymphocytes and tumor-associated macrophages on recurrence at early stage of non-small cell lung carcinoma. AACR annual meeting, 2019. e-Pub 2019.
149. Su D, Zhang D, Jin J, Ying L, Han M, Chen K, Li B, Wu J, Xie Z, Zhang F, Lin Y, Cheng G, Wang J, Huang M, Li J, Zhang J, Li F, Xiong L, Futreal PA, Mao W. A novel approach identifies the potential biomarkers of targeted drug sensitivity in esophageal squamous cell carcinoma. AACR annual meeting, 2019. e-Pub 2019.
150. Lee W, Gomez D, Zhang J, Jalali A, Roh W, Reuben A, Lu W, Wu C, Chow C, Fujimoto J, Antonoff M, Moran C, Sulman E, Rao G, Swisher S, Heymach J, Heymach J, Futreal PA, Zhang J. Comprehensive molecular profiling of primary tumors and paired distant metastases in non-small cell lung cancer. AACR annual meeting, 2019. e-Pub 2019.
151. Tran H, Zhang J, Vasquez M, Fossella F, Simon G, Tsao A, Gibbons D, Elamin Y, Banks K, Lanman R, Papadimitrakopoulou V, Heymach J. Retrospective Review Clinical Use of a cfDNA Blood Test for Identification of Targetable Molecular Alterations in Patients with Lung Cancer. The 17th World Conference on Lung Cancer, 2018. e-Pub 2018.
152. Elamin Y, Rinsurongkawong W, Tran H, Gold KA, Lewis J, Roarty E, Futreal PA, Zhang J, Heymach J. The impact of genomic landscape of EGFR mutant NSCLC on response to targeted and immune therapy. The 17th World Conference on Lung Cancer, 2018. e-Pub 2018.
153. Gomez D, Tang C, Zhang J, Blumenschein G, Hernandez M, Lee J, Ye RD, Camidge R, Skoulidis F, Doebele R, Gaspar L, Gibbons D, Karam J, Kavanagh B, Palma D, Louie A, Tsao A, Sepesi B, Swisher S, Heymach J. Local Consolidative Therapy (LCT) Improves Overall Survival (OS) Compared to Maintenance Therapy/ Observation in Oligometastatic Non-Small Cell Lung Cancer (NSCLC): Final Results of a Multicenter, Randomized, Controlled Phase 2 Trial. Annual Meeting Steering Committee of the American Society for Radiation Oncology (ASTRO), 2018. e-Pub 2018.
154. Tran H, Lam V, Vasquez M, Hong L, Colen R, Elshafeey N, Hassan I, Prado E, Papadimitrakopoulou V, Blumenschein G, Carter B, Simon G, Byers L, Altan M, Elamin Y, Lanman R, Raymond V, Tsao A, Gibbons D, Fossella F, Zhang J, Heymach J. Clinical Evaluation of Plasma-Based (cfDNA) Genomic Profiling in Over 1,000 Patients with Advanced Non-Small Cell Lung Cancer. The 19th World Conference on Lung Cancer, 2018. e-Pub 2018.
155. Negrao M, Reuben A, Chen R, Sepesi B, Karpinets T, Parra E, Federico L, Vence L, Weissferdt A, Tran H, Vaporciyan A, Haymaker C, Forget M, Vasquez M, Prado E, Chow C, Zhang J, Li J, Fujimoto J, Roth J, Meraz I, Roarty E, Landry L, Wagner H, Bogatenkova E, Bernatchez C, Futreal A, Wistuba I, Swisher S, Heymach J, Gibbons D, Zhang J. Prospective immunogenomic profiling of non-small cell lung cancer: genomic and immune profiling updates from Project ICON. The 19th World Conference on Lung Cancer, 2018. e-Pub 2018.
156. Shi Q, Williams L, Vaghani V, Hirschmann M, Lacerada L, Roarty E, Zhang J, Rinsurongkawong W, Lewis J, Cleeland C, Lee J, Roth J, Swisher S, Heymach J, Simon G. Profiling the Symptom Burden of Patients with Metastatic NSCLC Receiving Either Chemotherapy or Targeted Therapy: Real-World Data. The 19th World Conference on Lung Cancer, 2018. e-Pub 2018.
157. Williams L, Dibaj S, Chandwani S, Vaghani V, Shi Q, Hirschmann M, Lacerda L, Roarty E, Zhang J, Rinsurongkawong W, Lewis J, Burke T, Cleeland C, Lee J, Roth J, Swisher S, Heymach J, Simon G. Real-World Patient-Reported Outcome Symptom Assessment of Patients with Metastatic Non-Small Cell Lung Cancer Prior to Treatment. The 19th World Conference on Lung Cancer, 2018. e-Pub 2018.
158. Negrao M, Reuben A, Robichaux J, Le X, Nilsson M, Elamin Y, Wu C, Landry L, Glisson B, Zhang J, Heymach J. Driver mutations are associated with distinct patterns of response to immune checkpoint blockade in non-small cell lung cancer. The 19th World Conference on Lung Cancer, 2018. e-Pub 2018.
159. Tang C, Lee W, Chang L, Tran H, Reuben A, Xia X, Yi X, Swisher S, Heymach J, Zhang J, Gomez D. Radiation Induced Changes in the Circulating T-Cell Repertoire and Circulating Tumor DNA in Oligometastatic Nsclc; Translational Correlatives from a Mature Randomized. ASTRO Annual meeting, 2018. e-Pub 2018.
160. Lam V, Tran H, Vasquez M, Li K, Yuen K, Vang F, Jaimovich A, Kennedy D, Odegaard J, Mortimer S, Olsen S, Raymond V, Vaporciyan A, Antonoff M, Walsh G, Roarty E, Lacerda L, Roth J, Swisher S, Bernatchez C, Sepesi B, Gibbons D, Zhang J, Heymach J. Circulating tumor DNA analysis with a novel variant classifier for recurrence detection in resected, early-stage lung cancer. The 19th World Conference on Lung Cancer, 2018. e-Pub 2018.
161. Weissferdt W, Sepes B, Pataer A, Kalhor N, Moran CA, William WN, Le X, Glisson B, Skoulidis F, Blumenschein G, Zhang J, Altan M, Rice D, Mehran R, Lee JJ, Vaporciyan A, Gibbons DL, Swisher SG, Heymach JV, Cascone T. Pathologic assessment following neoadjuvant immunotherapy or chemotherapy demonstrates similar patterns in non-small cell lung cancer (NSCLC). ESMO 2018 Congress, 2018. e-Pub 2018.
162. Vaghani V, Chandwani S, Hirschmann M, Dibaj S, Landry LL, Roarty E, Zhang J, Rinsurnogkawong W, Lewis J, Lee J, Jack A Roth AJ, Swisher S, Heymach J, Burke T, Simon G. Computing the Impact of Immunotherapy on the Non-Small Cell Lung Cancer (NSCLC) Therapeutic Landscape. World Conference on Long Cancer, 2018. e-Pub 2018.
163. Whisenant M, Williams L, Vaghani V, Shi Q, Garcia Gonzalez A, Haq S, Cleeland C, Zhang J, Heymach J, Simon G. Defining the Symptom Burden of Non-Small Cell Lung Cancer. World Conference on Long Cancer, 2018. e-Pub 2018.
164. Welsh J, Hess K, Tang C, Cushman T, Simon G, Skoulidis F, Chang J, Gomez D, Mott F, Zhang J, Raju U, Shaaban S, Heymach J, Papadimitrakopoulou V, Glisson B. Phase II Trial of Pembrolizumab and Wide-field versus Hypofractionated Stereotactic Radiation Therapy in Patients with Non-Small Cell Lung Cancer. ASCO Annual Meeting, 2018. e-Pub 2018.
165. Weissferdt A, Cascone T, Pataer A, Kalhor N, Moran C, Antonoff M, Walsh G, Bernatchez C, Gibbons D, Wistuba I, Roth J, Zhang J, Roarty E, Landry L, Vaporciyan A, Heymach J, Swisher S, Sepesi B. Histopathologic Parameters Define Features of Treatment Response to Neoadjuvant Chemotherapy in Non-Small Cell Lung Cancer. The 19th World Conference on Lung Cancer, 2018. e-Pub 2018.
166. Sepesi B, Federico L, Mitchell K, Parra E, Francisco-Cruz L, Ravelli A, Haymaker C, Karpinets T, Cascone T, Weissferdt A, Antonoff M, Walsh G, Bernatchez C, Roth J, Zhang J, Roarty E, Landry L, Vaporciyan A, Swisher S, Heymach J, Wistuba I, Gibbons D. PD-L1 Expression is Predominant in CD68+ Tumor-Associated Macrophages in Stage I-III Non-Small Cell Lung Cancers. The 19th World Conference on Lung Cancer, 2018. e-Pub 2018.
167. Jin Y, Bao H, Le X, Fan X, Tang M, Fan Y, Zhang Y, Xu Y, Wu X, Shao Y, Yan J, He J, Chen M, Zhang J, Yu X. Distinct resistant mechanism and genomic evolution during TKI treatment in non-small cell lung cancer patients with or without acquired T790M mutation. ASCO Annual Meeting, 2018. e-Pub 2018.
168. Peng W, Wu L, Chang L, Li J, Bai J, Zhang Y, Guan Y, Jiang M, Pu C, Xu L, Wang Q, Xu F, Chen B, Cao J, Yi X, Yang L, Xia X, Zhang J. Pathogenic germline mutation profile in Chinese lung cancers and related driver mutation pattern. ASCO Annual Meeting, 2018. e-Pub 2018.
169. Hong H, Dibaj S, Negrao M, Reuben R, Roarty E, Rinsurongkawong W, Lewis J, Gibbons D, Sepesi B, Papadimitrakopoulou V, Glisson B, Blumenschein Jr. G, Futreal PA, Wistuba I, Roth J, Swisher S, Heymach J, Simon G, Lee J, Zhang J. Spatial and Temporal Heterogeneity of PD-L1 and its Impact on Benefit from Immune Checkpoint Blockade in Non-Small Cell Lung Cancer (NSCLC). ASCO Annual Meeting, 2018. e-Pub 2018.
170. Reuben A, Zhang J, Lin H, Little L, Gumbs C, Tran H, Wang L, Haymaker C, Mehran R, Rice D, Walsh W, Lee J, Wistuba I, Swisher S, Vaporciyan A, Futreal PA, Sepesi B, Heymach J, Gibbons D, Cascone T. T cell repertoire analysis of non-small cell lung cancer patients treated with neoadjuvant nivolumab alone or in combination with ipilimumab (NEOSTAR trial). ASCO Annual Meeting, 2018. e-Pub 2018.
171. Mitchell K, Diao L, Tran H, Negrao M, Karpinets T, Wang J, Parra-Cuentas E, Corsini E, Reuben A, Federico L, Bernatchez C, Vaporciyan A, Swisher S, Cascone T, Wistuba I, Heymach J, Zhang J, Gibbons D, Haymaker C, Sepesi B. Association of relative neutrophilia with a distinct immunoinhibitory milieu in non-small cell lung cancer. ASCO Annual Meeting, 2018. e-Pub 2018.
172. Zhuo M, Guan Y, Yang X, Hong L, Wang Y, Li Z, Chen R, Abbas H, Zhong J, Chen H, Dong Z, Zhu X, Li J, Roarty E, Rinsurongkawong W, Lewis J, Futreal PA, Xia X, Zhang J, Zhao J. cfDNA analysis to reveal association of genomic features with chemotherapy response and survival in patients with pulmonary large-cell neuroendocrine carcinoma. ASCO Annual Meeting, 2018. e-Pub 2018.
173. William Jr. W, Lee W, Lee J, Lin H, Eterovic AK, El-Naggar AK, Gillenwater A, Pisegna M, Tong P, Li L, Tian X, Tran H, Saintigny P, Wang J, Papadimitrakopoulou V, Lippman S, Futreal PA, Heymach J, Zhang J. Genomic and transcriptomic landscape of oral pre-cancers (OPCs) and risk of oral cancer (OC). ASCO Annual Meeting, 2018. e-Pub 2018.
174. Cascone T, Sepesi B, Lin H, Kalhor N, Zhang J, Fossella F, Tsao A, Lam V, Lu C, Mott F, Simon G, Antonoff M, Mehran R, Rice D, Vaporciyan A, Godoy M, Lee J, Swisher S, William W, Heymach J. A phase I study of neoadjuvant cisplatin (C), docetaxel (D) and nintedanib (N) for resectable non-small cell lung cancer (NSCLC). ASCO Annual Meeting, 2018. e-Pub 2018.
175. Hu X, Fujimoto J, Chen R, Chow C, Sun W, Song X, Mao X, Scheet P, Kadara H, Behrens C, Wu C, Lee J, Antonoff M, Vaporciyan A, Swisher S, Zhang J, Heymach J, Wistuba I, Futreal PA, Zhang J. Genomic evolutions in the progression from lung preneoplasia to adenocarcinoma. ASCO Annual Meeting, 2018. e-Pub 2018.
176. Negrao M, Reuben A, Robichaux J, Le X, Nilsson M, Wu C, Zhang J, Landry L, Roarty E, Rinsurongkawong W, Swisher S, Simon G, Futreal PA, Glisson B, Zhang J, Heymach J. Association of EGFR and HER-2 exon 20 mutations with distinct patterns of response to immune checkpoint blockade in non-small cell lung cancer. ASCO Annual Meeting, 2018. e-Pub 2018.
177. Skoulidis F, Carter B, Zhang J, Wistuba I, Papadimitrakopoulou V, Heymach J. Association of STK11/LKB1 mutations with primary resistance to PD-1/PD-L1 axis blockade in PD-L1 positive non-squamous NSCLC. ASCO Annual Meeting, 2018. e-Pub 2018.
178. Tang X, Lu W, Zhang J, Berhens C, Parra E, Wineman J, Zhang J, Gibbons F, Koeppel M, Kerns B, Stern M, Sepesi B, Lee J, Wistuba I. Gene expression difference (GED) revealed immune function gene down-regulation as tumor-associated inflammatory cell (TAIC) infıltration in microenvironment in non-small cell lung cancer (NSCLC). AACR Annual Meeting, 2018. e-Pub 2018.
179. Parra E, Jiang M, Zhang J, Behrens C, Lee J, Heymach J, Forget M, Haymaker C, Bernatchez C, Moran C, Zhang J, Gibbons D, Wistuba I. Immunofluorescence profıling of co-expression of multiple immune checkpoints in malignant and tumor infıltrated lymphocytes in non- small cell lung carcinomas using image analysis system. AACR Annual Meeting, 2018. e-Pub 2018.
180. Le X, Negrao M, Nilsson M, Robichaux J, Roarty E, Rinsurongkawong W, Glisson B, Zhang J, Heymach J. Mechanisms of resistance for osimertinib for patients with EGFR- mutant lung cancer: MD Anderson Cancer Center single institution experi- ence with osimertinib resistance. AACR Annual Meeting, 2018. e-Pub 2018.
181. Quek K, Lam V, Hillman T, Tang T, Song X, Mao X, Fujimoto J, Chow C, Eterovic K, Parra E, Behrens C, Wu X, Ye Y, Wu C, Little L, Gumbs C, Scheet P, Kadara H, Antonoff M, Vaporciyan A, Swisher S, Herbst R, Zhang J, Heymach J, Hong W, Wistuba I, Futreal PA, Zhang J. Mutational landscape of non-small cell lung adjacent normal. AACR Annual Meeting, 2018. e-Pub 2018.
182. Stewart C, Gay C, Xi Y, Siva V, Fujimoto J, Tong P, Diao L, Li L, Bolisetty M, Kalhor N, Lawson P, Vasquez M, Tran H, Wistuba I, Glisson B, Zhang J, Swisher S, Roth J, Heymach J, Robson P, Wang J, Byers L. Single-cell profıling of small cell lung cancer circulating tumor cell- derived xenograft models reveals intratumoral heterogeneity among media- tors of chemoresistance. AACR Annual Meeting, 2018. e-Pub 2018.
183. Francisco-Cruz A, Parra E, Jiang M, Fujimoto J, Chow C, Rodriguez-Canales J, Behrens C, Kalhor N, Weissferdt A, Heymach J, Swisher S, Sepesi B, Lee J, Moran C, Futreal PA, Zhang J, Wistuba I. Characterization of the immunologic intra-tumor heterogeneity in early stages of non-small cell lung carcinoma using multiplex immunofluo- rescence and image analysis approaches. AACR Annual Meeting, 2018. e-Pub 2018.
184. Reuben A, Gittelman R, Zhang J, Quek K, Vence L, Behrens C, Chen R, Fujimoto J, Chow C, Wu X, Allison J, Sharma P, Zhang J, Lee J, Sepesi B, Gibbons D, Heymach J, Futreal PA, Wistuba I, Zhang J. ICON-PROSPECT Team. Association of the T-cell receptor landscape with survival in non-small cell lung cancer. ASCO-SITC Clinical Immuo-Oncology Symposium, 2018. e-Pub 2018.
185. Federico L, Haymaker LC, Forget MA, Andrea Ravelli A, Bhatta A, Karpinets T, Zhang R, Weissferdt A, Fang B, Zhang J, Cascone T, Vaporciyan AA, Futreal A, Wistuba II, Sepesi B, Heymach J, Gibbons DL, Bernatchez C. A preclinical study of tumor-infiltrating lymphocytes in NSCLC. ASCO-SITC Clinical Immuo-Oncology Symposium, 2018. e-Pub 2018.
186. Mitchell K, Negrao M, Parra E, Li J, Reuben A, Vaporciyan A, Swisher S, Roth J, Lacerda L, Wistuba I, Bernatchez C, Haymaker C, Futreal PA, Chow C, Zhang J, Tran H, Vasquez M, Prado E, Rodriguez-Canales J, Celestino M, Weissferdt A, Roarty E, Cascone T, Gibbons T, Heymach J, Zhang J, Sepesi B, ICON Team. Clinicopathological and Immune Microenvironment Features Associated with High Tumor Mutational Burden and PD-L1 Expression in Resected Non-Small Cell Lung Cancer. The annual meeting of the Society of Thoracic Surgeons, 2018. e-Pub 2018.
187. Nelson D, Mitchell K, Wang J, Fujimoto J, Behrans C, Zheng X, Zhang J, Sepesi B, Vaporciyan A, Hofstetter W, Mehran R, Rice D, Walsh G, Swisher S, Moran C, Kalhor N, Weissferdt A, Wistuba I, Roth J, Antonoff M. Immune Regulatory Markers of Lepidic-Pattern Adenocarcinomas Presenting as Ground Glass Opacities. The annual meeting of the Society of Thoracic Surgeons, 2018. e-Pub 2018.
188. Federico L, Haymaker C, Forget M, Vence L, ICON team, Sharma P, Allison J, Fang B, Zhang J, Wagner H, Bogatenkova E, Wistuba I, Sepesi B, Heymach J, Gibbons D, Bernatchez C. Phenotypic and Functional Profiling of Tumor-Infiltrating Lymphocytes (TIL) in Early Stage Non-Small Cell Lung Cancer (NSCLC). The 17th World Conference on Lung Cancer, 2017. e-Pub 2017.
189. Ferguson S, Zheng S, Xiu J, Zhou S, Khasraw M, Brastianos P, Kesari S, Hu J, Rudnick J, Salacz M, Piccioni D, Suyun H, Davies M, Glitza I, Heymach J, Zhang J, Ibrahim N, de Groot J, McCarty J, O’Brien B, Sawaya R, Verhaak R, Reddy S, Priebe W, Spetzler D, Heimberger A. Pan-cancer profiles of brain metastases: prioritization of therapeutic targets. The 22nd Annual Meeting and Education Day of the Society for Neuro-Oncology, 2017. e-Pub 2017.
190. Lam V, Li L, Wang J, Tran H, Rinsurongkawong W, Lanman R, Lewis J, Roth J, Swisher S, Papadimitrakopoulou V, Lee J, Zhang J, Heymach J. Characteristics of Lung Cancer Cell-Free Tumor DNA (CfDNA) Shedding and Correlation with Tumor Burden as Measured by RECIST. The 18th World Conference on Lung Cancer, 2017. e-Pub 2017.
191. Hu X, Fujimoto J, Ying L, Reuben A, Chen R, Chow C, Rodriguez-Canales J, Sun W, Hu J, Parra E, Carmen B, Wu C, Mao X, Song X, Li J, Gumbs C, Swisher S, Zhang J, Heymach J, Hong W, Wistuba I, Futreal PA, Su D, Zhang J. Investigation of Genomic and TCR Repertoire Evolution of AAH, AIS, MIA to Invasive Lung Adenocarcinoma by Multiregion Exome and TCR Sequencing. The 18th World Conference on Lung Cancer, 2017. e-Pub 2017.
192. Lam V, Wang J, Gong Y, Nong J, Yi Y, Guan Y, Yang L, Jia H, Zhang S, Yi X, Liao Z, Papadimitrakopoulou V, Wistuba I, Heymach J, Glisson B, Futreal PA, Xia X, Zhang J. The Potential of ctDNA Sequencing in Disease Monitoring and Depicting Genomic Evolution of Small-Cell Lung Cancer Under Therapy. The 18th World Conference on Lung Cancer, 2017. e-Pub 2017.
193. Skoulidis F, Albacker L, Hellmann M, Awad M, Gainor J, Goldberg M, Schrock A, Gay L, Elvin J, Ross J, Rizvi H, Carter B, Erasmus J, Halpenny D, Plodkowski A, Long N, Nishino-Habatu M, Denning W, Rodriguez-Canales J, Villalobos P, Parra E, Sholl L, Sauter J, Elamin Y, Zhang J, Leonardi G, Wong K, Stephens P, Papadimitrakopoulou V, Wistuba I, Wolchok J, Shaw A, Jänne P, Rudin C, Miller V, Heymach J. STK11/LKB1 Loss of Function Genomic Alterations Predict Primary Resistance to PD-1/PD-L1 Axis Blockade in KRAS-Mutant NSCLC. The 18th World Conference on Lung Cancer, 2017. e-Pub 2017.
194. Altan M, Fossella F, Zhang J, Landry L, Roarty E, Roth J, Swisher S, Heymach J. Single Institutional Experience of the Use of PD-1 Inhibitors to Non-Small Cell Lung Cancer Patients with Preexisting Autoimmune Diseases. The 18th World Conference on Lung Cancer, 2017. e-Pub 2017.
195. Federico L, Haymaker LC, Forget MA, Vence L, Icon Team, Sharma P, Allison J, Fang B, Zhang J, Wagner H, Bogatenkova E, Wistuba I, Sepesi B, Heymach J, Gibbons DL, Bernatchez C. Phenotypic and Functional Profiling of Tumor-Infiltrating Lymphocytes (TIL) in Early Stage Non-Small Cell Lung Cancer (NSCLC). The 18th World Conference on Lung Cancer, 2017. e-Pub 2017.
196. Simon G, Chandwani S, Vaghani V, Hirschmann M, Landry L, Roarty E, Zhang J, Shi Q, Rinsurnogkawong W, Lewis J, Williams L, Cleeland C, Burke T, Lee J, Roth J, Swisher S, Heymach J. Computing the Impact of Immunotherapy on NSCLC Landscape: The Advanced Non-Small Cell Lung Cancer Holistic Registry (ANCHoR). The 18th World Conference on Lung Cancer, 2017. e-Pub 2017.
197. Zhang J, Sepesi B, Icon Team, Gibbons D. Update on Prospective Immunogenomic Profiling of Non-Small Cell Lung Cancer (ICON Project). The 18th World Conference on Lung Cancer, 2017. e-Pub 2017.
198. Reuben A, Gittelman R, Zhang J, Chen R, Quek K, Vence L, Fernandez-Cubelo I, Behrens C, Gao J, Yusko E, Emerson R, Benzeno S, Vignali M, Tipton C, Jalali A, Lee W, Wu C, Li J, Wu X, Ye Y, Eterovic A, Little L, Gumbs C, Bernatchez C, Haymaker C, Forget M, Federico L, Cascone T, Robins H, Roarty E, Rodriguez J, Parra E, Wargo J, Allison J, Sharma P, Zhang J, Lee J, Sepesi B, Swisher S, Gibbons D, Heymach J, Futreal PA, Wistuba I, Zhang J. Immune, Molecular and T Cell Repertoire Landscape of 235 Resected Non-Small Cell Lung Cancers and Paired Normal Lung Tissues. The 18th World Conference on Lung Cancer, 2017. e-Pub 2017.
199. Robichaux J, Elamin Y, Zhang J, Futreal PA, Roarty E, Rinsurongkawong W, Lewis J, Tran H, Swisher S, Heymach J. Identification of Novel Potentially Targetable Genomic Alterations in Paired Tumors with Acquired EGFR TKI Resistance by NGS. The 18th World Conference on Lung Cancer, 2017. e-Pub 2017.
200. Seth S, Lee W, Zhang J, Fujimoto J, Behrens C, McDowell C, Kalhor N, Weissferdt A, Papadimitrakopoulou V, Heymach J, Gibbons D, Futreal PA, Wistuba I, Amit M, Kadara H, Zhang J. Genomic and transcriptomic profiling of localized sarcomatoid carcinoma of the lung to reveal association between immune activation and a lower risk of recurrence. ASCO Annual Meeting, 2017. e-Pub 2017.
201. Lee W, Gomez D, Zhang J, Jalali A, Roh W, Reuben A, Lu W, Chow C, Wu C, Fujimoto J, Antonoff M, Moran C, Sulman E, Rao G, Swisher S, Heymach J, Wistuba I, Futreal PA, Zhang J. Oligomets Study Team; Comprehensive molecular and immune profiling of non-small cell lung cancer and matched distant metastases to suggest distinct molecular mechanisms underlying metastasis. ASCO Annual Meeting, 2017. e-Pub 2017.
202. Schvartsman G, Peng S, Bis J, Lee J, Benveniste M, Zhang J, Rinsurongkawong W, Lewis J, Roarty E, Lacerda L, Roth J, Swisher S, Heymach J, Fossella F, William W. Response to single-agent (SA) chemotherapy (CTx) after immunotherapy exposure in non-small cell lung cancer (NSCLC). ASCO Annual Meeting, 2017. e-Pub 2017.
203. Tang M, Kalhor N, Ramineni M, Fujimoto J, Zhang J, Li J, Chow C, Mao X, Song X, Little L, Gumbs C, Behrens C, William W, Weissferdt A, Lee J, Swisher S, Heymach J, Wistuba I, Futreal PA, Zhang J. Histology determination of lung cancers: A report on genomic profiling of lung cancer of mixing histology. ASCO Annual Meeting, 2017. e-Pub 2017.
204. Skoulidis F, Hellmann M, Awad M, Rizvi R, Carter B, Denning W, Elamin Y, Zhang J, Leonardi G, Halpenny D, Plodkowski A, Long N, Erasmus J, Papadimitrakopoulou V, Wong K, Wistuba I, Janne P, Rudin C, Heymach J. STK11/LKB1 co-mutations to predict for de novo resistance to PD-1/PD-L1 axis blockade in KRAS-mutant lung adenocarcinoma. ASCO Annual Meeting, 2017. e-Pub 2017.
205. Reuben A, Gittelman R, Zhang J, Yusko E, Wu C, Emerson R, Zhang J, Tipton C, Vignali M, Fujimoto J, Rodriguez-Canales J, Swisher S, Heymach J, Robins H, Lee J, Futreal PA, Wistuba I, Zhang J. TCR repertoire sequencing of 254 resected non-small cell lung cancers to reveal TCR clonality in normal tissues compared to tumor tissues. ASCO Annual Meeting, 2017. e-Pub 2017.
206. Hu X, Su D, Fujimoto J, Ying Y, Chow C, Sun W, Zhang J, Hu J, Behrens C, Antonoff M, Ostrin E, Godoy M, William W, Swisher S, Lee J, Wistuba I, Hong W, Futreal PA, Rodriguez-Canales J, Coyle M, Gumbs C, Li J, Little L, Kalhor N, Mao X, Parra E, Song X, Thornton R, Vaporciyan A, Weissferdt A, Wu C, Zhang J. Multiregion whole exome seuquencing of pre- and early neoplastic lung lesions. ASCO Annual Meeting, 2017. e-Pub 2017.
207. Jalali A, Wang J, Lee W, Zhang J, Wu C, Gibbons D, Tang X, Kalhor N, Izzo J, Behrens C, Fossella F, Tsao A, Lee J, Swisher S, Heymach J, Futreal PA, Wistuba I, Herbst R, Papadimitrakopoulou V, Zhang J. Interplay between immune infiltration and tumor progression and survival in non-small cell lung cancer: An analysis of institutional and public data. ASCO Annual Meeting, 2017. e-Pub 2017.
208. Quek K, Li J, Fujimoto J, Zhang JH, Wang J, Chow C, Behrens C, Little L, Gumbs C, Antonoff M, Kalhor N, Weissferdt A, William W, Swisher S, Lee J, Heymach J, Wistuba I, Futreal PA, Zhang J. Intratumor heterogeneity of stage IA lung adenocarcinoma by multiregion whole exome sequencing and association with survival. ASCO Annual Meeting, 2017. e-Pub 2017.
209. Elamin Y, Gomez D, Papadimitrakopoulou V, Tran H, Rinsurongkawong W, Lewis J, Lacerda L, Roarty E, Lee J, Roth J, Swisher S, Zhang J, Heymach J. Local consolidation therapy (LCT) after first line tyrosine kinase inhibitor (TKI) for patients with EGFR mutant metastatic non-small cell lung cancer (NSCLC). ASCO Annual Meeting, 2017. e-Pub 2017.
210. Jin Y, Zhang J, Chen M, Shao Y, Shi X, Zhao J, Wu X, Yu X. Novel resistance mechanisms to first-generation EGFR tyrosine kinase inhibitors: A perspective study in NSCLC patients using targeted next generation sequencing. ASCO Annual Meeting, 2017. e-Pub 2017.
211. Sepesi B, Lacerda L, Zhang J, Bernatchez C, Karpinets T, Vaporciyan A, Wistuba I, Roarty E, Heymach J, Gibbons D, ICON Team. Immunogenomic profiling of non-small cell lung cancer: The ICON project. ASCO Annual Meeting, 2017. e-Pub 2017.
212. Lee W, Diao L, Wang J, Zhang J, Roarty E, Chow C, Fujimoto J, Behrens C, Cascone T, Peng W, Kalhor N, Moran C, Johnson F, William W, Swisher S, Heymach J, Wistuba I, Futreal PA, Zhang J. Multiregion gene-expression profiling to reveal heterogeneity in molecular subtypes and immunotherapy response signatures in lung cancer. ASCO Annual Meeting, 2017. e-Pub 2017.
213. Cuentas E, Behrens C, Rodriguez-Canales J, Jiang M, Pataer A, Correa A, Swisher S, Sepesi S, Weissferdt A, Kalhor N, Zhang JX, Lee J, Heymach J, Moran C, Zhang J, Gibbons D, Wistuba I. Neoadjuvant chemotherapy influence changes of the immune response in non-small cell lung carcinomas immune response in non-small cell lung carcinomas. AACR Annual Meeting, 2017. e-Pub 2017.
214. Ning M, Xu T, Gomez D, Tran H, Komaki R, Wei X, Lin S, Hahn S, Prado E, Zhang J, Heymach J, Liao Z. Circulating cytokine levels predictive of Grade≥3 radiation pneumonitis: Preliminary secondary analysis of a randomized controlled trial of definitive chemoradiation in locally advanced NSCLC. AACR Annual Meeting, 2017. e-Pub 2017.
215. Tang C, Zhang J, Tran H, Welsh J, Liao Z, Tsao A, Wistuba I, Swisher S, Heymach J, Gomez D. Correlative analysis of systemic markers from a randomized trial assessing local consolidative therapy for non-small cell lung cancer (NSCLC) patients with oligometastatic disease. AACR Annual Meeting, 2017. e-Pub 2017.
216. Parra E, Behrens C, Rodriguez-Canales J, Jiang M, Pataer A, Correa A, Swisher S, Sepesi B, Weissferdt A, Kalhor N, William W, Lee J, Heymach J, Moran C, Zhang J, Gibbons D, Wistuba I. The Influence of Neoadjuvant Chemotherapy, On Immune Response Profile In Non Small Cell Lung Cancer. The 17th World Conference on Lung Cancer, 2016. e-Pub 2016.
217. Parra E, Villalobos P, Zhang JX, Behrens C, Mino B, Swisher S, Sepesi B, Weissferdt A, Kalhor N, Heymach J, Moran C, Lee J, Zhang J, Gibbons D, Rodriguez-Canales J, Wistuba I. Image Analysis-based Expression of Nine Immune Checkpoints Identifies Distinct Immunoprofiling Patterns in Non-Small Cell Lung Carcinomas. The 17th World Conference on Lung Cancer, 2016. e-Pub 2016.
218. Tang H, Zhang J, Hu X, Xu Y, Dong B, Wang J, Kong Y, Ma H, Liao Z, Zhang J, Byers L, Gibbons D, Glisson B, Wistuba I, Heymach J, Gomez D, Futreal PA, Chen M. EGFR mutations in small cell lung cancer (SCLC): genetic heterogeneity and prognostic impact. The 17th World Conference on Lung Cancer, 2016. e-Pub 2016.
219. Lam V, Tran H, Banks K, Rinsurongkawong W, Papadimitrakopoulou V, Wistuba I, Futreal PA, Lanman R, Swisher S, Heymach J, Zhang J. Circulating tumor DNA (ctDNA)-based genomic profiling of known cancer genes in lung squamous cell carcinoma (LUSC). The 17th World Conference on Lung Cancer, 2016. e-Pub 2016.
220. Sepesi B, ICON Team, Sharma P, Allison J, Fang B, Zhang J, Wagner H, Bogatenkova E, Wistuba I, Heymach J, Bernatchez C, Gibbons D. Prospective ImmunogenomiC PrOfiling of Non-small cell lung cancer (ICON Project). The 17th World Conference on Lung Cancer, 2016. e-Pub 2016.
221. Skoulidis F, Elamin Y, Papadimitrakopoulou V, Tong P, Wang J, Lewis J, Rinsurongkawong W, Chu C, Roarty E, Zhang J, Tran H, Rodriguez-Canales J, Parra E, Behrens C, Kadara H, Wistuba I, Heymach J. Impact of major co-mutations on the immune contexture and response of KRAS-mutant lung adenocarcinoma to immunotherapy. The 17th World Conference on Lung Cancer, 2016. e-Pub 2016.
222. Tang H, Zhang J, Hu X, Hu Y, Dong B, Kong Y, Zhang X, Liao Z, Zhang J, Byers L, Gibbons D, Glisson B, Wistuba I, Heymach J, Gomez D, Futreal PA, Chen M. Preliminary analysis of genomic profiling of small cell lung cancer in Chinese population revealed frequent PIK3CA hotspot mutations, 2016. e-Pub 2016.
223. Zhang J, Fujimoto J, Yusko E, Zhang J, Vignali M, Song X,, Rodriguez-Canales J, Parra E, Behrens C, Benzeno S, Robins H, Gibbons D, Swisher S, Heymach J, Futreal PA, Wistuba I. Intra-tumor heterogeneity of T cell receptor repertoire in lung cancers and its association with tumor genomic profile, 2016. e-Pub 2016.
224. Goldstein J, Beird H, Zhang J, Belmont C, Lari B, Mynhier M, Pathak D, Basu P, Jin J, Barbosa G, Kell T, Punugoti V, Suh E, Smith B, Chin L, Futreal PA. Tackling "big data" for accelerating cancer research, 2016. e-Pub 2016.
225. Omez D, Blumenschein G, Lee J, Hernandez M, Camidge D, Doebele R, Gaspar L, Gibbons D, Karam J, Kavanagh B, Komaki R, Louie A, Palma D, Tsao A,, William W, Zhang J, Swisher S, Heymach J. Local consolidative therapy (LCT) to improve progression-free survival (PFS) in patients with oligometastatic non-small cell lung cancer (NSCLC) who receive induction systemic therapy (IST):  Results of a multi-institutional phase II randomized study, 2016. e-Pub 2016.
226. Narayanan S, Beird H, Goldstein J, Zhang J, Belmont C, Lari B, Pathak D, Jin J, Barbosa G, Kell T, Punugoti V, Suh E, Smith B, Futreal PA. Visualization techniques for identifying patient cohorts for hypothesis-testing in cancer research, 2016. e-Pub 2016.
227. Beird H, Goldstein J, Zhang J, Narayanan S, Belmont C, Lari B, Fassett B, Pathak D, Akella P, Jin J, Barbosa G, Kell T, Punugoti V, Suh E, Smith B, Futreal PA. A case-study using big data to increase scientific productivity in cancer research, 2016. e-Pub 2016.
228. Tran H, Elamin Y, Simon G, Blumenschein G, Tsao A, Papadimitrakopoulou V, Gibbons D, Fossella F, Lanman R, Banks K, Byers L, Zhang J, Heymach J. Clinical utilization of a CLIA-certified cell-free DNA (cfDNA) blood test for identification of targetable molecular alterations in patients with non-small cell lung cancer (NSCLC). ASCO, 2016. e-Pub 2016.
229. Beird H, Goldstein J, Zhang J, Belmont C, Lari B, Basu P, Pathak D, Fassett R, Jin J, Barbosa G, Kell T, Punugoti V, Suh E, Smith B, Futreal PA. A methodological framework for establishing a translational research accelerator (TRA) for cancer research, 2016. e-Pub 2016.
230. Zhang J, Wu C, Zhang J, Fujimoto J, Song X, Mao X, Sun H, Seth S, Thornton R, Coyle M, Little L, Gumbs C, Behrens C, Chow C, Sulman E, Rao G, Swisher S, Wistuba I, Heymach J, Futreal PA, Gomez D. Integrated exome and transcriptome sequencing of primary lung cancers and paired distant metastases, 2016. e-Pub 2016.
231. Xing Y, Zhang J, Li J, Zhang J, Chang J, Futreal PA. Multiple different mutations of same cancer genes in the same tumors from lung adenocarcinoma patients. AACR, 2016. e-Pub 2016.
232. Zhang J, Wu C, Zhang J, Fujimoto J, Song X, Mao X, Sun H, Seth S, Thornton R, Coyle M, Little L, Gumbs C, Behrens C, Chow C, Sulman E, Rao G, Swisher S, Wistuba I, Heymach J, Futreal PA, Gomez D. Integrated exome and transcriptome sequencing of primary lung cancers and paired distant metastases. AACR, 2016. e-Pub 2016.
233. Xing Y, Zhang J, Li J, Zhang J, Chang J, Futreal PA. Multiple different mutations of same cancer genes in the same tumors from lung adenocarcinoma patients, 2016. e-Pub 2016.
234. Zhang J, Liu Y, Zhang J, Gomez D, Fujimoto J, Behrens C, Zhang J, Correa A, Gumbs C, Mao X, Seth S, Song X, Heymach J, Lee J, Swisher S, William W, Hong W, Gao Y, Wistuba I, Futreal PA. Genomic heterogeneity of lung cancers and its potential clinical implications, 2015. e-Pub 2015.
235. Skoulidis F, Byers F, Diao L, Papadimitrakopoulou V, Tong P, Izzo J, Behrens C, Kadara H, Parra E, Rodriguez-Canales J, Zhang J, Giri U, Gudikote J, Cortez M, Yang C, Fan Y, Peyton M, Girard L, Coombes K, Toniatti C, Heffernan T, Choi M, Frampton G, Miller V, Weinstein J, Herbst R, Wong K, Zhang JH, Sharma P, Mills G, Hong W, Minna J, Allison J, Futreal A, Wang J, Wistuba I, Heymach J. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles and therapeutic vulnerabilities. AACR, 2015. e-Pub 2015.
236. Zhang J, Gold K, Swisher S, Lippman S, Lee J, Kim E, William W. Relationship between tumor and survival in non-small cell lung cancer ( NSCLC): An analysis of the surveillance, Epidemiology, and End Results ( SEER) registry. ASCO, 2015. e-Pub 2015. PMID: 25590605.
237. Zhang J, Liu Y, Lin Li, Zhang JH, Yin G, Lin D, Liu X, Cheung H, Seth S, Song X, Mao X, Zhang J, Cheng S, Futreal A, Gao Y. Genome sequencing reveals the multicentric nature of multiple synchronous lung adenocarcinomas, 2015. e-Pub 2015.
238. Zhang J, Gold K, Lin H, Swisher S, Xing Y, Lee J, Kim E, William W. Relationship between tumor size and survival in non-small cell lung cancer (NSCLC): an analysis of the Surveillance, Epidemiology, and End Results (SEER) registry. WCLC, 2014. e-Pub 2014.
239. Xing Y, Zhang J, Lin H, Sturgis E, Garden A, Gold K, Lee J, William W. Relationship between level of lymph node metastasis and survival in locally advanced head and neck squamous cell carcinoma. ASCO, 2013. e-Pub 2013.
240. Zhang J, Rotolo J, Stancevic B, Donepudi M, Haimovitz-Friedman A, Fuks Z, Kolesnick R. Role of membrane lipid rafts in the response to ionizing radiation, 2007. e-Pub 2007.
241. Zhang J, Rotolo J, Donepudi M, Paris F, Cremesti A, Aimovitz-Friedman A, Fuks Z, Kolesnick R. Membrane lipid rafts transduce an ionizing radiation death signal, 2005. e-Pub 2005.
242. Zhang J, Rotolo J, Donepudi M, Paris F, Cremesti A, AdHaimovitz-Friedman A, Fuks Z, Kolesnick R. Membrane lipid rafts transduce an ionizing radiation death signal, 2004. e-Pub 2004.
243. Zhang J, Tran H, Elamin Y, Simon G, Blumenschein G, Tsao A, Papadimitrakopoulou V, Gibbons D, Fossella F, Lanman R, Banks K, Byers L, Zhang J, Heymach J. Clinical utilization of a CLIA-certified cell-free DNA (cfDNA) blood test for identification of targetable molecular alterations in patients with non-small cell lung cancer (NSCLC), 2001. e-Pub 2001.
244. Zhang J, Fan Z, Bai J, Li C, Gao Y, Cheng S. Detection of Bladder Cancer in the Chinese by Microsatellite analysis: Possible Racial and Etiological Differences between the East and the West, 2000. e-Pub 2000.

Letters to the Editor

1. Xu X, Bao C, Deboever N, Chen D, Wang T, Antonoff M, Xu Y, Fan Y, Zhang J, Mao W. Immunogenomic analysis of concurrent lung cancer and tuberculosis reveals distinct immune milieu. Mol Biomed 6: 93, 2025.
2. Li, J, Shaw, VR, Lin, Y, Wang, X, Aminu, M, Li, Y, Wu, J, Zhang, J, Amos, CI, Cheng, C. The prognostic effect of infiltrating immune cells is shaped by proximal M2 macrophages in lung adenocarcinoma. Molecular cancer 23, 2024.
3. Tang Z, Zhang J, Chen H, Lu S, Cheng J, Tang G, Medeiros LJ. Reply to Lambros et al. Mod Pathol 31: 541-542, 2018.

Patents

1. Can-Prevent-Lung: Use of interleukin-1 beta binding antibodies. Patent Number: MDA21-079.
2. Personalized Ranking and Identification of Onco-Reactive Immunoreceptors in T cells (PRIORI-T): A method to predict tumor-reactive T cell receptors in solid tumors. Patent Number: MDA21-045.